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Packed red blood cell (PRBC) transfusions continue to result in adverse inflammatory responses 
and increased rates of morbidity despite modifications in processing such as leukodepletion. It 
remains unknown if this is due to adverse physiological responses, inflammatory processes 
related to transfusion related immunomodulation (TRIM) or both. Washing of PRBCs may 
reduce the immunomodulatory potential and transfusion related adverse outcomes. This study 
aimed to investigate whether transfusion with washed leukodepleted PRBCs in the preterm 
newborn reduces post-transfusion inflammatory cytokine responses compared to transfusion 
with unwashed leukodepleted PRBCs, improving physiological stability.  
Extremely preterm newborns (n=154) were randomised to transfusion with unwashed or 
washed leukodepleted PRBCs, determined by the restrictive threshold of the PINT transfusion 
study, until primary hospital discharge (77 per arm). Plasma cytokines, markers of endothelial 
activation and measures of cardiorespiratory stability where measured pre- and post-
transfusion.   
Transfusion with washed PRBCs resulted in decreases in pro-inflammatory cytokines while 
unwashed PRBCs resulted in increases in IL-17A and TNF. By the 3rd transfusion this response 
to unwashed PRBCs was associated with increases in MIF and PAI-1, markers of endothelial 
activation, an effect not seen with washed PRBCs. This response was influenced by donor sex 
with exposure to PRBCs from a female donor resulting in increases in pro-inflammatory 
cytokines, an effect ameliorated by PRBC washing. Changes over time and in response to the 
type of packed red blood cells transfused were seen with a greater reduction in cardiac output 
and increase in systemic vascular resistance and mean airway pressure seen in those infants 
transfused with washed PRBCs. However, none of these alterations met the current accepted 





The current study suggests that the association between transfusion and poor outcome have a 
predominantly immunomodulatory basis, a relationship that may be altered by the use of 
washed packed red blood cells for the extremely preterm infant. The apparent lack of 
significant changes in cardio-respiratory responses to a transfusion may reflect the need for 
specific diagnostic criteria for transfusion related complication in the preterm newborn. The 
current results provide strong mechanistic data supporting a potentially beneficial effect of 
transfusion of washed packed red blood cells in this high-risk population. The next critical step 
is investigating whether the use of washed packed red blood cells is associated with a significant 
reduction in clinical outcomes, a finding which would have wide ranging implications for both 
transfusion medicine and the field of neonatology. 
 
 














1  Preterm Birth  
1.1 Epidemiology of Prematurity  
In Australia and New Zealand there are over 300,000 registered births each year. Of these, 3% 
(10,161) are born preterm (<37 weeks’ gestation) or low birth weight (LBW) (<2500 grams) 1. 
Despite substantial advances in perinatal management 2,  preterm and/or LBW infants continue 
to have significant rates of both long term morbidity and mortality 3. Further, over the past 
decade there has been a steady increase in the number of live births of extremely premature 
infants (<28 weeks’ gestation) 1, with 8.7% of live births in 2017 classified as preterm (<37 
weeks’ gestation) 4. It has been estimated that in Australia the incremental cost of each single 
extremely preterm infant reaching adulthood is $141,200 (AU) per annum with the estimated 
total cost of preterm birth $4.42 billion per annum 5. As a result, this high-risk population 
imposes a significant economic burden to families and society, as well as the enormous stress 
and emotional toll. The economic burden is in part due to ongoing morbidity which persists 
beyond childhood and adolescence. In addition, infants born preterm in high-income countries 
are half as likely to achieve a higher education compared to their term counterparts and earn 
approximately 16% less as an adult, which is equivalent to a nearly 2% loss of total population 
earned income 6. Therefore, while prolonging gestation in preterm births by just 1 week has 
been estimated to have the potential to save $25 million in direct hospital costs 6, identifying 
risk factors for morbidity related to preterm birth and developing novel interventions to 
prevent them is also critical. 
1.2 Morbidity and Mortality Associated with Prematurity  
Preterm infants are one of the most vulnerable hospital populations 7.  In developed countries 
preterm birth accounts for 70% of deaths during the neonatal period 8. All preterm infants, but 
particularly those born extremely premature, are susceptible to a number of potentially fatal 
or severely disabling conditions including bronchopulmonary dysplasia (BPD), necrotising 




periventricular leukomalacia (PVL), sepsis and anaemia 9. Importantly, all of these conditions 
are associated with long-term physical and neurodevelopmental consequences 9. While the 
mechanism of each condition is not fully understood, and with all likely multifactorial, they all 
have an inflammatory basis 10-13. Therefore, inflammation could be the linking mechanism of 
neonatal morbidity and mortality.  
1.2.1 Bronchopulmonary Dysplasia  
BPD or chronic lung disease is characterised by the need for supplemental oxygen at 36 
corrected weeks as a result of disrupted alveolar growth 10,14. It is the predominant neonatal 
morbidity that occurs as a consequence of prematurity 14. BPD predisposes infants to 
significantly higher rates of cardiopulmonary, vision and hearing impairments, growth failure, 
neurodevelopmental delay and more importantly, neonatal mortality 14. While studies have 
identified that preterm infants suffer less severe chronic lung disease with decreased risk of 
mortality than what was originally observed and described by Northway 15, the incidence in 
surviving infants born at less than or equal to 28 weeks’ gestational age has been relatively 
stable at approximately 40% over the last few decades 16. 
The exact mechanism that underpins BPD is not fully understood. However, there are a number 
of factors that contribute to the pathogenesis such as lower gestational age and exposure to 
mechanical ventilation. It is now acknowledged that inflammation has a central role, 
particularly exposure to prenatal and postnatal infection. The contribution of inflammation is 
supported by the association between BPD and increased plasma levels of Interleukin (IL)-1β, 
IL-6, IL-8, and IL-10 10 and appears related to an inability to mount an effective anti-
inflammatory response 10. While aberrant cytokine production is associated with BPD, it has 
been proposed that some cytokines actually have a protective role, in particular macrophage 
migration inhibitory factor (MIF) 17. In animal models, MIF has been shown to influence and 




syndrome (RDS) there is significantly less circulating MIF 17 18.  However, MIF is an upstream 
regulator of the innate immune system and has been implicated in a number of inflammatory 
conditions in adults highlighting a complexity of roles in the balance between injurious and 
beneficial cytokine production.  
1.2.2 Necrotising Enterocolitis  
NEC is an inflammatory condition of the gastrointestinal system, predominantly seen in 
preterm or LBW infants 19 with a reported incidence of between 3-15%.  Importantly, despite 
advances in neonatal care, little progress has been made in the treatment of NEC in recent 
decades, partly due to the unclear aetiology. Recognised risk factors for the development of 
NEC include prematurity, growth restriction and exposure to hypoxic ischemic events 20. The 
highest mortality rate is in those infants requiring surgery for NEC with 1 in 3 infants dying 
within the first postoperative year 21. While the exact pathogenesis of NEC is not fully 
understood, as for BPD it is considered to be multi-factorial. Recognised factors that play a role 
in its pathogenesis include immaturity of the gut, hypoxia-ischemia, microbial dysbiosis and a 
vulnerable gut barrier with impaired inflammatory defence mechanisms 20.  
Fundamentally, NEC is the end result of a disruption to the integrity of gut barrier defences 20. 
The gastrointestinal system (GI) is unique in its barrier defence mechanisms with the epithelial 
lining  predominated by enterocytes, absorptive cells which act as the physical barrier between 
the lumen, GI tract and the lamina propria 11. Enterocytes are integral in mucosal immunity and 
defence. The homeostatic state is achieved through a closely monitored cycle of proliferation, 
migration and apoptosis of enterocytes, which occurs every 3 to 5 days 11. If there is disruption 
to this cycle, then bacterial translocation may occur, resulting in vulnerability to intestinal injury 
11.  
While the preterm infant’s immune system is inherently immature, it has been proposed that 




However, in tissue samples from both animal models and preterm infants with NEC, Treg 
number is significantly reduced. In addition, there are increased levels of pro-inflammatory 
cytokines, in particular T-helper (Th) 17 family cytokines and IL-6 which is required for Th17 cell 
expansion and stabilisation. The critical role of the Th17 family of cytokines is supported by 
murine models deficient in functional T and B cells where intestinal injury and mucosal cytokine 
production is greater, secondary to increased production of Th17 cytokines and disruption of 
the enterocyte homeostatic cycle 11. This was characterised by weakened enterocyte junctions, 
increased enterocyte apoptosis and decreased enterocyte proliferation 11.  
1.2.3 Intraventricular Haemorrhage 
While there is a recognised link between conditions such as NEC and BPD with inflammatory 
cytokines, the association between inflammation and IVH is not as clearly established. IVH is 
categorised by a grading system, with the most severe grades 3 and 4 characterised by blood 
within the ventricular spaces with prominent ventricular dilation and/or haemorrhage with 
parenchymal infarction 22 and associated with significant morbidity and mortality 23. 
Recognised risk factors for IVH include preterm delivery without administration of antenatal 
glucocorticoids, lower gestational age,  and sepsis 23. Approximately 90% of IVH occurs within 
the first 72 hours of birth 24 with severe IVH associated with higher risk of mortality and 
significant long-term morbidity such as cerebral palsy, hearing and vision deficits and later 
learning disability 25. Despite advances in neonatal care resulting in improved survival, there 
has been little impact on the prevalence of IVH 26. 
Increased concentrations of IL-6 in cord blood and maternal peripheral blood have been 
associated with the development of IVH 12. This is thought to be due to an interaction between 
inflammation and the microvasculature 12, 27. Systemic inflammation not only independently 
induces damage but is also able to initiate a cascade of events within the central nervous 




the CNS are capable of upregulating inflammatory cells, triggering neutrophil chemotaxis and 
attachment, ultimately damaging surrounding tissue 27. The damaged endothelium is then able 
to promote the upregulation of adhesion molecules such as soluble intercellular adhesion 
molecule (sICAM) and vascular cell adhesion molecule (sVCAM) initiating a cascade of 
additional pro-inflammatory processes 28, 29.  Further, this upregulation results in vasoparalysis 
and damage to the germinal matrix and white matter injury 12, 27.  
1.2.4 Retinopathy of Prematurity  
A meta‐analysis of 13 population‐based studies over the past decade from countries with a 
neonatal mortality rate <5 per 1000 births reported 22% (95% CI 17–27%) of infants of <32 
weeks’ gestation develop ROP of any stage 30. The most recent Australian and New Zealand 
Neonatal Network (ANZNN) report shows that severe ROP (stages 3 or 4) occurs in 5–6% of 
infants with a gestational age <31 weeks or birthweight <1250 g. Treatment is administered to 
roughly half of these, with the most severe disease confined to infants of <27 weeks’ gestation 
31.  
 
The pathogenesis of ROP is not primarily thought to be a consequence of inflammation but the 
result of excessive and prolonged oxygen therapy 32.  It is a unique preterm condition affecting 
retinal development and is the main cause of visual impairment and blindness 33. Retinal 
development typically begins during the fourth month of gestation and therefore preterm 
infants are born with a highly underdeveloped visual system 34. Numerous cell types play critical 
roles in retinal development including endothelial cells, astrocytes and microglia 32.  
 
There are two important stages in retinal development which involve the signalling cytokine 
vascular endothelial growth factor (VEGF) 35.  During normal retinal development, astrocytes 
are the key drivers. These cells are highly sensitive to hypoxic conditions which results in them 




initiates the proliferation of new blood vessels towards the VEGF source 34. Therefore, new 
blood vessel formation occurs changing the predominantly hypoxic state to a hyperoxic one 34. 
In the presence of hyperoxia, VEGF mRNA expression is ceased resulting in discordant 
vascularisation 34. Supplemental oxygen inhibits the necessary hypoxic state leading to a 
reduction in VEGF production causing damage or destruction of the vasculature. This is 
considered to be phase one of ROP development. In phase 2, there is upregulation of VEGF 
production causing discordant vascular growth 34. While not thought to be primarily a 
consequence of dysregulated inflammation, excessive VEGF release is shown to be 
substantially increased by high IL-6 13.  
 
In summary, the pathogenesis of these significant morbidities is clearly multi-factorial. 
However, all have been shown to be associated with inflammation. Importantly, for each of 
these, exposure to a red blood cell (RBC) transfusion during the neonatal period has been 
identified as an independent risk factor for their occurrence 36. A common pathway linking 
susceptibility to these morbidities is likely to be increased pro-inflammatory cytokine 
production in response to packed RBC (PRBC) exposure 37, 38. This raises the possibility that the 
pro-inflammatory response seen in the transfused recipient could be a common contributing 
pathway leading to the development of inflammatory morbidities. Clearly, with the knowledge 
gaps identified for each morbidity, there is a pressing need to increase our understanding of 
how a transfusion influences morbidity and mortality outcomes in preterm infants.  
1.3 Anaemia of Prematurity 
A decline in circulating RBCs is observed in all newborn infants after the first 24 h of age and 
continues to fall over the first weeks of postnatal life 39, 40. This postnatal decrease in 
haemoglobin (Hb) is termed physiological anaemia of infancy 41. However, unlike term infants, 
in the preterm infant this fall is exaggerated and more rapid with a nadir at 4–6 weeks postnatal 




that of an adult and an immature bone marrow response to anaemia resulting in insufficient 
RBC production 44.  Additionally, a premature infant is deprived of placental iron transport from 
the mother during the final trimester of pregnancy 41. In addition, and directly related to the 
degree of prematurity, iatrogenic blood loss due to repeated blood sampling as part of routine 
neonatal care is a significant contributor to the development of anaemia in the preterm infant 
and further exacerbates the increased risk of physiological anaemia 44.  
Term infants are generally asymptomatic from this physiological anaemia however in preterm 
infants the fall in Hb is commonly accompanied by physiological symptoms including feeding 
difficulties and poor weight gain, apnoea, tachycardia, hypotension and lethargy 39, 42.  This is 
collectively termed anaemia of prematurity (AOP) and represents a pathologic extreme of 
physiologic anaemia in a high-risk population of newborns. Further, it is the commonest reason 
for a transfusion in the neonatal period 42.  
While there are a number of strategies employed to minimise the decrease in Hb, such as 
delayed cord clamping 44, preterm infants remain susceptible to AOP. As a result, PRBC 
transfusion is used to preserve oxygen carrying capacity to tissues, replace blood volume, 
prevent apnoeic episodes and foster weight gain and growth 39, 45. Ninety percent of all LBW 
premature infants will develop AOP and will receive at least one PRBC transfusion 41, however 
a number will require multiple transfusions (3-5) during their primary hospital admission 46. The 
decision to transfuse an infant with AOP is generally centred upon the use of a transfusion 
algorithm based on either Hb or haematocrit, modified by chronologic age and need for 
respiratory support 41, 47, 48. To date, the question of what constitutes the safest transfusion 




This thesis will explore potential pathways through which PRBC transfusion could result in 
adverse neonatal outcome and propose a novel approach to improve transfusion safety in this 
high-risk preterm population.  
1.4 Transfusion Associated Mortality and Morbidity 
1.4.1 Mortality and Transfusion Exposure 
Considerable evidence suggests that transfusion is associated with an increased risk of death 
in critically ill adult patients. Studies have reported associations between low volume PRBC 
transfusion 49, increased PRBC transfusion exposure 50 increasing age of transfused RBCs 51 and 
increased short and long-term mortality risk 52. More limited evidence supports a similar 
association in the paediatric population 53. Preterm infants are one of the most heavily 
transfused patient groups 54 and represent one of the most vulnerable hospital populations 
with preterm birth accounting for 70% of deaths during the neonatal period 8. Despite this, 
neonatal data linking RBC transfusion exposure and increased mortality is scarcer.  
Dos Santos, in a large retrospective observational study of preterm infants <1500 grams (n= 
1077), reported an approximately 50% increase in intra-hospital mortality in infants who 
received any leukodepleted PRBC transfusion in the first 28 days of life after adjusting for 
confounding variables. Further, mortality after day 28 of postnatal life was almost 2 times 
greater in infants who received 2 or more transfusions 55. Similarly, in a recent cohort study in 
ELBW infants, the number of PRBC transfusions in the first 7 days of life correlated with 
mortality rate before 1 month of age 56. However, other data supporting an association 
between exposure to leukodepleted PRBC transfusion in infants <30 weeks’ gestation (n= 490), 
after 21 days postnatal age and significant neonatal respiratory morbidity did not find an 
association with mortality 57. 
 
The proposed mechanisms underlying the association between RBCs and post-transfusion 




acute lung injury, and haemolytic reactions are the leading causes of allogeneic blood 
transfusion-related deaths in adults 58, they are seldom recognised in infants. Some authors 
have suggested that PRBC transfusions are associated with pro-inflammatory and 
immunosuppressive responses, together termed transfusion-related immunomodulation 
(TRIM), which contribute to the development of multi-system organ failure 59. TRIM represents 
a biologically plausible, pathophysiologic process linking PRBC transfusion exposure and 
subsequent morbidity and mortality. As described previously, extremely premature infants are 
susceptible to numerous potentially fatal or severely disabling conditions, including NEC, BPD, 
ROP and IVH, all of which have been shown to be related to inflammation. While a number of 
observational studies have raised the possibility of an association between PRBC transfusion 
and adverse neonatal outcome, the extent to which transfusion exposure contributes to their 
pathophysiology is unresolved and controversial 60. The significance and mechanistic basis of 
transfusion-related neonatal morbidity is inadequately addressed in the medical literature and 
represents a significant knowledge gap. 
1.4.2 Necrotising Enterocolitis and Transfusion Exposure 
NEC typically develops in a vulnerable preterm host with a hypoxic, ischemic, or infectious 
bowel insult. In the 1980’s, the association between PRBC transfusion and NEC was thought to 
occur as a result of T-crypt-antigen activation, leading to the use of washed or anti-T blood 
products 61. Recently the term TANEC has been used to describe transfusion-associated 
necrotising enterocolitis. TANEC has been reported to be associated with approximately 30% 
of NEC cases, with these infants at greatest risk of developing surgical NEC 62. While a number 
of mechanisms have been proposed to result in TANEC,  it is generally thought to be secondary 
to an immune response to biological mediators contained within stored blood 62. Indeed, PRBC 
transfusion exposure results in increases in pro-inflammatory cytokines associated with 





Other investigators have focused on the temporal relationship between enteral feeding at the 
time of PRBC transfusion and the development of NEC, demonstrating that the anticipated 
postprandial blood flow increase through the superior mesenteric artery is ablated in infants 
receiving PRBC transfusions. The resultant postprandial period of relative intestinal hypo-
perfusion may then contribute to the development NEC 64. Finally, it has been suggested that 
anaemia itself, rather than a transfusion, increases the risk of NEC 64. This hypothesis is 
supported by evidence from a prospective observational study (n= 598) of very low birth weight 
preterm infants (<1500 grams) in whom PRBC transfusion in a given week was not significantly 
related to the rate of NEC. However, the rate of NEC was significantly increased in those infants 
with severe anaemia compared to those without anaemia 65.  
 
While a previous meta-analysis of eleven case-control and one cohort study suggested an 
association between PRBC transfusion and NEC 66, the most recent meta-analysis of available 
observational data found no such effect 67.   Further, a recent systematic review of randomised 
trials on blood transfusion thresholds in ELBW infants failed to support an association between 
transfusion and NEC 68. Rather than supporting a lack of association between PRBC transfusion 
and NEC, this likely reflects that most available studies are affected by unadjusted differences 
in baseline patient characteristics and indication for transfusion, the lack of a specific definition 
of TANEC and, critically, significant inconsistency in the direction of results 68. 
1.4.3 Bronchopulmonary Dysplasia and Transfusion Exposure  
In adults, acute respiratory decompensation is a well-recognised complication of PRBC 
transfusion 69. This may be either transfusion-associated lung injury (TRALI), commonly 
occurring 6 hours following exposure to RBCs 70, transfusion-associated circulatory overload 
(TACO), defined as acute respiratory distress, tachycardia, elevated blood pressure, acute or 
worsening pulmonary oedema and evidence of positive fluid balance, or transfusion-associated 




71.  TRALI is one of the leading causes of severe post-transfusion morbidity and acute mortality 
72. However, TRALI is thought to be underreported and under-recognised in all patients, 
particularly in preterm infants 73.   The incidence of TRALI has been reported to vary from 0.08% 
to 15% of adult patients receiving a transfusion 74 but the incidence in neonates is unknown.  A 
two-event hypothesis has been postulated as central to the pathogenesis of TRALI 75. The first 
event is the patient’s underlying clinical condition, causing inflammation with priming of the 
pulmonary neutrophils. The second event is the transfusion product itself, with bioactive 
molecules or antibodies which have accumulated during RBC storage, activating primed 
neutrophils in the recipient 75. Although TRALI has previously been described in the paediatric 
population 73 there is a paucity of data in neonates. 
 
BPD is among the most common and serious sequelae of preterm birth. This chronic condition 
is characterised by the need for supplemental oxygen at 36 corrected weeks and is the result 
of disrupted alveolar growth. BPD is inherently multifactorial; therefore, there is no consensus 
on the precise pathogenesis. Interestingly, the incidence of BPD is significantly higher in infants 
transfused during the neonatal period 76 and increases with the total number of transfusions 
76. There is growing recognition of the significant contribution of inflammation and oxidative 
stress to the pathogenesis of BPD, processes similar to that seen with TRALI 77. While rates of 
post-transfusion lung injury (defined as a sustained increase in mean airway pressure of >2cm 
or FiO2 >0.15 occurring within 6 hours post transfusion exposure and persisting for up to 18 
hours post exposure) are reported to be as high as 10% in preterm neonates, failure to take 
into account very high rates of respiratory instability in this population limits interpretation of 
this data 78. In a retrospective study of 108 infants transfused a total of 373 times the rate of 
post-transfusion respiratory deterioration was 8.3% 78. However, meta-analysis of randomised 
trials comparing restrictive versus liberal transfusion thresholds fails to demonstrate an 




to acknowledge that both observational and randomised studies are limited by the lack of an 
accepted definition of TRALI in the preterm infant in addition to the difficulty in differentiating 
the contribution of underlying lung pathology versus a transfusion-related effect. As a result, 
prospective studies with significantly larger sample sizes are required to definitely prove or 
disprove any association 79. 
1.4.4 Retinopathy of Prematurity and Transfusion Exposure 
Red cell exposure and the development of ROP remains controversial. A number of 
observational studies support an association with RBC exposure and ROP 80-82. Most report a 
significant association between both gestational age and transfusion frequency with the 
development of ROP 80, 82. Others report a significant association between transfusion exposure 
and ROP following adjustment for gestational age 81. Hesse and colleagues adjusted for 
gestational age and duration of mechanical ventilation in a population of ELBW infants and 
found the relative risk for ROP development was 6.4 (95% CI 1.2 to 33.4) in those who received 
16-45 ml/kg of RBCs, doubling for those receiving >45 ml/kg over their admission 83, an effect 
proposed to be associated with products of iron metabolism 82. Conversely, the sole 
randomised study investigating the relationship between transfusion exposure and the 
incidence of ROP failed to demonstrate an increase in the risk for ROP in those infants allocated 
to the liberal transfusion threshold arm 84. However, this study is confounded by high attrition 
rate overall, variability in haematocrit in the liberal transfusion arm and very small sample size 
for a study with a clinical outcome.  Unsurprisingly, as for BPD, meta-analysis of randomised 
trials comparing restrictive versus liberal transfusion thresholds fails to demonstrate increased 
incidence of ROP with greater transfusion exposure 60.  
 
Unlike NEC and BPD, the underlying pathogenesis of ROP is not primarily a consequence of 
inflammation. Exposure to biologically active substances from the transfusion pack may 




significant enough to contribute to the pathogenesis of ROP remains unknown 85. Other 
potential mechanisms linking transfusions with ROP development include lowering the ratio of 
fetal haemoglobin (HbF) to adult Hb with transfusion exposure, shifting the oxygen dissociation 
curve to the right and increasing oxygen availability to the developing retina 86. Finally, anaemia 
itself may result in retinal hypoxia and subsequently retinal neovascularisation 84.   
1.4.5 Intraventricular Haemorrhage and Transfusion Exposure 
An association with PRBC transfusion exposure was first reported in 1998 87 with  each 
subsequent PRBC transfusion in the first week of life in ELBW infants doubling the relative risk 
of severe IVH 23. Further, in a retrospective study of 417 infants already diagnosed with a grade 
1 IVH, subsequent transfusion exposure, along with lower gestational age, was the most 
significant predictive factor in the 46 infants who subsequently developed grade III or IV 
haemorrhage 88. Similarly, in a prospective cohort of 4283 preterm infants, those who received 
a transfusion had a 64% greater chance of diagnosis with grade III/IV haemorrhage 89. There is 
also evidence supporting an association between PRBC transfusion and IVH from a transfusion 
compliance study. Following the implementation of a standardised transfusion approach which 
was associated with a 23% reduction in the number of very low birth weight infants transfused, 
the incidence of severe IVH decreased from 17% to 8% 22.  
 
However, interpretation of results from retrospective studies is limited by their failure to 
adequately deal with confounding variables and the inherently greater risk of bias. For instance, 
the association between transfusion and IVH is likely related to the clinical reason for which the 
transfusion was required versus the transfusion itself.  If the relationship between PRBC 
transfusion exposure and subsequent IVH is truly causal then any intervention that reduces or 
prevents the need for early PRBC transfusion should be associated with a reduction in IVH 
occurrence 90. One such approach is delayed cord clamping, resulting in both reduced need for 




this intervention on neonatal outcome failed to show a significant reduction in IVH rates in the 
delayed cord clamping group 92. As such, the latest meta-analysis of available studies (including 
the APTS study 92) reports no difference in incidence of IVH despite a 10% reduction in 
transfusion exposure in infants randomised to delayed cord clamping 93.  
1.4.5 Summary 
Does PRBC transfusion contribute to development of neonatal morbidity? The majority of data 
supporting an association between PRBC transfusion and adverse outcome comes from small 
retrospective and observational studies. Consequently, it is important to acknowledge 
limitations of much of the primary evidence. This includes the failure to recognise confounding 
variables and limitations of the studies due to their susceptibility to bias. Therefore, while 
retrospective investigations may be hypothesis generating and report associations, they rarely 
conclusively prove a causal relationship.  
 
The most recent systematic review of PRBC transfusion exposure and adverse outcomes in the 
preterm neonatal population investigated clinical adverse effects and associations attributable 
to RBC exposure in 61 randomised and non-randomised trials 60.  The authors concluded that 
there was no evidence that mortality risk was greater between liberal or restrictive transfusion 
thresholds. However, they cautioned that many studies were likely confounded by indication 
bias, with the more critically ill infants more likely to receive PRBC transfusion 60. While 
approximately one-third of identified studies were randomised, the sample sizes in many were 
considered inadequate to address harm 60. Importantly, they conclude there is a “pressing need 
for larger studies with clear definitions of adverse events to be conducted prospectively, so 
that uncertainty about the safety of transfusion can be addressed in a population of recipients 




1.5 Transfusion Related Immunomodulation 
The proposed mechanisms underlying the association between RBC and the spectrum of post-
transfusion multi-organ morbidity and mortality remain poorly understood. Numerous pre-
clinical studies demonstrate that RBC products can directly modulate immune cell function 59. 
This may represent a common pathway linking RBC exposure to adverse outcomes, a process 
termed TRIM 94.  TRIM describes both adverse pro-inflammatory and immunosuppressive 
responses. In the preterm neonate it may be the central process underlying TRALI; associated 
with an increase in BPD and TRAGI; linked to an increase in the occurrence of NEC 95.  
 
TRIM was first described in the late 1970’s by Opelz and Terasaki. They discovered that as the 
number of transfusion exposures increased kidney graft survival improved suggesting that 
transfusion produced an immunosuppressive response 96. However, subsequent in vitro and 
clinical trials have demonstrated a transfusion has both pro- and anti-inflammatory potential.  
TRIM has been proposed to be a “two-insult” process. While two independent insults alone are 
harmless, sequential insults can cause pathophysiologic inflammation 97. Initial sensitisation to 
inflammatory processes results in priming of host neutrophils (first insult). Subsequent 
exposure to biological response mediators passively transfused along with the RBCs results in 
a pro-inflammatory immune response (second insult) 98. In vitro data supports the ability of the 
supernatant from stored RBCs to “prime” unstimulated  allogeneic neutrophils inducing the 
release of IL-8 and altering the cells chemotactic properties 99. Further, TRIM appears to be 
characterised by activation of vascular endothelial cells and platelets. These cells are highly 
sensitive to inflammatory signals and may release toxic bioactive mediators following activation 
by donor blood 98. This can result in recruitment of suppressor T cells (that are important in 
regulating pro-inflammatory immune responses), apoptosis of immune cells, and the 





While these pathological processes are yet to be fully characterised, the biological response 
mediators implicated in the second “hit” may include donor antibodies, bioactive lipids, free 
haemoglobin, red cell membrane fragments and cytokines that accumulate during blood 
product storage 95. Through normal storage processes (PRBCs stored for up to 42 days and kept 
at 6 degrees) the RBCs undergo structural and biochemical changes resulting in ‘shedding’ of 
an outer membrane, a process exacerbated as storage time increases 102. As homeostasis of 
the red cell is lost through normal erythrocyte aging the phospholipid membrane is disrupted, 
adenosine triphosphate (ATP) is depleted, and oxidation and haemolysis occurs. This results in 
the shedding and accumulation of microparticles and other inflammatory cells in the 
supernatant, a process commonly referred to as “storage lesion” 102. Whilst the inflammatory 
cells within the supernatant induce an inflammatory response themselves, microparticles 
indirectly stimulate immune responses through the recipient’s antigen presenting cells 
inducing a T-cell immune response 103. When a patient is transfused macrophages attempt to 
clear the RBC microparticles inducing an inflammatory response 102, 103. In vitro studies have 
shown that when stimulated, mononuclear cells significantly increase the production of more 
than 20 cytokines and chemokines including IL-1α, IL-1β, IL-17 and TNF 103. All of these have 
been identified as important cytokines in the underlying pathophysiology of a number of 
neonatal morbidities.      
Non-transferrin bound iron (NTBI) has also been identified as a bioactive substance which may 
contribute to TRIM 85. NTBI is detected in PRBC transfusion packs as early as day three of 
storage 104, 105 and is a potential contributor to the development of transfusion-associated 
morbidities 85.  In the transfusion recipient, the accumulation of NTBI is prevented by 
caeruloplasmin and transferrin.  However, this enzyme and protein are significantly reduced in 
prematurity 85. In a mature circulating system, when free iron is detected caeruloplasmin 
converts pro-oxidant ferrous into a ferric state allowing transferrin to bind the ferric iron, in 




saturated resulting in NTBI accumulation 105. This may result in the production of reactive 
radicals, resulting in oxidative damage and cytokine production 85.  
 
Newborn infants represent a unique patient population with the neonatal immune system, 
particularly one preterm, very different from adults 106. As a result, while a two-insult process 
may be common across all age groups, what induces TRIM in the preterm infant may be very 
different from the pathophysiologic process in adults. Further, the clinical endpoint may also 
differ. For instance, while TRALI may represent the commonest transfusion related morbidity 
in more mature patients, TRAGI presenting as NEC may be more common in the preterm infant. 
For instance, the mucosa of the naïve neonatal gut is particularly rich in neutrophils and on first 
exposure to gut flora and /or nutrient antigens is prone to an exaggerated immune response 
with a conversion from a TH2 to TH1 phenotype involving primed neutrophils 107. Nevertheless, 
it is clear that the immune response to transfusion exposure in the preterm infant, and how 
this relates to later morbidity, remains a significant knowledge gap. 
 
While TRIM has not been definitively proven in preterm infants, they are potentially at greater 
risk of immunomodulation due to their immature immune system. The in utero environment is 
generally proposed to be sterile with immune protection of the fetus predominantly of 
maternal origin 106.  Initially, the neonate relies solely on their innate immune system to defend 
against potential pathogens 106. This is principally the ability of circulating neutrophils to 
phagocytose and respond to pathogens 106. Neonatal neutrophils are markedly different to 
their adult counterparts; their numbers are less than 10% of circulating adult neutrophils and 
they have reduced adhesion and phagocytic ability 106. Further, these differences are 
exaggerated with increasing prematurity. As a result, the preterm infant is uniquely vulnerable 




is thought to be biased towards a Th2 cell response 108 with a predominantly anti-inflammatory 
response observed during the neonatal period 109.  
 
In healthy term infants the innate immune response does not tend to result in a Th17 response 
110. This cytokine family is important in mediating chronic inflammation. An inflammatory 
environment influences the differentiation of naïve Th cells into the Th17 lineage 111. Th17 cell 
numbers are initially very low in the neonatal circulation. However, IL-6, IL-21, IL-23 and TGFβ 
predominate in the early neonatal period and promote maturation and stabilisation of Th-17 
cell expansion 112. Through the production of IL-17113, Th17 cells subsequently aid in the 
recruitment of phagocytic cells, primarily neutrophils and predominantly at mucosal surfaces 
112, 113, enabling future adaptive immune responses 109.  
 
Importantly, excessive production of IL-17 has been implicated in certain inflammatory disease 
conditions including inflammatory bowel and lung disease 114. In adult patients with chronic 
lung disease those with the most severe disease had the highest expression of Th17 mRNA and 
protein 112. High concentrations of TGF, IL-6, IL-23 and/or IL-21 result in increased ROR-c 
expression, a transcription factor that induces the Th17 phenotype 111. Sustained IL-23 
production stabilises the Th17 cell enabling continued production of Th17 cytokines IL-17A, IL-
17F, IL-21 and IL-22 111. It is thought that the Th17 lineage is regulated differentially according 
to maturity, such that preterm infants may not have the ability to balance anti- and pro-
inflammatory responses in the neonatal period resulting in over-production of Th17 cytokines 
113. 
 
Perinatal and early life events are known to contribute to the development of immune 
disorders later in life. This is likely secondary to programming of the neonatal immune system, 




programming of the neonatal immune system include maternal infection, tobacco exposure, 
growth restriction and chorioamnionitis 116. The balance in T helper cell response is essential 
for maintaining immune homeostasis and when disrupted results in disturbances to the normal 
cellular and humoral immune regulation 116.  Chorioamnionitis, for example, has been linked to 
postnatal chronic inflammatory conditions, such as BPD, NEC and ROP.   
 
Animal data supports the hypothesis that the hyper-inflammatory environment caused by 
exposure to intra-uterine inflammation results in impaired innate and adaptive immune 
interactions, disrupting the homeostatic environment 115. In a murine model of intra-uterine 
inflammation employing exposure to low-dose lipopolysaccharide, the result is a profound pro-
inflammatory response extending beyond the original infected tissue 115. This inflammatory 
response reflects a change in T-cell response from a predominantly anti-inflammatory Th1/2 
response to one far more damaging.  This is thought to be due to plasticity of the neonatal 
lymphocyte favouring a Th17 response, resulting in a change from a T-regulatory response to 
a pro-inflammatory response. Subsequently, the alteration to this adaptive pro-inflammatory 
phenotype alters the trajectory of future immune responses.   
2  Modifications to Transfusion Practice  
Our growing understanding of TRIM and the relationship between transfusion exposure and 
significant morbidity and mortality has led to a number of different approaches designed to 
minimise the risk of adverse outcomes following PRBC transfusion being trialled and 
subsequently adopted into clinical practice. Modifications to transfusion practice and to RBC 
processing have both been areas of active research. Interventions have included the use of 
restrictive versus liberal transfusion triggers 48, the transfusion of fresh versus older RBCs 117, 
and pre-storage leukodepletion 118. However, these studies have had varying degrees of 




2.1 Minimising Transfusion Exposure 
Transfusion therapy represents a unique balance between predisposing patients to potential 
transfusion related adverse outcomes whilst managing the clinical consequences related to 
anaemia. As a result, transfusion protocols are inherently ill-defined. Many are based on a 
predetermined haemoglobin or haematocrit threshold, while others rely on patient signs and 
symptoms 119. For many years there has been a decrease in the number of transfusions patients 
are exposed to as a result of an increased understanding of transfusion-associated morbidities. 
Consequently, decreases in haemoglobin are increasingly tolerated. Despite this also being the 
case for newborns, preterm infants remain a particularly heavily transfused population 120.  
 
There is little consensus on an acceptable or tolerable fall in haemoglobin in the newborn infant 
and therefore inconsistencies exist between hospitals and clinicians 120. Much concern remains 
regarding the potential adverse consequences of chronic anaemia, particularly its effect on 
growth in extremely preterm infants 121 with blood transfusions associated with improved 
weight gain. As a result, there remains a fine balance between the risk of harm from anaemia 
itself and the risk of transfusion-associated morbidities.  
 
Adherence to transfusion guidelines decreases exposure to donor blood and therefore possible 
adverse outcomes. Preterm infants cared for in clinical environments which do not have 
transfusion guidelines are two times more likely to receive a blood transfusion than those that 
are 122. Therefore, much attention has been directed towards understanding and reaching a 
consensus on acceptable limits for falling haemoglobins in the preterm population and the 
identification of a transfusion “threshold”. A restrictive threshold requires that a patient’s 
haemoglobin or haematocrit falls below a specific value before a transfusion is “triggered”. In 
adult patients a commonly used restrictive threshold is 7 to 8 g/dL. The use of a specific 




Conversely, a liberal threshold allows for smaller falls in Hb concentration (10 to 11 g/dL). 
Current Australian medical guidelines state that the evidence is unclear whether one 
transfusion threshold provides more benefit than another 123.   
 
While no benefit of a restrictive transfusion threshold over a more liberal threshold has been 
demonstrated in adults 124, whether adoption of a restrictive approach is associated with an 
increased risk of harm remains unresolved125-127. Studies in cardiac and oncology patients have 
reported no benefit in a restrictive haemoglobin transfusion threshold 122, 126 with no difference 
in length of hospital stay, or incidence of organ dysfunction or sepsis 124.  In fact, two studies 
show there were significantly more deaths in the restrictive group at 90 days post-surgery 124, 
128. The authors of both these studies concluded that for these patient populations the use of 
a restrictive threshold may place patients at greater risk of harm. Therefore, the question as to 
which is the best approach remains unanswered 124, 128. Conversely, in burns patients, adoption 
of restrictive transfusion thresholds resulted in no difference in in-hospital or 90-day 
mortality126. Clearly the conflicting results described by these studies could be a result of the 
widely differing patient groups. Further, both the cardiac and oncology studies had a number 
of methodological limitations. In both the restrictive and liberal arms were only marginally 
different in haematocrit concentrations. In particular, the study conducted by Murphy et al 
applied a very small 1 g/dL difference between the liberal and restrictive arms. Therefore, both 
studies may have identified the increased risk of death associated with a transfusion rather 
than falling haemoglobin. In addition, the Murphy study does not state what type of blood is 
used 124. This is of particular importance as a transfusion with standard blood has previously 
been shown to significantly increase the risk of morbidity and mortality, where the rates are 





In paediatric intensive care patients, a restrictive versus liberal transfusion threshold has been 
reported to have no effect on the development of multiple organ dysfunction syndrome 
(MODS; including respiratory, cardiovascular, hematologic, hepatic, gastrointestinal, 
neurological and renal dysfunction) 130. While a trend towards increased sepsis susceptibility 
was observed in those randomised to the restrictive arm of the study, this finding is inconsistent 
with other studies which report that as transfusion exposure increases, rates of infection and 
mortality also increase 118.  Karam et al. conducted a post hoc analysis on this same population 
specifically focussing on patients who had septic shock 131. This is particularly pertinent due to 
the two-hit hypothesis of TRIM where the first hit involves sensitisation by an underlying 
inflammatory condition. While no difference in any of the morbidity outcomes between the 
restrictive and liberal arms was found, the study was not blinded. This can lead to bias with 
clinicians more likely to break protocol and transfuse or withhold transfusion based on their 
interpretation of the patient’s stability.  
 
Two clinical trials, comparing a liberal versus restrictive transfusion schedule based on Hb or 
haematocrit 47, 48 are the foundation of current neonatal transfusion practice. Bell and 
colleagues randomised 100 newborns weighing 500-1300 g at birth, to either a restrictive or 
liberal transfusion threshold based upon haematocrit  47. This trial reported a difference in the 
primary outcome of number of transfusions with fewer in the restrictive group. However, 
secondary outcomes of in-hospital survival, ROP, BPD, time in supplemental oxygen or growth 
were not different. While a non-significant difference in the incidence of brain injury diagnosed 
on cranial ultrasound was reported, with rates higher in the restrictive arm, only half of the 
study cohort were examined.  
 
The Preterm Infants in Need of Transfusion (PINT) study also randomised preterm neonates 




sample size of 451 newborns no differences were reported in a composite measure of mortality 
and/or significant neonatal morbidity (defined as BPD, vision threatening ROP or brain injury 
on cranial ultrasound) between the restrictive and liberal arms. As a result, the investigators 
concluded that lowering the haemoglobin transfusion threshold was safe for low-birth-weight 
preterm infants 48.  
 
Both studies also undertook longer term follow-up. The PINT study assessed the potential 
neurocognitive effects of transfusion thresholds by employing a combined measure of death 
and severe adverse neurodevelopmental outcomes at 18 months 132. The authors found that 
there was a greater number of patients with a cognitive impairment in those allocated to the 
restrictive threshold 121. However, studies have shown that cognitive development scales used 
in infancy are poor predictors of later cognitive development 133.  
Nopoulos and colleagues compared brain structure and function in children enrolled in the 
original Bell study at 13 years of age comparing both the restrictive and liberal groups to a 
control group 134. They found that despite the short-term outcomes favouring a more liberal 
transfusion approach, long-term outcomes suggested the restrictive threshold provided a 
protective element to neurodevelopment 134. Patients in the liberal group had significantly 
greater loss of intracranial volume compared to their control term counterparts, while patients 
in the restrictive threshold did not 134. However, the follow-up rate was less than 40% and the 
study was under powered to obtain this outcome. Interestingly, female participants had the 
greatest volume decrease, despite being born at a later gestation, a known protective factor 
for neurocognitive impairment. While infants in the restrictive group had a higher incidence of 
IVH and PVL, at 13 years they seemed to be spared from volume loss. Erythropoietin (EPO) was 
thought to contribute to the potential neurocognitive benefits demonstrated by the restrictive 
group, with EPO previously shown to have neuroprotective capabilities 135. As part of the 




group having significantly higher concentrations of EPO compared to those in the liberal group. 
It is important to note that this long term follow up only assessed brain structure and did not 
assess cognitive ability. While previous studies have shown that changes in white and grey 
matter strongly predict neurodevelopmental outcomes, by merely assessing a single aspect 
through cortex volume without cognitive and behavioural assessments it is difficult to predict 
what the true neurodevelopmental outcomes are.   
The subsequent Cochrane meta-analysis of all available neonatal transfusion threshold studies 
concluded that from the limited long-term data available, there was no clear benefit to the use 
of liberal versus restrictive Hb thresholds in very low birth weight neonates 136. However, given 
the growing evidence supporting an association between PRBC transfusion exposure and 
adverse outcome in the neonatal period, it could be argued that a restrictive transfusion 
practice is preferable as more extremely preterm infants avoided transfusion without a worse 
outcome 66. An alternate interpretation may be that a liberal transfusion practice is better due 
to the potential for a longer-term neurodevelopmental advantage 132.  
2.2 Limiting Red Blood Cell Storage Time 
Following donation, national guidelines require all RBC packs to be stored for no longer than 
42 days. However, for more vulnerable populations such as neonates, current guidelines 
suggest, where possible, they should only be exposed to RBCs stored for a maximum of 2 weeks 
123. These guidelines are employed due to both morphological changes in the RBCs and 
accumulation of bioactive substances in the RBC packs as they age. After 2 weeks of storage 
the RBC is no longer a biconcave disk 137. Following 3 weeks of storage it is irreversibly damaged, 
resembling a deformed sphero-echinocyte 137. These structural changes alone have been 
identified as an independent risk factor for morbidity risk in trauma patients 97, 137. Further, 
these changes are associated with red cell lysis and loss of membrane integrity, a decrease in 




production of reactive oxygen species (ROS) 98. There is concurrent accumulation of bioactive 
substances within the pack supernatant with an increase in lactate, extracellular potassium, 
RBC microparticles and cell debris 98. Collectively called “storage lesion”, these changes are 
thought to contribute to TRIM and the increased risk of adverse clinical outcomes seen 
following a transfusion. Current storage practices are aimed at minimising these changes 
through optimising storage procedures and therefore increasing the time allowed for storage. 
In spite of these guidelines, there is long-standing debate on the optimal storage time and 
whether increased storage mitigates the benefits of a blood transfusion 138.  
2.2.1. RBC Storage Lesion 
As the red cell breaks down cell debris and microparticles accumulate. These are thought to 
exhibit immunomodulatory potential. Microparticles are able to attach to or near the 
endothelium allowing free nitric oxide to be scavenged 102. This can result in platelet 
aggregation, endothelial activation and the production of ROS 102. Microparticles have been 
identified as important contributors in a number of biological processes such as inflammation, 
immune function and apoptosis 139. Microparticle generation results from a change in the 
asymmetry of the lipid bilayer of the cellular membrane. Physiological microparticle generation 
takes place concomitant to apoptosis of different cells and the presence of microparticles in 
the blood of healthy individuals is seemingly constant 140.  
 
Microparticle generation may also arise due to physiological/pathological events resulting from 
cell activation by agonists141. During red cell storage several factors trigger microparticle 
formation. These include shear stress (due to the close contact between RBCs in the storage 
bag), anticoagulant-dependent effects, oxidative stress, calcium index and pro-apoptotic 
stimulation 140. It is also known that the storage length is critical to microparticle formation. In 
addition, donor age and sex have been described to influence microparticle release upon 




Erythrocyte derived microparticles act on the innate immune system as paracrine messengers 
and as pro-inflammatory mediators inducing or propagating inflammatory signals 143. It has 
recently been postulated that microparticles are likely to be mediators for TRALI through the 
binding and activation of neutrophils 144. Further, complement and IgG are enriched in 
microparticles from "old" RBCs due to the storage lesion and can activate neutrophils via Fc 
receptors. In addition, microparticles exhibit potent pro-coagulant activity through the 
expression of anionic phospholipid phosphatidylserine (PS), which is critical for assembly of 
coagulation factors into active complexes for thrombin generation 145. 
 
A pro-inflammatory response in the transfusion recipient, characterised by increased 
production of pro-inflammatory cytokines, is likely to be a significant component of the 
pathological processes resulting in transfusion-related morbidity and mortality. It would seem 
logical to expect that along with time-dependent accumulation of microparticles there might 
also be a progressive increase in cytokine concentrations as the blood pack ages 97, 98, 146, 147. 
Bal et al found that whilst the majority of cytokines tested for were non-detectable, IL-17A 
progressively increased 147. Interestingly, as IL-17A concentrations increased, Th1 expression 
was suppressed. This observation may partially explain the apparently contradictory findings in 
some in-vitro studies where pro-inflammatory cytokine concentrations and the pro-
inflammatory response following exposure to supernatant from older packs was lower 148.  
 
However, when untreated whole blood is exposed to supernatant from ‘fresh’ RBC packs (1, 6 
or 15 days), IL-6 concentrations increase 97. In a murine model Hod et al. found that fresher 
murine blood was still able to result in a significant inflammatory event. This pro-inflammatory 
response characterised by elevated IL-6, TNF, monocyte chemoattractant protein (MCP-1) and 
macrophage inhibitory protein-1β (MIP-1β) was even greater in those transfused with RBCs 




supernatant to accentuate LPS induced pro-inflammatory cytokine (IL-1, IL-6 and TNF) 
production increased with the age of the transfusion pack.  Although in vitro studies have 
provided evidence for how length of storage affects inflammatory pathways, if and how this is 
translated clinically is far less definitive 51, 149.  
2.2.2 Storage Lesion and Transfusion Associated Morbidities   
Many studies have suggested a link between PRBC storage time and morbidity and mortality, 
although the evidence does not universally support such an association. Purdy et al, in 1997, 
reported the first evidence of an association between increased mortality rate and age of PRBCs 
transfused. In a cohort of adult intensive care patients diagnosed with sepsis the median age 
of PRBC units transfused to survivors was 17 days (range 5-35) vs 25 days (range 9-36) for those 
that died 150. Offner et al found an association between the incidence of major infections in 
trauma patients (such as pneumonia, meningitis, lung, abdominal or pelvic abscesses) and the 
duration of red cell storage prior to transfusion 149. This was thought to result from primed 
neutrophils previously found to occur following 2 weeks of storage 151. When controlling for 
patient age, sex and mechanism of injury, those that received PRBCs stored for 14 days or 21 
days had an independent increased risk for development of infection 149. Similar findings were 
reported in a large single site study conducted by Koch et al which investigated the effects of 
transfusion storage duration and cardiac surgery outcomes 51. Patients in this study were at an 
increased risk of developing a serious adverse event such as renal failure, multiple organ failure 
and sepsis, as well as a reduced survival rate 51. Additionally, there was a 30% increased relative 
risk of post-operative death for those who received blood older than 14 days. It is important to 
note, however, that the length of storage time between the two groups did not differ 
substantially. Therefore, comparing a true fresh and older pack (>20 days of storage) remains 





An important consideration in the interpretation of this data is the potential confounding 
effects of repeat exposure, a known risk factor for transfusion associated morbidities and 
mortality. Of the 61 patients in the study conducted by Offner et al there were a total of 732 
transfusions within the first 12 hours of the sustained injury 149. This transfusion rate equates 
to an average of 12 units per patient which is extremely high. While transfusion exposure was 
lower for patients in the study by Koch et al, on average 3 transfusions per patient, additional 
analysis identified a dose response effect for the composite morbidity outcome 51.  Further, 
while both where large clinical studies, it is difficult to truly attribute increased morbidity and 
mortality risk solely to storage time as any identified associations may be an end product of 
volume exposure 152.  
 
Importantly, some adult studies have failed to demonstrate any difference in outcomes 153. For 
example, only a 0.3% difference in mortality rate and no difference in length of hospital stay 
was seen in a study of over 3000 patient outcomes when analysed by receipt of fresh blood 
compared to packs stored for a longer duration 153. In fact, those exposed to packs with the 
shortest storage duration had a higher mortality rate. While not designed to investigate the 
underlying mechanism/s, the authors proposed that this could be related to significantly higher 
cytokine concentrations in ‘fresher’ packs described by earlier in-vitro studies 153.  
 
Similar to studies conducted in adults, paediatric clinical studies report conflicting results. In 
older paediatric populations, increased storage time affects RBC cytokine concentration and 
clinical outcomes 97, 154. Gauvin et al. found that the incidence of multi-organ dysfunction 
syndrome (MODS) was higher in patients who were transfused with older PRBCs (21 days) 
compared to those who received PRBCs stored for <14 days 154.  Similarly, Karam et al. found 
that patients who were exposed to older blood were more likely to develop MODS sooner than 




preterm infants are exposed to either fresh or older blood, no differences are seen between 
morbidity or mortality outcomes 155. It is important to acknowledge the generalisability of this 
data from other patient populations to the newborn infant. However, it does highlight 
consistent associations between the age of the PRBC pack and adverse patient outcome and 
therefore the potential for the PRBC pack to be biologically active in the critically unwell.  
 
While in-vitro studies have consistently shown that older blood has the greatest potential to 
initiate immunomodulation97, 146 it remains unknown if this is translated clinically. Recently it 
has been suggested that the immunomodulatory potential is dependent on the severity of 
illness the patient is experiencing at the time of transfusion exposure, similar to the two-hit 
hypothesis of TRIM 137. It seems logical that sicker patients are far more likely to experience 
increased morbidities irrespective of PRBC exposure. In an attempt to control for underlying 
disease severity. This may explain why some studies show an increase in adverse outcomes 
while others show no difference. Gauvin et al, found that patients were more likely to 
experience storage associated adverse effects when their degree of illness severity was 
substantial 154. However, Weinberg et al in a mild to moderately injured intensive care unit 
patient cohort, have reported that the receipt of blood stored beyond 2 weeks was 
independently associated with mortality, renal failure, and pneumonia. This data suggests that 
the deleterious effect of older blood on patient outcome may not be limited to the most unwell 
152.  
 
The potential for transfusion with “fresh blood” to reduce the incidence of adverse outcomes 
in the neonatal population was investigated in the ARIPI randomised controlled trial. In this 
study preterm infants weighing less than 1250 g received either a ‘fresh’ transfusion pack (<7 
days old) or standard (2-42 days old) 155.  No difference in mortality or morbidity rates was 




average age of the PRBC packs in the standard arm was only 14 days meaning that many babies 
in the standard group also received fresh donor blood.  Interpretation of the data is further 
confounded by a lack of a standard transfusion threshold between participating hospitals. This 
resulted in variability in the number of transfusions infants received between the study centres.  
This is an important consideration as it is already known that as the number of transfusions 
increase the chance of being exposed to immune inducing pathogens also increases 48.   
 
While in vitro studies demonstrate biologically plausible immune effects in response to 
prolonged storage which could have the potential to effect morbidity and mortality 137, whether 
they are clinically significant remains open to question. As a result, any link between age of 
transfused red blood cells and adverse outcome still needs to be definitively answered. At best, 
it could be proposed that for patients with an underlying illness exposure to fresh blood may 
be beneficial, but once there is repeat transfusion exposure, any clinical benefit is lost.  
2.3 Pre-Storage Leukodepletion  
Due to the accumulation of immune-active molecules in RBCs with storage, attempts have been 
made to ameliorate these time-dependent processes.  This has primarily centred upon pre-
storage leukodepletion of RBCs which is currently the standard procedure in most hospitals 
worldwide 123.  This process involves filtering blood following collection to reduce the white 
blood cell (WBC) count by 99.9%.  This processing step was developed on the premise that it 
would reduce transfusion-associated adverse outcomes by reducing immunomodulatory 
effects secondary to transfusion of leukocytes along with red blood cells.  
 
Sparrow and colleagues investigated the effects of different PRBC preparations (length of 
storage time, untreated blood, buffy coat deplete or leukodepleted) on accumulation of 




as the age of the pack increased, whereas blood that was both WBC-reduced pre-storage and 
buffy coat-poor had undetectable levels of IL-8 99. Leukodepleted PRBCs did not demonstrate 
induction of CD11b expression previously shown to be an important marker of neutrophil 
priming and transfusion related immunomodulation 99, 156. This is an important observation as 
primed neutrophils are thought to be a key component in the mechanism behind transfusion 
associated morbidities. When neutrophil priming occurs they are able to produce toxic oxygen 
metabolites ultimately resulting in a respiratory burst 156. Cardo et al reported similar results 
with in vitro exposure to leukodepleted blood resulting in significantly lower CD11b expression 
and a failure to prime cultured neutrophils 156.  
 
One of the first clinical studies to successfully demonstrate the benefit of leukodepletion was 
conducted by van de Watering et al 157. Patients were transfused with standard buffy coat 
deplete packs, packs which underwent leukodepletion prior to storage or packs filtered 
following storage. Patients exposed to buffy coat deplete packs had significantly greater 
mortality rates than those exposed to the leukodepleted packs irrespective of the time of 
filtration 157. Interestingly, some patients received a mixture of buffy coat and filtered packs. 
These patients still had a reduced mortality rate compared to those that exclusively received 
buffy coat deplete 157 suggesting that even  limited exposure to leukodepleted blood improves 
outcome. If the two-hit hypothesis underlying TRIM holds, this finding would suggest that 
despite sensitisation of the immune system following exposure of the buffy coat deplete pack 
there is no activation of the immune system with subsequent exposure to leukodepleted PRBC. 
Ultimately, the most important risk factors for mortality appear to be the cumulative exposure 
and timing of exposure 157.  
 
Similarly, Bilgin and colleagues found leukodepletion of PRBCs was associated with reduced 




undergoing cardiac surgery 118. However, in both standard and leukodepleted groups, as the 
number of transfusions increased mortality rates also increased supporting a dose response 
effect 118. Rates of infection were also decreased with leukodepleted transfusions. Likewise, 
when leukodepletion was universally instigated in the Canadian healthcare system there was a 
significant overall decrease in mortality rates, fever and antibiotic use 158. Initially the national 
Canadian healthcare study was designed to identify changes in infection rates. However, it also 
identified a strong association between exposures to buffy coat deplete blood and mortality 
rates, similar to that of Bilgn et al, with patients exposed to standard unfiltered RBC packs 
having two times higher mortality than the leukodepleted group 118, 158.  
 
A common criticism of transfusion trials identifying mortality risk is their failure to prove a 
causal relationship between changes in clinical practice and the outcome of interest and the 
heterogeneous nature of the study participants. For instance, Watkins et al proposed that the 
reduction in mortality associated with leukodepletion could be as a result of a reduction in 
acute lung injury following a transfusion 159. However, while respiratory distress was slightly 
less apparent for those exposed to the leukodepleted packed cells packs the overall incidence 
of Acute Lung Injury did not decrease 159. To control for patient heterogeneity, investigators 
have attempted to stratify participants within their allocated study arms to ensure equal 
distributions of common baseline characteristics which could influence the study outcomes. 
While this has resulted in a lessening of the benefit of leukodepletion on adverse outcome the 
effect remains 160, 161.  
 
Pre-storage leukodepletion of small volume pedi-packs used for neonatal transfusion results in 
undetectable levels of cytokines (TNF, IL-1, IL-6 and IL-10) within packs stored for 3, 21 and 42 
days, used in a population of very preterm infants (n= 27 PRBC units) 162. Furthermore, no 




leukodepleted PRBCs with the authors concluding that it was unlikely that pre-filtered RBCs 
result in cytokine changes in the recipient. This finding should be viewed with caution as patient 
sampling was discontinued early and samples were taken very early (1 hour post-transfusion), 
potentially missing any subsequent changes to cytokine levels. This is particularly important 
given that the cytokines sampled included early onset cytokines such as IL-1 and TNF which 
have an acute onset, whereas IL-6 and IL-10 show a later and more prolonged response 
potentially not peaking at the time point that the samples were taken 163. In the largest 
randomised controlled trial investigating the potential beneficial effect of using leukodepleted 
PRBC transfusions in preterm infants, Fergusson et al. found that the group of infants, 247 
infants born <1250 grams transfused with leukodepleted blood had a lower incidence of 
common neonatal morbidities such as ROP, BPD, and NEC, as well as a trend towards a 
reduction in bacteraemia and IVH 129.   
 
However, leukodepletion may not completely abrogate the immunomodulatory effect of PRBC 
transfusion with implications for longer term clinical outcomes. Keir et al. reported that 
leukodepleted RBCs continue to have an immune-modulatory effect in this population of high-
risk preterm infants.  Pre- and post-transfusion samples were obtained from 28 preterm infants 
(<28 weeks’ gestation) who received a transfusion of leukodepleted RBCs 63. Following 
transfusion of leukodepleted  PRBCs circulating levels of pro-inflammatory cytokine 
concentrations (IL-1ß, IL-8, TNF) and markers of endothelial activation (macrophage migration 
inhibitory factor and soluble intracellular adhesion molecule) increased in the neonatal 
circulation 63. Similar findings were reported by Dani and colleagues with interferon gamma 
(IFNγ), IL-17 and MCP-1 remaining elevated for 48 hours post-transfusion 37. Interestingly, 
these studies propose an additional mechanism, endothelial activation, which may contribute 




2.4 Repeated Transfusion Exposure 
Numerous observational studies have observed a dose response effect with increasing 
transfusion exposure and/or cumulative volume of blood transfused associated with a greater 
risk of morbidity and mortality 165. While this has led to a more restrictive approach to PRBC 
transfusion 47, 48, limiting both overall volume and donor exposure, the evidence supporting 
improved outcomes remains questionable 136.  
 
Most studies investigating adverse immune responses to transfusion have focused on a single 
transfusion event 162. Further, the majority of studies assessing the presence of a dose response 
effect have been retrospective analyses and, as such, have a number of methodological 
limitations.  Bernard and colleagues investigated the association between repeated transfusion 
exposure, post-operative infection rate and a composite morbidity score 49. The incidence of 
septic shock, pneumonia and a higher score on the composite morbidity rating scale increased 
not only after one transfusion but demonstrated a positive linear relationship with the number 
of transfusion units received 49. A similar, cumulative response was observed by Santos and 
colleagues with intra-hospital death within the first month of coronary artery bypass in adults 
increasing by 77% with every additional transfusion 50 .  
 
It could be argued that such a relationship is unsurprising with the increase in morbidity and 
mortality in fact reflecting greater physiological instability or number of co-morbidities in 
patients requiring multiple transfusions. However, when potential confounding factors are 
controlled for, such as surgery type, complexity and duration, mortality rates remain 
significantly higher following repeat PRBC transfusion exposure compared to those who did not 
receive a transfusion 49. Additionally, patients who were originally considered morbidity free 





While a “two-insult” hypothesis has been proposed to underlie TRIM, the exact mechanism/s 
causing this dose response effect remains poorly understood. It has been suggested that TRIM 
results in long term or permanent alteration to immune function 167 which is compounded by 
repeat transfusion exposure 50. While the volume needed to induce TRIM is likely highly patient 
specific 49, numerous studies have demonstrated immunomodulation following exposure to 3 
to 4 PRBC transfusions 49, 50, 166, 168.  While there is evidence for alterations in pro-inflammatory 
cytokine production and endothelial activation in response to single transfusion exposure 63, 
no studies have specifically investigated if repeat transfusion exposure results in similar adverse 
responses.  There is, however, circumstantial evidence that repeat transfusion may indeed lead 
to endothelial activation and increased morbidity with an association between repeat PRBC 
transfusion exposure and increased ischemic damage reported in adult cardiac patients 168.  
 
In the older paediatric population, oncology patients who received more than one transfusion 
with leukodepleted RBCs had lower survival rates than those exposed to only one transfusion 
169. Survival rates decreased further in those who received more than five transfusions 169.   
Other than the randomised controlled trials of restrictive versus liberal transfusion thresholds 
47, 48 and therefore, by default, repeat transfusion exposure in a significant proportion of the 
enrolled subjects, there is little data on the effect of repeat PRBC transfusions in the preterm 
population. Dos Santos et al have reported an independent dose response effect in response 
to transfusion exposure in the preterm, low birth weight population for morbidity and mortality 
risk 170. Over a thousand preterm or low birth weight infants were enrolled in this study with 
46% receiving their first transfusion within the first 28 days of life and over 30% subsequently 
receiving repeat transfusion exposures. If a transfusion occurred within the first 28 days of life, 
there was a 50% increased risk of mortality during the primary hospital admission and infants 
repeatedly transfused were two times more likely to die compared with non-transfused infants. 




respiratory distress syndrome (RDS), early and late onset sepsis, IVH and NEC 170, each of which 
are associated with poorer morbidity and mortality outcomes, transfusion remained an 
independent predictor of mortality when these factors were controlled for.  
2.5 Washed Transfusions 
Implementation of revised transfusion protocols that incorporate both leukodepletion and 
decreased storage time have not reduced the rate of transfusion-associated morbidities in 
preterm neonatal populations.  This has led to the study of additional blood processing steps 
prior to transfusion, designed to remove any residual immune-modulatory agents.  One such 
process is RBC washing where leukodepleted RBC packs are triple washed with 0.9% saline to 
remove the remaining microparticles, plasma proteins and antibodies 163. Initial research has 
shown promising results, with adult and paediatric patients transfused with leukodepleted, 
washed RBCs having significantly less morbidity compared to those transfused with only 
leukodepleted packs 171.   
 
RBC washing removes proteins, extracellular potassium, inflammatory cytokines and 
chemokines, as well as cell-free haemoglobin and RBC microparticles 172. This substantial 
reduction occurs not only when packs were washed at the initial storage time, but also 
following storage for a number of days. Biffl and colleagues investigated the influence of 
prolonged storage of RBCs on the beneficial effects of washing 173. Blood was collected from 
healthy adult volunteers with half undergoing leukodepletion on day one and the remainder 
left untreated. The transfusion packs were then stored for 42 days, with selected aliquots 
washed before isolation of the supernatant taken on days 1, 14, 21 and 42 of storage. As 
expected, with increasing storage time, the neutrophil priming ability increased irrespective of 
leukodepletion. However, when the packs reached the maximum storage time (42 days) in the 




of the RBC, with activity comparable to that seen with RBCs on the day of collection 173. 
Furthermore, in vivo studies have shown that incubation of pulmonary endothelial cells with 
supernatant from washed RBC transfusion packs is not associated with increased endothelial 
permeability or pro-inflammatory cytokine and chemokine release that is observed following 
incubation with supernatant from standard RBCs 172, 174.   
 
The evidence from clinical studies appears to support the beneficial effect of RBC washing on 
patient outcome. Cholette and colleagues investigated the effects of transfusing washed PRBCs 
on plasma cytokine concentrations in paediatric patients (<18 years of age) during cardiac 
surgery 163. At 6- and 12-hours post-surgery the ratio of pro-inflammatory (IL-6) to anti-
inflammatory (IL-10) cytokines was lower in patients transfused with washed versus unwashed 
PRBCs. While IL-6 concentrations were undetectable in both groups pre-operatively, the post-
transfusion increase in IL-6, peaking at 6 hours, was lower in patients transfused with washed 
PRBCs. There is also clinical data supporting an effect of RBC washing on survival following a 
diagnosis of acute myeloid or lymphoid leukaemia 171. Age of the pack and type of leukaemia 
were strong determining factors for predicting outcomes for patients >50 years of age 171. This 
did not influence outcomes for younger patients. However, exposure to washed PRBCs was 
associated with significantly longer survival rates for patients <50 years of age. When a bone 
marrow or stem cell transplant and a transfusion occurred together, receipt of a washed pack 
significantly increased survival compared to exposure of leukodepleted PRBCs. While younger 
patients initially had a greater likelihood of attaining and prolonging remission compared to 
that of older patients, the survival rate of 75% could not be explained by a mere age effect and 
is proposed to be a benefit of receiving washed blood. 
 
Not all evidence supports a beneficial effect of red blood cell washing. Wozniak and colleagues 




difference in perioperative serum IL-8 values or concentrations of plasma RBC microvesicles, 
platelet and leukocyte activation, plasma cell-free haemoglobin, endothelial activation, or 
biomarkers of heart, lung, or kidney injury in adult patients undergoing cardiac surgery 175. 
Further, the washing process itself may result in a decrease in haemoglobin and haematocrit 
and RBC damage and subsequent release of biologically active substances, including 
microparticles 172. Some studies have shown that patients who have been exposed to washed 
PRBCs require significantly more transfusions than those who receive standard PRBCs 175, 176. 
This has been proposed to be secondary to a reduction in red cell quality (up to 10-25%) 176. 
Despite this, animal data suggests the washing process does not significantly or irrevocably 
damage RBC appearance or function. While there were increases in cell-free haemoglobin, it 
was estimated that only 0.5% of erythrocytes were damaged. As a result, inflammatory 
cytokine levels were significantly decreased, not only within the pack, but also in the transfused 
recipient 177.  
 
Weisbach and colleagues investigated the effect of RBC washing on red cell quality in vitro and 
reported a significant reduction in free haemoglobin, 2, 3-DPG and an increase in lactate 176.  It 
is possible that these alterations could have been secondary to the fact that the RBC transfusion 
packs were stored at room temperature. This is known to result in a significant decrease in ATP, 
pH and 2, 3-DPG,  important components in red blood cell integrity 178, and an increase in 
haemolysis 179. The increase in microparticle number is thought to result from the additional 
filtration processes used to wash RBCs 172.  Using flow cytometry, antibodies to glycophorin A 
(GPA) and annexin V (AV) can be used to quantify RBC microparticles 172. The washing process 
changes the phenotype of microparticles from GPA, AV positive to GPA intermediate, AV 
negative 172.  Although the proportion of GPA, AV positive was significantly decreased, it was 




of this is not known, it is possible the new phenotype could have a different immunomodulatory 
effect on the recipient’s immune system.  
 
It is evident that transfusion-related injury is not merely dependent on one factor, e.g. storage 
time or exposure, but a myriad of influences. While appropriately designed and powered 
randomised trials have been conducted in adult 171 and paediatrics patients 163, there is a 
pressing need to conduct studies investigating the effect of pre-washing RBCs in the preterm 
newborn population, who are heavily transfused and have significant rates of morbidity and 
mortality . The knowledge gap in the adult population has been recognised and is currently 
being addressed by the Washing of Allogeneic Red Blood Cells for the Prevention of Respiratory 
Complications (WAR-PRC) study (ClinicalTrials.gov Identifier: NCT02094118) 180. However at the 
present time, there is insufficient evidence to support or refute the use of washed RBCs for 
transfusion in preterm infants to prevent morbidity or mortality 181. It is hoped that this 
question may be definitively answered by the Transfusion with washed versus unwashed red 
blood cells to reduce morbidity and mortality in infants born less than 28 weeks’ gestation: a 
multi-centre, blinded, parallel group, randomised controlled trial: (The WashT) study 
(Australian and New Zealand Clinical Trials Registry: ACTRN12613000237785) which is due to 
commence recruitment. 
3  Physiological Response to Transfusion  
While pre-clinical and emerging clinical data indicate an ability of RBC products to directly 
modulate immune cell function, a number of other pathophysiologic pathways have been 
postulated to contribute to the association of transfusion and subsequent adverse outcome. 
Anaemia itself, rather than transfusion exposure, may be the driving force behind the 
development of apparent transfusion-associated morbidities 182. In particular, the degree of 




infant 65. This is based on the clinical consequences of anaemia such as tachycardia, apnoea, 
and lactic acidosis, which have traditionally led to the clinical decision to transfuse. 
Furthermore, it is possible that the recognised major transfusion-related morbidities, 
particularly TRALI, TACO, and transfusion-associated dyspnoea represent exaggerated 
physiological responses to transfusion. As a result, a clear understanding of the normal 
response to progressive anaemia and the cardiovascular, respiratory and haemodynamic 
response to subsequent transfusion is critical. 
3.1 Cardiovascular Responses to Packed Red Blood Cell Transfusion  
A number of studies have documented compensatory haemodynamic changes in response to 
anaemia and subsequent transfusion. Fredrickson and colleagues found infants with a low 
haemoglobin (haematocrit ≤9) following transfusion demonstrated a significant improvement 
in cardiac output, 301 mL/min/kg pre-transfusion verses 253 mL/min/kg post-transfusion 120. 
These changes were seen in conjunction with a decrease in lactate and increases in a number 
of measures representing oxygenation. In a population of sick, ventilated preterm infants, 
Cambonie and colleagues found that following a transfusion in the first postnatal week there 
was a significant increase in both stroke volume and left ventricular output (LVO) 183. 
 
Alkalay and colleagues investigated the effects of progressive anaemia and its impact on the 
cardio-respiratory system. In a group of preterm infants considered “stable”, extubated and 
with no evidence of a patent ductus arteriosus, tachycardia, tachypnoea or apnoea, transfusion 
resulted in an increase in systolic and diastolic blood pressure, but contrary to the Cambonie 
study, no change in left ventricular function or stroke volume 119. However, on closer inspection 
of the data, those infants with the lowest haematocrit exhibited a larger increase in cardiac 
output with a significantly greater left ventricular end diastolic and systolic diameter in addition 
to increased stroke volume 119. Interestingly, in those infants with higher haematocrits, 




cardio-respiratory effects following transfusion. It remains unclear if this may be due to 
alterations in pulmonary blood flow following transfusion or inflammatory processes as seen in 
TRALI secondary to TRIM.  
 
As previously stated, a transfusion is given in order to correct the consequences of anaemia, 
such as tachycardia, tachypnoea and apnoea. Therefore, theoretically there should be a 
decrease in cardiac output due to an increase in haemoglobin and therefore oxygen delivery. 
Kanmaz and colleagues studied 35 ‘stable’ preterm infants who were less than 35 weeks’ 
gestation. Following a 15mL/kg leukodepleted PRBC transfusion there was a significant 
decrease in cardiac output and lactate and an increase in perfusion index 184. However, the 
degree of anaemia (determined by haematocrit) correlated poorly with the post-transfusion 
changes in cardiac function. Similar findings are reported by Yu and colleagues with significant 
decreases in cardiac output and stroke volume following a PRBC transfusion, but no change in 
heart rate or blood pressure noted 185.  
3.2 Cerebrovascular Changes and Red Blood Cell Transfusion 
Fluctuations in systemic and cerebral blood flow have been associated with the development 
of IVH in the preterm infant 186. Therefore, it is possible that PRBC transfusion-associated 
changes in haemodynamic responses may have a detrimental effect on the developing 
cerebrovascular system primarily due to immaturity of cerebral autoregulation 186. Nelle and 
colleagues found that following a transfusion there was a significant decrease in cardiac output 
and stroke volume 187. While blood flow velocities decreased significantly in the anterior 
cerebral artery and the internal carotid artery, red cell transport in the internal carotid artery 
but not the anterior cerebral artery rose. Assuming that the blood flow velocities in cerebral 
arteries reflect the actual blood flows, this suggests that the overall oxygen transport to the 





These findings have been replicated by a number of studies. In a small study of 23 transfused 
preterm infants. Quante et al described initially high cardiac output and anterior cerebral artery 
blood flow pre-transfusion which both fell and remained significantly lower up to 72 hours post 
transfusion 188. Similarly, Ramaekers and colleagues showed that cerebral blood flow velocity 
in stable preterm infants decreases with transfusion in accordance with the increase in oxygen 
supply 189. This has been confirmed by studies employing Near Infra-Red Spectroscopy (NIRS) 
and Cerebral Doppler Ultrasonography that confirm that blood transfusion related 
improvements in cerebral oxygen supply occur hand-in-hand with decreases in cerebral blood 
flow velocity 190-192.  
3.3 Peripheral Haemodynamic Response and Red Blood Cell Transfusion 
While most attention has been given to cardiovascular and cerebro-vascular responses to 
packed red blood cell transfusion, transfusion also impacts upon the perfusion and oxygenation 
of other tissues. Perhaps the most pertinent in the preterm infant are transfusion related 
alterations in blood flow to the gut which are proposed to be a contributary factor in the 
development of NEC 193. Intriguingly, the cerebro-splanchnic oxygenation ratio where near 
infra-red spectroscopy derived tissue oxygenation of the cerebral and splanchnic circulations is 
compared, decreases in NEC, consistent with independent regulation of the gut and cerebral 
vascular beds 194. Is it proposed that the splanchnic circulation in the preterm infant is less 
adept to vascular regulation 194, therefore a transfusion can lead to variability in perfusion and 
oxygen delivery 194.  
 
Preterm infants receiving a blood transfusion in the presence of a significant Patent Ductus 
Arteriosus (PDA) show a reduction in mesenteric flow 4 hours after transfusion, an effect 
proportional to the volume of a PRBC transfusion 193. However, even in the absence of a 
clinically significant PDA, transfusions per se are associated with increases in viscosity and 




measurement of gut regional tissue oxygenation 190, 195. However, evidence for changes in 
mesenteric vessel mean flow velocity is more contentious with some studies in stable preterm 
infants showing no change in splanchnic and mesenteric arterial blood velocity 196.  
 4  Role of the Sex of Transfusion Donor  
While characteristics of the donor have been extensively investigated in the solid organ 
donation literature, characteristics of blood donors has been relatively under researched. This 
is despite a blood donation having the potential to exert a similar immunological effect in the 
recipient to that of organ donation 197. Emerging evidence suggests that blood donor 
characteristics may indeed influence a recipient’s response, although the biological 
mechanisms underpinning this response remain elusive 198. While the majority of research to 
date has focused on plasma and the morbidities associated with plasma exposure, there is 
increasing awareness that exposure to red blood cells poses a similar risk 199. In addition, the 
majority of existing studies in the literature are observational and retrospective, meaning the 
risk of bias is high and the interpretation of results limited.  
4.1 Human Leukocyte Antibodies  
In 1983, Popovsky and colleagues described a condition in which patients experienced 
respiratory complications following a transfusion 200. These complications were 
undistinguishable from the adult presentation of acute respiratory distress syndrome 200 and 
consequently the term TRALI was coined. They identified that 90 percent of patients thought 
to meet a TRALI diagnosis had been exposed to blood products from a donor containing 
antibodies reacting to either Human Leukocyte Antigen (HLA) or Human Neutrophil Antigen 
(HNA) in the transfusion serum 201. While the exact pathogenesis behind TRALI development is 
still unclear, HLA antibody involvement has been as a proposed mechanism, particularly for 
blood products from a from a female donor where the induction of anti-fetal antibodies occur 




HLA molecules are part of the human major histocompatibility system (MHC) and are a family 
of cell surface glycoproteins that bind to intracellular and extracellular peptides 203. The HLA 
family is located on chromosome 6, which contains hundreds of genes, including 40 of which 
encode leukocyte antigens 204. The HLA family is further separated into two distinct functional 
and structural groups; HLA Class I and HLA Class II 205. Class I HLA antigens are carried in varying 
degrees on almost all nucleated cells. Class II antigens are carried on immune cells such as 
activated T cells, B cells, macrophages, dendritic cells, cells of the thymus with other cells are 
able to express Class II molecules through exposure to interferon-γ 204.  The HLA molecule is 
critical for the induction and regulation of immune responses 205.  In a normal immune response 
circulating T-cells recognise and interact with foreign HLA molecules, resulting in T-cell 
activation. Through this activation there is a significant increase in T-cell number and 
consequently a release of cytokines resulting in an immune response 205. The mechanisms in 
which the two HLA classes work are different. HLA Class I molecules directly present invading 
viruses to CD8 T-cells which destroy the infected cell 205. HLA Class II molecules present 
exogenous peptides to CD4 T-cells, which stimulate a widespread immune response 205.  
 
In the setting of an inappropriate immune response, such as with organ transplant or 
transfusion, the immune response produced by the HLA molecules is rapid and extremely 
robust 206. The HLA response is thought to be so powerful due to a high degree of polymorphism 
increasing the possibility of transfusing incompatible products or tissues 207 and the HLA 
system’s ability to not only elicit an immune response directly but also indirectly 204. This is 
thought to occur through HLA molecules circulating through the spleen allowing splenic 
macrophages and dendritic cells to stimulate the recipient’s adaptive immune response 205. An 
aberrant HLA response has been identified in a number of autoimmune conditions as well as 




haemochromatosis 208. However, the most widely researched area is transplant medicine 206, 
208 where donor specific HLA antibodies have been linked to transplant injury 209.  
 
How HLA antibodies cause a transfusion reaction is not fully understood for all transfusion 
associated conditions. In the case of TRALI, it is thought that anti-HLA or HNA antibodies bind 
and stimulate circulating leukocytes, neutrophils and other cytotoxic cells which subsequently 
release reactive oxygen species resulting in pulmonary microvascular endothelial damage 210. 
This initiates an inflammatory response in the lungs, causing an increase in oedema and fluid 
in the alveoli and the respiratory complications likened with TRALI 206. However, not all 
transfused patients go on to develop antibody-mediated complications with the individual’s 
predisposition being the greatest determining factor 210. In the setting of TRALI, this may be 
trauma or an inflammatory condition involving the lung. A threshold model has also been 
proposed with the HLA antibodies ability to prime cells of the inflammatory system reliant on 
the patient’s predisposition. This then dictates the oxygen sufficiency and oxygen requirement 
and in turn the severity of TRALI 210.  Both HLA Class I antibodies and HLA Class II antibodies 
have been linked with development of TRALI. However, Class I antibodies are thought to pose 
the greatest mortality risk with one study finding that 62% of mortality cases were associated 
with HLA Class I antibodies with Class II antibodies accounting for just 11% 211. 
 
To date, platelets and plasma products have been the key blood products thought to have a 
role in antibody-mediated pathophysiological processes 212. With platelets the HLA molecule 
on the platelets’ surface is readily detached during storage 205. Therefore, over the course of 
storage, a significant number of HLA antigens are shed and the transfused patient potentially 
exposed to a high dose of donor HLA antigens 205. Universal leukodepletion and storage time 
limits were thought to be the solution to the risk posed by HLA 207. However, this has not been 




Class I is present at low levels or absent from erythrocytes 205. Therefore, the role of RBCs in 
antibody-mediated transfusion reactions has been largely overlooked. However, a single RBC 
can carry around 100 to 2000 Class I HLA and with 1000 times more red blood cells to 
leukocytes in a leukodepleted PRBC transfusion pack, the HLA content may still be as large 212.  
4.2 Sex of Donor and Plasma Transfusions 
Historically, the greatest risk posed by transfusion has been the potential for the transmission 
of viral infections, yet with considerable research and technical advances focussed on 
minimising this risk, the risk of transfusion related viral infections is now extremely low 202. In 
fact, blood product transfusions are now the safest they have ever been 213. As a result, 
transfusion related inflammatory conditions are now of greatest concern. One of these 
inflammatory conditions is TRALI which has become one of the leading transfusion related 
morbidities 202. In the early 90’s rates of TRALI were worryingly high and therefore the Serious 
Hazards of Transfusion (SHOT) group in the United Kingdom conducted the largest study 
focusing on a ten-year period specifically looking at the incidence of TRALI, leukocyte antibodies 
and proposed risk reduction steps. Chapman and colleagues investigated the clinical and 
practical implementations of a male donor only plasma strategy and found that simply through 
adoption of a male only donor strategy a 79% reduction in highly likely or probable TRALI cases 
could be achieved 202. However, this reduction was only seen for patients exposed to fresh 
frozen plasma (FFP) and platelets (PLTs). Interestingly, FFP was almost 7 times more likely to 
be associated with a TRALI diagnosis than RBCs and PLTs were 8 times more likely than RBCs 
202.  In addition, and consistent with very early work 214, 215, was the significant number of 
antibody positive female donors associated with all TRALI episodes, with 65% having an 
identified antibody type 202. Interestingly, HLA Class II accounted for 61% of antibodies detected 





The high levels of HLA Class II antibodies is contradictory to previous research, showing an 
increased association between TRALI and the presence of HLA Class I antigens rather than HLA 
Class II 211. A role for HLA Class II antibodies in TRALI has previously been questioned, as they 
are not carried on neutrophils 216, the immune cell thought to be central to the pathogenesis 
of this condition 210. Reil and colleagues tested over five thousand donors to specify HLA and 
HNA type and linked this with an acute respiratory event and reported similar findings to the 
SHOT study. While HLA Class I antibodies represented 73% of the antibodies detected, only 
19% were associated with an acute respiratory event 217. The authors postulated that while HLA 
Class I antibodies were more common, they are less potent 217. Interestingly, when all 
respiratory events were investigated, they found that over 81% of cases were associated with 
HLA Class II and HNA antibodies, despite these representing only 36% of the overall antibodies 
detected in the donor pool 217. This may be the result of a secondary mechanism through which 
HLA Class II antibodies can induce neutrophils 218. It is thought that HLA Class II antibodies may 
activate accumulated neutrophils in the pulmonary microvasculature by binding to monocytes 
and consequently releasing pro-inflammatory cytokines 218 explaining the strong association 
between the less frequently expressed Class II antibody and post-transfusion respiratory 
deterioration. 
 
Despite the significant reduction in the incidence of TRALI following the adoption of the male 
only donor plasma strategy, a number of questions remain. In Australia, the most recent data 
from the National Blood Authority of Australia reports rates of TRALI of 1.4%, suggesting a high 
level of underdiagnoses, particularly compared to levels reported internationally 219. The SHOT 
study relied on clinician awareness of the research studies aim when reporting whether 
patients met the current guidelines at the time, introducing an element of bias from both 
under- and over-reporting 202. Therefore, the 79% reduction in TRALI cases may not be an 




types was not taken into account. This is likely to be important with data for PRBC transfusion, 
for instance, reporting a significantly greater mortality risk in patients exposed to multiple 
transfusions (3 or more) even following adjustment for confounding variables 49, 166. 
 
Tynell and colleagues, investigating short-term mortality rates after plasma transfusion in 
adults specifically addressed the issues of donor sex and multiple transfusion exposure 220. In a 
retrospective analysis of almost 100,000 patients in 30 Swedish hospitals, they found that it 
was not until patients were exposed to 3 or more transfusions that there was an increase in 
mortality. Further, 14-day mortality rates were higher in those patients who received plasma 
from female donors compared to those who received plasma from males (8.43% versus 7.5%). 
After controlling for potential confounding variables, the relative risk of mortality increased in 
those exposed to 5 or more plasma transfusions compared to 3-4 (1.32 (CI1.17-1.49) versus 
1.16 (CI 1.06-1.27). While the influence of disease severity remains an important consideration, 
they concluded that transfusion of plasma from female donors confers a short-term survival 
disadvantage, an effect that appeared dose dependent 220. Eder and colleagues evaluated the 
implementation of a similar male donor only policy throughout the American Red Cross in a 
heterogenous population of oncology, cardiac and infectious disease patients with a particular 
focus on mortality 215. Although the study design again raises the possibility of selection bias, 
the data from this study is consistent, with over 71% of patients with TRALI who subsequently 
died receiving plasma from an antibody positive female 215. 
 
Very few studies have looked at the effects of mixed transfusions, an element that we know 
may change or suggest the overall severity of the patient’s clinical state. Gajic and colleagues 
investigated the effect of exposure to 3 or more transfusion components (platelet and/or 
plasma) from either male or female donors on respiratory instability. While rates of lung injury 




more male donor packs were more likely to have fewer ventilated days 221. Further, in patients 
that were exposed to a transfusion product from a female donor, the PaO2/FiO2 ratio worsened 
significantly 221. PaO2/FiO2 ratio is commonly used as a proxy measure for lung injury in the 
adult and paediatric populations and has been shown to have a strong relationship with disease 
severity and mortality risk 222. While the authors concluded that high volume transfusions of 
FFP and PLTs seemed to be more clinically important than transfusions of RBCs, almost 95% of 
patients exposed to FFP or PLTs also require a PRBC transfusion 223.   
 
Interestingly, all studies observed a significant increase in the number of deaths in patients who 
were exposed to a multiparous woman’s blood. This is primarily thought to be due to the 
generation of anti-fetal antibodies in pregnancy. The only prospective double blinded 
randomised trial in donor sex research investigated whether using blood from a female who 
had previously been pregnant resulted in both an inflammatory response (characterised by 
circulating cytokines) and clinically significant sequelae. Patients requiring at least 2 
transfusions of plasma were eligible and these patients either received blood from a ‘non-
immunised’ donor (never pregnant or transfused) or ‘immunised’ donor (previously had 3 or 
more live births). TNF concentrations significantly increased following transfusion exposure 
irrespective of whether they received plasma from an immunised or non-immunised donor 224. 
However, the increase in TNF was far more pronounced in those who received plasma from 
immunised donors. In addition, patients in this study arm had a significant decrease in their 
PaO2/FiO2 ratio, whereas mean blood pressure (MBP) significantly increased for patients in the 
non-immunised study arm 224. The authors proposed that together, the changes in PaO2/FiO2 
and TNF concentration represented impairment and severity of lung injury. What mechanism/s 
underlie the association between adverse outcome and repeated exposure to blood products 





The retrospective nature of donor gender studies does mean, as a result of inherent bias, they 
are methodologically flawed. It has been suggested that the true effect of female donor 
exposure will only be definitively worked out through a randomised trial. Interestingly, many 
patients exposed to transfusion packs from a female donor do not exhibit any negative 
consequences. Therefore, it is highly likely to be patient specific and related to the proposed 
two-hit hypothesis or threshold model. It is clear that universal leukodepletion has not 
accomplished prevention of antibody mediated TRALI 207 and that TRALI is not limited to 
exposure to plasma and platelet transfusions. All studies have failed to acknowledge the role 
that red blood cells may play in the donor effect with most concluding that the evidence for 
red cells is not strong enough to justify any need for change in red cell practice. While it was 
previously thought that 50% or more of plasma is required to illicit a TRALI response it is now 
hypothesised that less than 10% of plasma may be needed 225. In fact, of the TRALI cases 
reported to the Canadian blood service between 1998 and 2004, 31% were implicated with 
PRBCs, 29% with PLTs and 18% with FFP 225. Taking into account the extremely low residual 
plasma in an PRBC transfusion, this highlights the danger that a PRBC transfusion may pose to 
the patient. 
4.3 Sex of Donor and Red Blood Cell Transfusions  
Red blood cell transfusions are one of the most common medical interventions with more than 
100 million red cell packs collected and transfused worldwide each year 197. Yet the RBC has 
been largely discounted as a contributor to HLA sensitisation due to the low levels carried on 
RBCs and RBC pack alterations such as leukodepletion. The adult literature specifically focusing 
on PRBC transfusion is conflicting with most concluding there is no effect of donor sex on the 
incidence of transfusion associated morbidities 226, 227. However, Chasse and colleagues have 
reported an association between donor sex and cumulative exposure and survival after PRBC 
transfusion. The transfusion of each additional PRBC unit from a female donor was associated 




1.08; 95% CI, 1.06-1.09 for each additional unit transfused; P < 0.001). They found that female 
sex was associated with reduced survival in both male recipients (adjusted HR, 1.08; 95% CI, 
1.07-1.10 for each additional unit transfused; P <0.001) and female recipients (adjusted HR, 
1.03; 95%CI, 1.02-1.05 for each additional unit transfused; P < .001).  
 
However, in a retrospective study of 9907 patients who had undergone coronary artery bypass 
grafting or aortic valve replacement surgery, Bjursten and colleagues investigated a range of 
transfusion related risk factors including the age of the blood product, sex of the donor, sex 
matching of the donor and recipient, as well as post-transfusion treatment 228.  While they 
found a significant association between mortality and transfusion of 1-2 units of non-
leukodepleted PRBCs they also found an excess of mortality for transfusions of sex mismatched 
PRBCs but not specifically transfusion recipients receiving blood from female donors 228.   
 
Importantly, a meta-analysis investigating the associations between donor characteristics and 
short- and long-term transfusion outcomes for the transfused recipient has re-visited the 
potential role of donor sex 229. From the 59 studies that met the eligibility criteria (50 
observational, 9 interventional), 17 donor characteristics where identified that influenced 
transfusion outcome. Donor sex demonstrated associations with reduced survival at 90 days 
and 6 months in male recipients who receive donated blood from females (hazard ratio 2.60 
[1.09, 6.20] and hazard ratio 2.40 [1.10, 5.24], respectively) 229. However, the risk of bias and 
confounding of all the included studies was high and the quality of evidence was graded as very 
low to low.  
 
There are numerous studies looking at potential inherent biological differences between male 
and female red cells 230-232. In vitro studies have shown that male RBCs have a greater level of 




contributor to transfusion associated morbidities 230. Meanwhile, RBCs from females show 
greater reductions in acetylcholinesterase enzyme activity and subsequent increased 
membrane rigidity following exposure to adrenaline 231. Whether sex-specific differences in the 
RBC themselves are of clinical importance and contribute to a sex-specific risk of transfusion 
related adverse outcome remains unknown. 
 
As previously stated, HLA sensitisation occurs following organ transplantation, pregnancy and 
previous blood transfusions 212. The complexity of HLA sensitisation and subsequent interaction 
is often overlooked for a far more simplified, however misconceived view of the RBCs’ role. 
Approximately 20% of multiparous women have circulating HLA antibodies, therefore a woman 
of child bearing age may pose the greatest risk to the transfused recipient 207. While no 
difference in transfusion related mortality is observed between recipients who receive blood 
from female donors with no history of pregnancy compared to from a male donor, the risk 
significantly increased for all male patients transfused with RBCs from a female donor with any 
history of pregnancy 233.  Importantly, this effect was enduring, with no limit to the time from 
pregnancy to transfusion and adverse outcome seen. Interestingly, this association was also 
influenced by the age of the transfusion recipient. The strongest association between 
transfusion with PRBCs from a previously pregnant female donor and mortality was seen for 
male patients 0 – 17 years of age (n= 2534) who received 2 or more transfusions. In fact, the 
youngest males were almost two times more likely to die if they received PRBCs from an ever-
pregnant female donor 233. However, this effect only occurred if all transfusions were from 
previously pregnant female donors.  
 
There is currently only a single study that has focused solely on the potential for donor sex 
specific effects in a preterm population. Murphy and colleagues looked at 170 extremely 




and female donor PRBCs. Infants who received any PRBC transfusions from a female donor had 
significantly higher rates of BPD, SIP/NEC and any morbidity or death. In addition, these infants 
also had significantly longer length of NICU stay 234. This group were, importantly, also exposed 
to a greater number of transfusions overall. When this was controlled for the effect of donor 
sex was lost, with only increasing transfusion exposure associated with BPD, any morbidity, and 
length of stay 234. However, subset regression analysis comparing PRBC transfusion from 
exclusively female donors with transfusion with male donor blood, demonstrated a significant 
interaction between female donor blood and number of transfusions for any morbidity. This is 
consistent with the result from the study by Chasse and colleagues where the odds of any 
morbidity increased when additional transfusions were from a female donor 234. The authors 
concluded that while their data appears to suggest that donor sex impacts the preterm infant’s 
response to transfusion, large prospective clinical trials are needed to determine not only the 
significance of the associations, but also the likely causal pathways involved. 
 
While contentious, these results seem to suggest that the greatest risk to the transfused 
population is exposure to blood from a female who has been pregnant. This has vast 
consequences for the donation community and in particular, the preterm population. It is clear 
that the challenge for transfusion medicine is to further minimise the risk of transfusion-
associated morbidities, while maintaining a healthy balance between those eligible and 
ineligible for the donor pool. While other common medical interventions such as 
pharmaceuticals are highly regulated and have almost no product variation, each blood donor 
and blood product are biologically different. The blood donor is therefore the greatest source 
of variability and still the least regulated step, with little likelihood of achieving standardisation 




5  Summary 
Although transfusion of packed red blood cells saves lives in the neonatal intensive care setting, 
there is increasing awareness that transfusion is an independent predictor of adverse outcome. 
Whether these associations are a response to RBCs themselves, the time-dependent 
accumulation of bioactive substances in the supernatant, or both, remains unknown. A growing 
body of data supports a potentially detrimental pro-inflammatory response to transfusion, 
resulting in endothelial activation in the extremely preterm infant, though these studies have 
focused on a single transfusion exposure during the convalescent period weeks after birth 37, 
63. However, extremely preterm infants are a particularly heavily transfused patient group, 
receiving on average 3-5 blood transfusions often early in their admission to NICU 48. 
 
Evidence in other critically ill populations supports significant benefit from modifications in 
blood product processing including RBC washing. This has never been studied in the preterm 
infant. Therefore, this thesis will compare the response to repeat transfusion exposure with 
standard unwashed leukodepleted PRBCs to transfusion with washed leukodepleted PRBCs in 
the extremely preterm infant. Specifically, I will focus on two potential pathways through which 
transfusion exposure may be related to adverse neonatal outcome. I will investigate if 
transfusion with washed packed RBCs results in a reduced transfusion-related inflammatory 
response. I will also investigate whether the acute physiological response to transfusion, in 
particular changes in cardio-respiratory stability, differs between those transfused with 
unwashed versus washed PRBCs and whether these physiological responses are influenced by 
transfusion-related immunomodulation. Finally, I will investigate if the sex of the PRBC donor 
confers additional benefit to the transfusion recipient, further reducing the risk of adverse 


















2.1  Background 
Extremely low gestational age infants are at a greater risk of poor outcome than any other 
population, thereby incurring substantial societal and economic cost. As such any reduction in 
mortality in combination with improvement in survival free of significant neonatal morbidity 
would be of substantial short and long-term benefit. Emerging evidence in other critically ill 
populations supports significant benefit from modifications in blood product processing 
including RBC washing, though this has never been studied in the preterm infant. There is 
increasing awareness that transfusion of blood products may be an independent predictor of 
adverse outcome with the incidence and severity of major neonatal morbidities including BPD, 
IVH, ROP and NEC, associated with the number and volume of PRBC transfusions 7. Limitations 
in the existing data, including retrospective study design and small sample size, mean there is 
a pressing need for large studies to be conducted prospectively to address ongoing uncertainty 
about the safety of transfusion in this heavily transfused population. 
Whether these associations are a response to red blood cells themselves, the time-dependent 
accumulation of bioactive substances in the supernatant (storage lesion), or both 100, remains 
unknown. This thesis will determine the potential for transfusion with washed PRBCs to modify 
the transfusion recipient’s immune response to transfusion exposure. This will be a critical first 
step which will inform large scale clinical studies powered to determine if this intervention 
reduces the incidence of transfusion associated neonatal mortality and increase survival free 
of significant neonatal morbidity when compared to current standard PRBC transfusion 
practice. As such, data from this thesis will contribute to bridging the gap between research 
regarding transfusion related adverse outcome and translation into practice. The study 
outcomes will likely have enormous clinical benefit to the extremely preterm infant in whom 




2.2  Aims 
The study will examine the potential benefit of using washed leukodepleted red blood cells as 
an alternate transfusion product for extremely preterm infants. 
1. To determine the effect of pre-transfusion washing of allogeneic red blood cells on end 
organ physiologic stability in preterm infants <29 weeks’ gestation receiving a transfusion. 
2. To determine whether transfusion of washed leukodepleted red blood cells results in a 
reduction in post-transfusion levels of pro-inflammatory cytokines and markers of 
endothelial activation.  
3. To establish the effect of pre-transfusion allogeneic red blood cell washing on donor sex 
related immune responses in the transfusion recipient. 
2.3  Hypotheses  
Based on previous research, I hypothesise that preterm infants <29 weeks’ gestation 
transfused with washed red blood cells will exhibit a reduced pro-inflammatory response 
compared to those transfused with unwashed red blood cells.  
1. Washed compared with unwashed leukodepleted allogeneic red blood cell transfusion will 
attenuate adverse physiological end organ responses in the preterm infant.  
2. Washed compared with unwashed leukodepleted allogeneic red blood cell transfusion will 
attenuate inflammatory and endothelial responses in the preterm infant  
3. Washed compared with unwashed leukodepleted allogeneic red blood cell transfusion will 
attenuate donor sex related effects on immune responses in the transfusion recipient, 
















3.2 Participant Recruitment and Randomisation 
3.2.1 Participant Recruitment  
Transfusion naïve extremely preterm infants born less than 29 weeks at the Women’s and 
Children’s Hospital, Adelaide, Australia and Flinders Medical Centre Neonatal Unit, Adelaide, 
Australia were eligible for study enrolment. Potential families were screened and approached 
at the time of delivery or prior to the newborns’ first elective transfusion. Infants with major 
congenital abnormalities or those infants who had already received an elective transfusion 
were excluded from recruitment. All parents gave written, informed consent for their 
newborns’ participation (Appendix 1.1 & Appendix 1.2). The study was approved by The 
Australian Red Cross Blood Service Human Research Ethics Committee (ethics approval number 
2013#06) (Appendix 2.1) and the Women’s and Children’s Hospital Human Research Ethics 
Committee (ethics approval number REC 2498/9/15, HREC/12/WCHN/5, SSA/12/WCHN/56, 
SSA/17/SAC/230) (Appendix 3.2) with site-specific approval obtained from Southern Adelaide 
Local Health Network. An amended ethics submission was approved by the Australian Red 
Cross to obtain the sex of the transfusion donor (ethics approval number 2013#06) (Appendix 
3.3).  
3.2.2 Haemoglobin Trigger for Transfusion  
The decision to transfuse was based on a pre-defined restrictive haemoglobin threshold as per 
the Premature Infants in Need of Transfusion (PINT) study (Table 3.1)48. Haemoglobin levels 










3.2.3 Subject Randomisation 
Subject randomisation for both study sites was undertaken by the on-call transfusion 
laboratory technician. Transfusion laboratory staff were unblinded to red cell pack type 
allocation in line with Australian Red Cross Blood Service guidelines for safe provision of RBCs 
for transfusion. A computer-generated randomisation schedule using balanced variable block 
design of 6 was generated with infants randomised into unwashed or washed groups with an 
allocation ratio of 1:1. Within each study arm, infants were stratified by gestational age, 23+0 
to 25+6 and 26+0 to 28+6 weeks. For any additional transfusions an infant required, RBC pack 
type consistent with the original allocation was issued. Infants were transfused according to 
standard nursery practice, fasting for 4 hours prior, for the duration of, and for 4 hours after 
the transfusion. At WCH site fasted infants received either total parenteral nutrition or for 
those who had already reached full enteral feeds prior to fasting, intravenous 10% dextrose. At 
the FMC site, infants requiring a transfusion were not fasted. The contribution of enteral 
feeding during transfusion to significant morbidity, specifically NEC, is debated and is the 
subject of the ongoing WHEAT randomised control trial 236. All transfusions were a fixed volume 
of 15mL/kg, transfused over 3 hours via a peripheral intravenous cannula.  
3.2.4 Red Blood Cell Manufacture, Blinding and Storage  
All RBCs were leukodepleted, O Rhesus (Rh) negative. Only O Rh negative packs were only used 
to limit pack wastage and was standard practice at the study sites. Three day old, 
Table 3.1 Transfusion algorithm based upon modified transfusion threshold employed in 
the PINT study 
Age 
(days) 
Blood sampling Respiratory  
support* 
No respiratory  
support* 
1-7 Capillary ≤135 ≤120 
 Central ≤122 ≤109 
8-14 Capillary ≤120 ≤100 
 Central ≤109 ≤90 
≥15 Capillary ≤100 ≤85 
 Central ≤90 ≤77 




leukodepleted, O Rh negative, RBC packs were washed by the Red Cross Blood Service. This 
involved three consecutive washing steps with 200mL 0.9% saline following collection and prior 
to storage. At each wash, saline was removed from packs by centrifugation at 2900 x g for 5 
minutes (wash 1 and 2) and 5000 x g for 5 minutes (wash 3). Red cells were then resuspended 
in 100mL Saline Adenine Glucose Mannitol (SAG-M) and divided into 4 paediatric packs and 
stored at 2 – 6 ֯ C for a maximum of 14 days. For both unwashed and washed packs, storage 
was limited to 14 days to control for ‘storage lesion’. Blood products required for the study (4 
unwashed leukodepleted packs and 4 washed leukodepleted packs) were obtained weekly 
from The Australian Red Cross Blood Service in Victoria and the order adjusted according to 
demand if needed. A washed pack was retained at the distributing site for quality control 
purposes. All packs leukodepleted and washed remained at the central WCH site and were 
issued to both neonatal nurseries by the WCH transfusion laboratory.  
 
Study investigators, attending clinicians and nursing staff and parents were blinded to product 
allocation through the use of an opaque sticker applied to the transfusion pack by the 
transfusion laboratory. This alteration was approved by the Australian Red Cross Ethics 
Committee (ID2013#6). Transfusion pack issue and administration complied with all other 
current ordering and safety protocols. Compliance with the randomised intervention was 
managed by the transfusion laboratory with each study participant and allocated product 
identified electronically.   
3.3 Clinical Data Collection 
3.3.1 Plasma Collection 
Infants had 0.4mL venous or peripheral capillary whole blood samples collected in lithium 
heparin tubes immediately prior to and 4-6 hours following the completion of the transfusion. 




at 3500 x g for 5 minutes and with the plasma aliquot stored at -20C for batched cytokine 
analysis.   
3.3.2 Cardio-Respiratory Data Collection 
In order to understand and determine the normal physiological responses to progressive 
anaemia and the hemodynamic, cardiovascular and respiratory responses to a transfusion, a 
number of physiological parameters were collected at the primary transfusion exposure. Data 
immediately prior to the transfusion, throughout and then up to 10 hours following their 
transfusion exposure was collected retrospectively from the subject’s medical record (Tables 
3.2, 3.3, 3.4). Systolic (SBP), diastolic (DBP) and mean arterial blood pressure (MBP) was 
measured invasively from an umbilical arterial catheter or peripheral arterial catheter, when 
present, or by non-invasive blood pressure measurement. Heart rate (HR) and respiratory rate 
(RR) were measured using ECG electrodes and the impedance pneumography waveform from 
the patients electronic monitoring (Phillips 600X monitoring system). Percentage time out with 
saturation target band was calculated from an hourly histogram using in-bedded software on 
the Phillips monitors. For ventilated neonates, mean airway pressure and fractional inspired 
oxygen was derived from the ventilator (Drager Infiniti C500) while for those infants on non-
invasive respiratory support (BCPAP or Optiflow) the set end-expiratory pressure and inspired 
oxygen was recorded. Collection of this data allowed determination of whether preterm infants 
exhibited signs of Neonatal transfusion associated circulatory overload (nTACO), Neonatal 
transfusion associated lung injury (nTRALI) and Neonatal transfusion associated dyspnea 
(nTAD), not previously identified in the preterm infant.  
 
In 2011, the International Haemovigilance Network proposed a set of standardised definitions 
for non-infectious transfusion reactions including a range of hemolytic reactions and non-
hemolytic transfusion definitions 71. As these definitions were specifically designed for the adult 




specifically for neonates. These definitions are the first of their kind for the neonatal population 
and were used as a guide for measuring the cardio-respiratory function of the current 
extremely preterm population. nTACO was defined as occurring within 6 hours post transfusion 
and the patient exhibiting 4 or more of the 5 conditions listed below (Table 3.5).  nTRALI was 
defined as no evidence of positive fluid balance and evidence of acute respiratory distress 
(ARDS) for up to 6 hours post transfusion and bilateral pulmonary infiltrates on x-ray up to 10 
hours post transfusion. nTAD was defined as occurring up to 28 hours following transfusion 
exposure and displaying ARDS but no evidence of nTACO or nTRALI. In addition to these 
definitions, a respiratory deterioration was defined as a sustained increase in fraction of 
inspired oxygen (FiO2) or any increase in MBP or a change in ventilator mode, initiated by a 
worsening of respiratory illness severity.  
Table 3.2 Haemodynamic parameters 
Prior to Transfusion Post Transfusion 
Haemoglobin (g/L) Haemoglobin (g/L) 
Pack cell volume (L/L) Pack cell volume (L/L) 





Table 3.3 Cardiovascular Parameters  
1-4 hours prior to 
transfusion 
During transfusion 1-4 hours post 
transfusion  









































In addition, a number of additional measures of cardio-respiratory function were derived from 
the physiological data including cardiac output (CO), pulse pressure (PP), oxygen delivery index 
and respiratory severity score (RSS). In the current study, to ensure minimal discomfort and 
interruption to normal clinical care, a non-invasive technique was used to estimate cardiac 
output. Validated in adult and paediatric populations against invasive measures of cardiac 
output 237, cardiac output was defined as: 
CO =
Pulse Pressure
(Systolic Blood Pressure +  Diastolic Blood Pressure) ×  Heart Rate 
 
With pulse pressure (PP) defined as systolic blood pressure minus diastolic blood pressure.  
The RSS is a non-invasive surrogate for oxygenation index and has been validated in 
mechanically ventilated preterm infants 238.  RSS was calculated from: 
RSS = Mean Airway Pressure × Fraction of Inspired Oxygen 
3.3.3 Sex of Transfusion Donor 
To determine the sex of each transfusion donor, pack and donor number were recorded 
allowing re-identification of donor sex by The Australian Red Cross Blood Service.  
Table 3.4 Respiratory Parameters  
1-4 hours prior to 
transfusion 
During transfusion 1-4 hours post 
transfusion  










FiO2 FiO2 FiO2 Respiratory Rate 
Respiratory Rate Respiratory Rate Respiratory Rate  
% time out of target 
band 
% time out of target 
band 
% time out of target 
band 
 
Table 3.5 Definitions of neonatal transfusion associated morbidities   
Acute Respiratory 
Distress 
Tachycardia Increased mean blood 
pressure 
Sustained rise in FiO2 
>20% 
Sustained rise in heart rate 
≥20% up to 4 hours post 
transfusion 
Sustained rise in MBP ≥20% up 
to 4 hours post transfusion 
Sustained rise in 
respiratory rate >15 per 
minute 
Any rise up to 10 hours post 
exposure 





3.3.4 Outcome Assessments 
While the primary outcome of this study was the immunological changes following the 
transfusion a number of neonatal morbidity measures were collected and defined as the 
following: 
- BPD: based on the need for ventilatory support or supplemental oxygen at 36 weeks 
postmenstrual age. 
- IVH: for the purposes of this study, grade III and IV IVH were included as an outcome. 
This grading system is based on standard criteria developed by Papile 239. The study 
centres followed a ultrasound protocol dictating a minimum number of scans (day 1-2, 
day 7 and day 42). 
- ROP: a grading of 3 or greater was considered as an outcome, as per the current 
standard international criteria 240. 
- NEC: a grading of stage 2 or greater was used based on the criteria proposed by Bell 241.  
- Nosocomial infection: blood culture positive sepsis at any point during primary hospital 
admission.  
3.4 Measurement of Neonatal Immune Function 
3.4.1 High Sensitivity T-Cell Multiplex Assay 
Circulating cytokine levels for each transfusion sample were analysed using a Milliplex® 96 well 
Human High Sensitivity T-Cell Magnetic Bead panel multiplex ELISA. Detection limits and inter-









Table 3.6 Minimal detectable cytokine concentrations for Human High 























Table 3.7 Inter-assay and Intra-assay precision for Human High 




Intra-assay %CV Inter-assay %CV 
IFNγ <5% <20% 
IL-10 <5% <20% 
IL-12 (p70) <5% <15% 
IL-17A <5% <20% 
IL-1β <5% <15% 
IL-6 <5% <20% 
IL-8 <5% <15% 
TNF <5% <15% 
 
 
All reagents, controls and standards were prepared according to manufacturer instructions. 
The multiplex ELISA was run on a MAGPIX® multiplexing system with xPONENT® software. 
There was no cross-reactivity between antibodies or analytes on this panel.  
 
3.4.2 Neonatal Sepsis Assay 
Markers for endothelial activation were measured for each transfusion sample, analysed using 
a Milliplex® 96 well human sepsis bead panel multiplex enzyme-linked immunosorbent assay 
(ELISA). The detection limits and inter-assay and intra-assay precision are listed below as per 






















Intra-assay %CV Inter-assay %CV 
MIF 1.6 13.6 
sICAM- 0.8 11.5 
sFasL 0.7 11.6 
sFas 1.2 9.7 
sVCAM-1 0.8 10.6 
PAI-1 1.2 9.9 
 
As for the Human High Sensitivity T-Cell Magnetic Bead panel multiplex ELISA, all reagents, 
controls and standards were prepared according to manufacturer instructions and each plate 
was run on the MAGPIX® multiplexing system with xPONENT® software. There was no cross-
reactivity between antibodies or analytes on this panel.  
 
3.5 Statistical Analysis 
3.5.1 Sample Size Calculation 
A range of pro-inflammatory cytokines have previously been demonstrated to increase 
following exposure to leukodepleted unwashed PRBCs. However, there is inconsistency in the 
timing of post-transfusion measurement in the literature. IL-17A has been shown to be 
increased at multiple time-points post-transfusion 37 therefore the current studies sample size 




from pilot data in 40 extremely preterm infants exposed to unwashed PRBCs. The mean 
change was 15.3 pg/ml with a standard deviation of 13.1 pg/ml. It was calculated that a 
sample size of 77 infant per group would provide 90% power to detect a group difference of 
6.6 pg/ml (on-half of a SD) of the mean IL-17A with an  =0.05. Since it could not be determined 
prospectively which infants would be transfused, enrolment exceeded that necessary for the 
sample size calculation to ensure adequate power for the primary aim in transfused subjects. 
3.5.2 Cytokine and Endothelial Marker Analysis  
Extremely preterm infants will have a median number of 3-5 transfusion exposures during their 
primary hospital admission. Therefore, we made an a priori decision to determine transfusion 
associated changes in circulating cytokines and markers of endothelial activation for the first 4 
transfusions. Analysis was conducted blinded to study allocation. All descriptive statistics are 
presented as median (interquartile range) or number (percentage) where appropriate.  
As the plasma cytokine concentrations were not normally distributed the Friedman test was 
used to assess differences between baseline cytokine concentrations prior to each transfusion 
exposure with the alpha level set at 0.01 to adjust for multiple comparisons.  Pre- and post-
transfusion levels of plasma cytokines are presented as median (interquartile range) with 
differences assessed using the Wilcoxon signed rank test with the p value <0.05 considered 
significant. Within subject temporal changes, in the pre- to post-transfusion changes in 
plasma cytokines and markers of endothelial activation, in each group across the three 
transfusion exposures were analysed using a Linear Mixed Model. Heterogenous compound 
symmetry was used as the repeated covariance type and LSD as the confidence interval 
adjustment, to compare changes within treatment groups. To investigate whether transfusion 
related changes in cytokines and markers of endothelial activation were influenced by 
gestational age, sex, age at first transfusion, and pre-transfusion haemoglobin, these variables 
were included as co-variates. Data were analysed using the Statistical Package for the Social 




3.5.2 Physiological Response to Transfusion Analysis  
Cardiovascular and respiratory parameters from preterm infants <29 weeks’ gestation prior, 
during and post their first transfusion exposure were collected. Demographic data were 
compared using ANOVA or Mann-Whitney U depending on distribution and differences in 
frequencies for categorical variables tested using the χ2 test or Fisher's exact test. To account 
for missing data points temporal changes in cardio-respiratory variables were analysed using 
Linear Mixed Models with transfusion pack type (unwashed or washed) used as a fixed factor 
and post-hoc paired t-tests with a Bonferroni correction. The delta (post-pre-transfusion 
difference between the 4-hour post transfusion time point and the immediate pre-transfusion 
time point) was calculated for both cardio-respiratory parameters and inflammatory cytokines 
and the relationship between the measures of interest assessed using spearman’s rho. Data 
were analysed using the Statistical Package for the Social Sciences (SPSS v26; IBM SPSS, 
Chicago, IL). 
3.5.3 Sex of the Donor Analysis 
Study groups were defined by the donor sex (those who received PRBCs from only male donors 
for the first three transfusions or those who received any PRBCs from a female donor) and 
whether they received unwashed or washed PRBCs. Cytokines and markers of endothelial 
activation data were therefore analysed as 4 groups: unwashed PRBCs male only donors; 
unwashed PRBCs any female donor; washed PRBCs male only donors; and washed PRBCs any 
female donor.  
 
Demographic data is presented as median (IQR) or N (%). Fisher’s Exact Test or Pearson Chi-
Square used for comparison between groups. As the cytokine and endothelial markers were 
not normally distributed the Kruskal-Wallis test was used to compare differences between pre- 
and post-transfusion concentrations for the 4 groups with a p<0.05 considered statistically 




groups, the magnitude of the difference (∆change) was compared by the Kruskal-Wallis test 
with Dunn’s post hoc test to investigate differences between the individual groups, with a 
p<0.01 used to correct for multiple comparisons. Further, hierarchical multiple regression was 
used to assess the impact of exposure of the four transfusion exposure groups (unwashed 
PRBCs male only donors; unwashed PRBCs any female donor; washed PRBCs male only donors; 
and washed PRBCs any female donor) on the magnitude of the change, after controlling for 
gestational age, newborn sex, and age at first transfusion. Data were analysed using the 































































Figure 4.1 Study consort diagram 
During the study period, 223 infants were enrolled with 154 reaching the PINT haemoglobin 
trigger resulting in randomisation and transfusion (Figure 4.1). The clinical characteristics of 
those enrolled but not transfused versus those randomised are shown in Table 4.1. Maternal 
antenatal diagnoses were collected from the South Australian Perinatal data set, with 
diagnostic criteria as per South Australian Perinatal Practice Guidelines 242. Those that required 
Analysed (n=77) 
- Excluded from analysis (n=0) 
Assessed for eligibility (n=300) 
Excluded (n=77) 
- Not meeting inclusion criteria (n=8) 
- Declined to participate (n=34) 
- Other reasons (n=35) 
Analysed (n=77) 
- Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (washed) (n=77) 
- Received allocated intervention (n=77) 
- Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (unwashed) (n=77) 
-  Received allocated intervention (n=77) 












a transfusion were a significantly younger gestation compared to those who were not 
transfused (p<0.01).  
Data presented at median (IQR) or N (%). Kruskal Wallis test and Fisher’s Exact test or Pearson 
Chi-Square used for comparison between groups.  
 
However, there was no significant difference in birthweight. Transfused infants were more 
likely to be born in the context of histological chorioamnionitis (p<0.01) and be exposed to a 
complete course of antenatal steroids (p<0.05), defined as Betamethasone 24mg divided dose 
completed between 12 and 36 hours (two intramuscular 11.4mg doses 24 hours apart) or 
Dexamethasone 24mg divided dose completed between 24 and 40 hours (four intramuscular 
doses of 6mg 12 hours apart) 243. Finally, transfused infants had significantly greater rates of 
ROP (p<0.001), BPD (p<0.01), days of mechanical ventilation (p<0.05), length of stay (p<0.05) 
and culture positive sepsis (p<0.05). No other differences were seen between enrolled and 
randomised and transfused infants. 
Table 4.1 Antenatal and Neonatal Clinical Characteristics  
 Enrolled (n= 223) Transfused (n= 154) P 
Gestation 28 (25 – 28+6) 26 (23 – 28+6) <0.01 
Male 35 (61) 97 (63) 0.47 
Birth Weight, grams 1060 (446 – 1625) 800 (380 – 1690) 0.1 
IUGR (<10th percentile) 4 (7) 23 (15) 0.08 
Multiple Birth 17 (30) 39 (26) 0.33 



















SIP 0 (0) 6 (4) 0.13 
NEC 2 (4) 7 (5) 0.52 
PVL 0 (0) 5 (3) 0.19 
IVH 3 (5) 20 (13) 0.07 
ROP 0 (0) 37 (25) <0.001 
BPD 16 (28) 86 (59) <0.01 
Length of ventilation, days 1 (0 – 9) 10 (0 – 55) <0.05 
Length of stay, days 59 (50 – 71) 95 (78 – 111) <0.05 
Sepsis, culture positive 4 (7) 13 (9) <0.05 




4.2 Clinical Characteristics of Transfused Newborns by Neonatal Unit 
Infants were recruited in two nurseries, The Women’s and Children’s Hospital (WCH) and the 
Flinders Medical Centre (FMC). The Women’s and Children’s site is the sole maternal-fetal 
medicine service in South Australia. Therefore, the patient populations cared for by the 
nurseries differed, with all high-risk pregnancies (including surgical and cardiac diagnoses which 
were excluded from enrolment) delivered at WCH. The transfusion threshold did not differ 
between the two sites with the PINT haemoglobin trigger implemented at both. However, 
transfusion protocols within the two units were not identical. While infants born at the 
Women’s and Children’s hospital were fasted prior to, throughout the PRBC transfusion, and 
for 4 hours after, infants at the FMC nursery were not routinely fasted.  The clinical 
characteristics of the randomised infants at the individual sites are shown in Table 4.2. More 
male infants were randomised at the FMC site (p=0.01). In addition, total length of stay was 
longer at the FMC site compared to WCH. While this may reflect individual practice differences 
between the two nurseries, it is also impacted on by the geographical nature of hospital down 
transfer in South Australia with more limited capacity to care for convalescent preterm 
newborns in the level 2, 3 and 4 nurseries aligned with FMC out with metropolitan Adelaide 
compared to those associated with WCH. No other significant differences were seen between 
the two nurseries.  
4.3 Clinical Characteristics by Red Blood Cell Type Exposure 
Of the 154 infants transfused during the study period, 77 were allocated to receive washed 
PRBCs and 77 were allocated to unwashed PRBCs. Maternal and neonatal baseline 





4.4 Baseline Transfusion Characteristics by Pack Type  
There were no differences in transfusion characteristics between the two study arms (Table 
4.4.) Infants in both groups were exposed to their first transfusion within the first week of 
postnatal life, 4 days (2-11) versus 3 days (2-7) (unwashed versus washed). For those infants 
who required additional PRBC transfusions, the median age at the second transfusion was 6 
versus 7 days, the third, 13 versus 19 days, and the fourth, 21 versus 25 days. Despite a 
transfusion protocol being used for the current trial, a number of infants were transfused out 
of the haemoglobin trigger. All received the allocated transfusion product in line with original 
allocation. In almost all cases this was a transfusion requested when a haemoglobin was 
recorded higher than what was required to trigger a transfusion. This was a result of clinical 
instability and was at the discretion of the on-call clinical team. However, there were no 
differences noted between the two groups in relation to transfusions occurring out of the trial 
protocol. 
Data presented at median (IQR) or N (%). Kruskal Wallis test and Fisher’s Exact test or Pearson 
Chi-Square used for comparison between groups.  
 
Table 4.2 Antenatal and Neonatal Clinical characteristics  
 WCH (n=128) FMC (n=29) P 
Gestation 26 (24 – 27) 25 (25 – 27) 0.1 
Male 73 (58) 24 (83) 0.01 
Birth Weight, grams 830 (650 – 966) 800 (720 – 1020) 0.49 
IUGR 21 (17) 3 (10) 0.57 
Multiple Birth 35 (28) 4 (14) 0.15 



















SIP 4 (3) 3 (10) 0.12 
NEC 7 (6) 0 (0) 0.35 
PVL 4 (3) 2 (7) 0.32 
IVH 18 (14) 2 (7) 0.37 
ROP 30 (24) 9 (31) 0.48 
BPD 71 (57) 19 (68) 0.4 
Length of ventilation, days 11 (3 – 19) 6 (2 – 23) 0.8 
Length of stay, days 88 (71 – 108) 100 (86 – 123) 0.03 
Sepsis, culture positive 26 (21) 6 (21) 1.0 




Table 4.3 Baseline Antenatal and Neonatal Characteristics  





Maternal    
Age, years 30 (26 – 35) 32 (27 – 36) 0.18 
Parity 1 (0 – 1) 1 (0 – 2) 0.24 





























Antibiotics 31 (40) 31 (40) 1.0 
Magnesium Sulphate 48 (62) 52 (67) 0.15 
Chorioamnionitis, histological 30 (39) 23 (30) 0.3 
High Vaginal Swab  20 (26) 19 (24) 1.0 
Diabetes, any 3 (4) 6 (8) 0.5 
Premature rupture of membranes 22 (29) 28 (36) 0.3 
Antepartum Haemorrhage 26 (34) 20 (26) 0.38 
Preeclampsia  2 (3) 5 (6) 0.27 
Multiple Birth 22 (29) 17 (22) 0.46 
Neonatal    
Gestation, weeks 26 (24 – 27) 26 (25 – 27) 0.72 
Male 50 (65) 47 (61) 0.74 
Birth Weight, grams  800 (660 – 966) 830 (650 – 990) 0.8 
IUGR 9 (12) 15 (19) 0.27 
Intubated at Delivery 31 (40) 40 (52) 0.2 
APGAR 5 minutes 7 (6 – 8) 7 (6 – 8) 0.9 
Data presented at median (IQR) or N (%). Kruskal Wallis test and Fisher’s Exact test or Pearson 
Chi-Square used for comparison between groups.  
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Data presented at median (IQR) or N (%). UW = Unwashed PRBC group W= washed PRBC group. Kruskal Wallis Test and Pearson Chi-Square used for 
comparison between groups. 
Table 4.4 Baseline Transfusion Characteristics  
Transfusion 
Exposure 
1  2  3  4  
 UW W p UW W p UW W p UW w p  
Postnatal Age  
(days) 
4  
(2 – 11) 
3  
(2 – 7) 
0.64 6  
(3 – 11) 
7  
(3- 18) 
0.88 13  
(6 – 26) 
19  
(7 – 28) 
0.58 21  
(10 – 32) 
25  





(103 - 135) 
122  
(102-131) 
0.54 115  
(97 -126) 
111  
(95 - 123) 




0.16 98  























Transfusion out  
of protocol 
22 (28) 17 (22) 0.7 15 (25) 8 (13) 0.4 13 (28) 11 (23) 0.84 10 (33) 8 (21) 0.88 
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4.4 Long-term Outcomes by Red Blood Cell Type Exposure  
There were no significant differences seen between the two groups in relation to long-term 
outcomes clinical outcomes. Of the 141 infants that reached hospital discharge, their clinical 
outcomes are shown in Table 4.5.   
 
Table 4.5 Long-term Outcomes   
 Unwashed 
PRBCs 
Washed PRBCs P 
RDS 74 (96) 72 (94) 0.72 
Surfactant 64 (83) 70 (91) 0.23 
Sepsis, culture positive 20 (26) 12 (16) 0.5 
Early (<48 hours) 1  3  
Late 19  9   
Total Transfusions 3 (2 – 6) 3 (2 – 6) 1.0 
Emergency Transfusion 21 (27) 21 (27) 1.0 
Received Platelets or Plasma 23 (31) 21 (29) 0.9 
SIP 5 (6) 2 (3) 0.44 
NEC 5 (6) 2 (3) 0.44 
PVL 2 (3) 4 (5) 0.7 
IVH 9 (12) 11 (14) 0.8 
ROP 21 (27) 18 (23) 0.7 
BPD 45 (58) 45 (58) 1.0 
Length of ventilation, days 10 (2 – 22) 11 (4 – 18) 0.9 
Postnatal Steroids 38 (49) 40 (52) 0.87 
Length of stay, days 91 (78 – 110) 92 (68 – 111) 0.49 
Death 5 (6) 8 (10) 0.4 
Data presented at median (IQR) or N (%). Kruskal Wallis test and Fisher’s Exact Test or 
Pearson Chi-Square used for comparison between groups.  
 
While there was no difference between the median number of transfusions infants in the 
unwashed and washed groups received during their hospital admission, the range was large. 
Out of the 154 randomised infants, 33 (21%) had a single transfusion, 24 (16%) had two, 22 
(14%) had three and 19 (12%) had four in total. The remaining 37% of the randomized infants 
had five or more PRBC transfusions prior to discharge with the maximal exposure being 
eighteen PRBC transfusion events. 
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4.5 Summary 
From the above data, it is clear that the study participants represent a widely generalisable 
population of extremely preterm newborns cared for in a tertiary neonatal intensive care 
setting. Importantly, other than a higher number of male infants recruited and randomised at 
the FMC site the populations of infants at both were similar. It is unsurprising that those infants 
who ultimately required one of more transfusions were of lower gestational age, as is the 
increased incidence significant morbidity associated with extremely preterm birth in this group, 
including length of ventilation, length of stay, BPD, ROP and sepsis, though similar rates of 
death. The higher rates of morbidity are also likely to be related to the higher incidence of 
chorioamnionitis and intra-uterine growth restriction and lower rates of completed antenatal 
maternal steroid administration, pregnancy complications known to result in greater instability 
in the neonatal period.  
 
Critically, no significant differences in any baseline antenatal or neonatal clinical characteristics 
were observed between the unwashed and washed groups. Further, the baseline transfusion 
characteristics, in particular postnatal age at transfusions 1 to 4 and degree of pre-transfusion 
anemia, were also identical between the groups. Taken together, this strengthens the 
likelihood that any significant difference in the transfusion recipients inflammatory and 
physiological post-transfusion responses between the unwashed and washed PRBC groups is 
not confounded by other clinical variables and is due to the difference in blood product 
exposure.  Although no differences were seen in long term outcomes, it is important to keep in 
mind, this study was not powered to assess long term outcomes and as a result does not 







































Iatrogenic blood loss, an immature bone marrow response to falling haemoglobin and 
shortened red blood cell life span all contribute to preterm infants being the highest transfused 
population. In fact, it has been estimated that in a single week, a preterm infant may lose 
between 15 to 30% of their total blood volume 35. Therefore, almost all extremely preterm or 
low birth weight infants will require a transfusion during their primary hospital admission 237.  
 
Theoretically, transfusion should be beneficial with improvements in oxygen-carrying capacity 
resulting in alterations in cardiac output and consumption in addition to an overall increase in 
physiological stability 238. However, in adult patients, transfusions may result in acute adverse 
physiological responses referred to as TACO and TRALI 244.  While there are accepted definitions 
for both these conditions in adults there is still debate as to their existence in the preterm infant 
245. While the preterm infant is at risk of adverse outcomes due to fluctuations in cardio-
respiratory stability due to anaemia, it remains unclear if this population also exhibit adverse 
consequences intrinsic to the transfusion exposure itself 245. In particular, the lack of an agreed 
classification for TACO or TRALI in this population has resulted in these important 
consequences of transfusion exposure being seldom recognised and potentially under-
reported.  
 
A range of morbidities related to preterm birth have repeatedly been shown to be 
independently associated with volume and number of transfusion exposures 36. Previous 
studies have demonstrated that in the ‘stable’ late preterm infant (>29 weeks’ gestation) a 
transfusion corrects the physiological response to anaemia and reduced oxygen-carrying 
capacity with a decrease in cardiac output, heart rate and lactate 120. However, the majority of 
transfusion exposure is predominantly in the very early neonatal period in the most preterm 
infants. This is a period of significant physiological instability characterised by respiratory 
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disease such as hyaline membrane disease and cardiovascular dysfunction manifesting as poor 
cardiac function and hypotension. It is also likely that the pathophysiologic processes that 
ultimately result in significant neonatal morbidity begin during this period. This raises the 
possibility that any additional cardio-respiratory dysfunction, potentially as a result of adverse 
responses to transfusion, could contribute to an increased risk of morbidity and mortality. 
 
Multiple factors contribute to the development of significant neonatal morbidities such as BPD, 
IVH and NEC, including transfusion exposure. Much attention has been given to the 
contribution of transfusion related immunomodulation as a potential link between transfusion 
and adverse outcome 246. However, it remains unknown if the potential harmful consequences 
of transfusion are due to acute adverse physiological responses, analogous with TACO and 
TRALI in other critically ill patient populations, inflammatory processes related to TRIM or both. 
To answer this complex question requires detailed characterisation of the cardio-respiratory 
responses to transfusion in the preterm infant particularly focusing on any physiological 
markers of deterioration in cardio-respiratory function which could be consistent with those 
observed in other patient groups in whom TACO and/or TRALI is a recognised complication. The 
aim for this chapter was to determine the cardio-respiratory response to transfusion exposure 
and ascertain if these responses differed with transfusion with washed versus unwashed 
leukodepleted PRBCs. Further, I investigated whether the cardio-respiratory responses to 
transfusion demonstrated any relationship with transfusion-related alterations in pro-
inflammatory cytokines to explore possible links between TRIM and physiological response to 
transfusion exposure.  
5.2 Methods 
5.2.1 Cardio-respiratory Data Collection 
Cardiovascular and respiratory parameters from preterm infants <29 weeks’ gestation prior, 
during and post their first transfusion exposure were collected. Physiological parameters 
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recorded included heart rate, systolic and diastolic blood pressure, mean arterial pressure, 
mean airway pressure, fraction of inspired oxygen, and respiratory rate. As described in 
Chapter 3, physiological data was collected from immediately prior to the transfusion, 
throughout and then up to 10 hours following their transfusion exposure retrospectively from 
the subject’s medical record. SBP, DBP and MBP was measured invasively from an umbilical 
arterial catheter or peripheral arterial catheter, when present, or by non-invasive blood 
pressure measurement. Heart rate and respiratory rate were measured using ECG electrodes 
and the impedance pneumography waveform from the patients electronic monitoring (Phillips 
600X monitoring system). For ventilated infants, mean airway pressure and fractional inspired 
oxygen was derived from the ventilator (Drager Infiniti V500). For those infants on non-invasive 
respiratory support (BCPAP or Optiflow) the set end-expiratory pressure and inspired oxygen 
was recorded. 
 
In addition, CO, RSS and systemic vascular resistance (SVR) were calculated from these 
physiological variables, in addition to percentage time out with saturation target band, defined 
as 90 – 94% which was calculated from an hourly histogram using in-bedded software on the 
Phillips 850 monitors. Due to ethical restrictions on additional invasive investigations in this 
population of extremely preterm infants, cardiac output was defined as:  
CO =
Pulse Pressure
(Systolic Blood Pressure +  Diastolic Blood Pressure) ×  Heart Rate 
 
 
This is a well-validated measure of cardiac output used in the adult population and was adapted 
for the current population 237. RSS is a proxy measure of oxygenation indices that has been 
validated in the preterm population 247. RSS was calculated from mean airway pressure and 
fraction of inspired oxygen. 
RSS = Mean Airway Pressure × Fraction of Inspired Oxygen 
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Percentage of time out of target band was calculated hourly and generated using the Nellcor 
oximetry algorithm in combination with the Philips Intellivue Mx 800 monitor. Oximetry data 
was obtained using a 15 second sampling time and presented hourly allowing the generation 
of a value of percentage of time out of target band. The saturation target band was based on 
the Cochrane individual patient meta-analysis for oxygen saturation targets 248.    
 
In the normal clinical setting, SVR is calculated using cardiac output, mean arterial pressure and 
central venous pressure. In the current study, SVR was calculated in the simplified form using 
mean arterial pressure and cardiac output.  
SVR = Mean Arterial Pressure ÷ Cardiac Output 
5.2.2 Plasma Sample Collection and Cytokine Analysis  
Plasma samples were collected from infants immediately prior to transfusion exposure and 4-
6 hours post transfusion completion. Samples were processed as previously described in 
section 3.3.1 Plasma Collection. Cytokines of interest including IFNγ, IL-10, IL-12, IL-17A, IL-1β, 
IL-6, IL-8 and TNF were assessed using Multiplex ELISA. These measures were paired with 
baseline and 4-hour post cardio-respiratory measurements.  
5.2.3 Statistical Analysis 
Clinical characteristics are presented as median (interquartile range) or number (percentage) 
where appropriate. Demographic data were compared using ANOVA or Mann-Whitney U 
depending on distribution and differences in frequencies for categorical variables tested using 
the χ2 test or Fisher's Exact test. To account for missing data points, temporal changes in cardio-
respiratory variables were analysed using Linear Mixed Models with transfusion pack type 
(unwashed or washed) used as a fixed factor and post-hoc paired t-tests with a Bonferroni 
correction. The delta (post-pre-transfusion difference between the 4-hour post transfusion 
time point and the immediate pre-transfusion time point) was calculated for both cardio-
respiratory parameters and inflammatory cytokines and the relationship between the 
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measures of interest assessed using spearman’s rho. Data were analysed using the Statistical 
Package for the Social Sciences (SPSS v26; IBM SPSS, Chicago, IL). 
5.3 Results 
 One hundred and fifty-four extremely preterm infants had physiological data recorded prior, 
during and following their first transfusion exposure (one-hour pre transfusion; throughout the 
3-hour PRBC infusion and four hours post). Neonatal transfusion characteristics are presented 
in Table 5.1.  
 Data presented at median (IQR) or N (%). Fisher’s Exact Test or Pearson Chi-Square used for 
comparison between groups. Echocardiographically significant PDA was defined as per 
Kluckow,M. et al, 1995 249 
 
Both the unwashed and washed groups received their first transfusion within the first week of 
postnatal life. No statistically significant differences were seen between the groups in regard 
to any of the transfusion characteristics. At the time of first transfusion exposure, the majority 
of infants were receiving invasive ventilatory support (57% in the unwashed group and 68% in 
the washed group). In both groups, almost half had a clinically significant PDA and 
approximately 30% were receiving inotropic support.  
 
Table 5.1 Transfusion Characteristics at First Transfusion 
 Unwashed 
PRBCs 
Washed PRBCs P 
Postnatal Age, days 4  
(2 – 11) 
3 
(2 – 7) 
 
ns 
Pre-transfusion Hb 122  
(103 - 135) 
122 
(102 – 131) 
 
ns 
Post-transfusion Hb 133  
(122-149) 
135  
(124 – 146) 
 
ns 
Transfusion out of protocol 22 (28) 17 (22) ns 











Inotropes 26 (34) 29 (38) ns 
PDA 33 (43) 32 (42) ns 
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Haemoglobin, packed cell volume and lactate levels were collected immediately prior to and 
following the transfusion. Pre-transfusion, there was no difference between the unwashed and 
washed groups in relation to any of these measures. Following the transfusion, there were 
significant increases in haemoglobin (p<0.001) and packed cell volume (p=0.003) for both 
unwashed and washed groups, with the magnitude of the increase similar between the groups.  
pH decreased following exposure to unwashed blood, although the fall did not reach 
significance (p=0.059), with no change in pCO2. For infants exposed to washed blood, there 
were no changes in pH or pCO2. No change in lactate was seen following transfusion for either 
group (p=0.754) (see Figure 5.1) 
Figure 5.1 Haematological response to first transfusion. Unwashed shown in the open box and 
whisker, washed shown in the grey box and whisker. † p<0.001. 
 107 
Temporal changes in cardiovascular parameters in relation to transfusion with unwashed or 
washed PRBCs are shown in Figure 5.2. Overall, cardiac output fell over time (t=-2.75 p<0.01 
95% CI -0.9 to -1.4). When assessing the effect of pack type, infants exposed to washed PRBCs 
exhibited a greater decrease in CO (t= -2.57, p<0.05, 95% CI -0.62 to -4.68). with a -0.50 fall at 
each time point (p<0.01). SVR increased with time (t=4.24, p<0.001, 95% CI 0.02 to 0.05) and 
was influenced by transfusion type (t=2.19, p=0.03, 95% CI 0.01 to 0.16), being higher in infants 
transfused with washed PRBCs.  
Figure 5.2 Cardiovascular changes following first transfusion exposure.   
 
While an increase in DBP (t=4.23, p>0.001 95% CI 0.28 to 0.78) occurred over time, no effect 
of transfusion type was seen. No temporal or transfusion type specific changes were observed 
Washed Unwashed ashed
Unwashed    UnwashedWashed
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in HR, SBP, MBP, or PP. Temporal changes in respiratory parameters in relation to transfusion 
with unwashed or washed PRBCs are shown in Figure 5.3.  
 
Figure 5.3 Respiratory changes following first transfusion exposure.     
 
RR increased with time (t=1.96, p<0.05, 95% CI 0.2 to 1.7) but was not influenced by pack type. 
MAP did not alter with time but was influenced by transfusion type, being consistently higher 
for infants exposed to washed blood compared to unwashed (t=3.72, p<0.01, 95% CI 0.49 to 
Washed Unwashed ashedUnwashed    UnwashedWashed
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1.62). No change in percentage of time out of target band, respiratory severity score, or fraction 
of inspired oxygen with either time or transfusion pack type.  
5.5 Discussion  
PRBC transfusion should be beneficial through reducing end organ oxygen consumption 
secondary to improvements in oxygen carrying capacity and therefore resulting in a net 
improvement in physiological stability 238. However, there is now an appreciation that it may 
result in acute adverse physiological responses particularly involving the cardio-respiratory 
system. It remains challenging to differentiate the perceived need for and consequent receipt 
of PRBC transfusion, with the possibility of a transfusion reaction in the context of an evolving 
critical illness. While these unwanted consequences of transfusion are more robustly defined 
in the adult critical care literature 244, it has been proposed that they may be under-recognised 
in other vulnerable patient groups, including the extremely preterm infant 245.  
 
Whilst recent attention has focused on TRIM as central to the link between transfusion 
exposure and  adverse outcome in the preterm infant 36, it remains unknown if the potential 
harmful consequences are due to acute adverse physiological responses, inflammatory 
processes related to TRIM, or both. This study of the cardio-respiratory responses to first 
transfusion exposure in extremely preterm infants found that, in addition to changing with 
time, CO and SVR changed in a transfusion type specific manner, with CO falling and SVR 
increasing to a greater degree in response to transfusion with washed compared to unwashed 
PRBCs. In addition, diastolic blood pressure and respiratory rate increased with time following 
transfusion. The mechanisms underlying this different response to washed and unwashed 
blood remain open to conjecture. 
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With respect to the cardiovascular response to transfusion, CO fell, while DBP and SVR 
increased. Previous studies of transfusion associated effects on cardiac output have produced 
conflicting results. While the majority of studies have reported a similar fall in CO 250-253, others 
have reported increases in CO, although this appears to be related to a greater degree of pre-
transfusion anaemia as measured by lower haematocrit 120, 183. As the pre-transfusion 
haemoglobin concentrations were similar between those infants transfused with unwashed 
versus washed blood, a different baseline does not explain the greater fall in CO observed 
following transfusion with washed blood.  
 
Anaemia results in a compensatory increase in CO in an effort to maintain systemic oxygen 
transport in the preterm infant. RBC transfusion then increases oxygen-carrying capacity by 
increasing haemoglobin concentration, but also oxygen off-loading to the tissues due to the 
rightward shift of the oxygen dissociation curve due to transfusion with adult Hb. Washing RBCs 
has previously been shown to decrease pH in the transfusion pack 254, further shifting the 
oxygen dissociation curve to the right making it easier for haemoglobin to release bound 
oxygen and therefore increasing the partial pressure of oxygen in the tissues. If this results in a 
reduction in end-organ oxygen extraction, as previously described 120, 250, the net result could 
ultimately manifest as greater fall in the compensatory increase in CO as observed in the 
current study. 
 
Diastolic blood pressure increased over time; an effect not influenced by transfusion type. DBP 
represents the resting pressure of blood on the vessels and is reflective of systemic vascular 
tone/resistance and intravascular blood volume status 255. Therefore, the increase in DBP is 
entirely in keeping with an increase in intravascular volume following transfusion in addition to 
the increase in SVR observed. Initial diastolic hypotension with preserved systolic pressure is 
common in the early postnatal period and reflects the initial stages where right ventricle (RV) 
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afterload declines and SVR rises after birth in the face of mild systemic end organ dysfunction 
256.  While the presence of a clinically significant PDA commonly complicates this period of early 
postnatal life, the majority of previous studies have excluded infants with a clinically significant 
PDA. As this study was conducted during the acute phase of physiological transition following 
preterm birth, a large proportion in both the washed and unwashed group had a significant 
PDA. It is likely that the volume of the transductal shunt was sufficiently large that 
cardiovascular compromise ensued characterised clinically by hypotension and the 
requirement for inotropic support 256.  With a significant number of infants in the current study 
receiving inotropes at the time of their first transfusion, the failure to observe transfusion-
associated alterations in heart rate or other blood pressure parameters may be due to the 
desired cardiovascular effects of these pharmacologic agents. 
 
The occurrence of TACO first received attention in the 1930s 257, although it was not until the 
1990s that renewed attention resulted in it being recognised as a distinct clinical entity 258. The 
estimated frequency of TACO varies from 1% in hemovigilance reports up to 11% in critically ill 
patients 249, 25, with an estimated incidence between 1.5% and 11% in the paediatric intensive 
care population 259. TACO presents with the onset of acute respiratory distress (hypoxemia) 
within 6 hours of a blood transfusion. The 2011 International Society of Blood Transfusion 
(ISBT) clinical criteria 260 defines TACO as any 4 of the following occurring within 6 hours of 
completion of transfusion: acute respiratory distress; tachycardia; elevated blood pressure; 
acute or worsening pulmonary oedema on chest x-ray; and evidence of positive fluid balance. 
Even without chest x-ray evidence, the current data does not support adverse cardiovascular 




Few studies specifically report the role of transfusion exposure and acute changes in respiratory 
stability in the newborn infant. Grev and colleagues have reported a retrospective cohort study 
of extremely low birth weight infants with acute respiratory decompensation defined as  ≥ 1 of 
the following: (1)  ≥ 10% increase in fraction of inspired oxygen from highest baseline, (2)  ≥ 2 cm 
H2O increase from highest baseline in mean airway pressure, or (3) escalation in mode of 
respiratory support 79. No difference in the frequency of acute respiratory decompensation was 
seen between the control and transfusion time periods for 110 PRBC transfusions in 25 infants. 
In the current study, with a much larger sample size, we observed an increase in respiratory 
rate with time, an effect not influenced by transfusion type. An increase in respiratory rate 
following transfusion has been previously reported in infants transfused at higher haematocrits 
119. It remains unclear if this response is due to alterations in pulmonary blood flow following 
transfusion or inflammatory processes as seen in TRALI secondary to TRIM 119.  
 
We also observed that MAP was consistently higher for infants exposed to washed blood 
compared to unwashed, although it did not alter over time. One explanation for this 
consistently higher MAP is that the infants in the washed group had more severe early neonatal 
lung disease. However, there were no differences in baseline clinical characteristics that might 
influence early respiratory function, such as gestational age, birthweight, or the proportion 
who received antenatal betamethasone. However, while there was no difference in other 
measures of respiratory illness between the groups, such as FiO2 or respiratory severity score, 
more were mechanically ventilated at the time of first transfusion although this did not reach 
statistical significance.   
 
Acute respiratory distress syndrome, of which TRALI is a subgroup, was first described clinically 
in 1967 261. Concerns regarding the application of this diagnosis to paediatric patients 
prompted the paediatric acute respiratory syndrome definition 262 which still excluded the first 
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month of life. This finally resulted in further refinement led to the Montreux definition 263 based 
on timing, lung imaging, absence of congenital heart disease including a patent ductus 
arteriosus, and an oxygen deficit measured by an oxygenation index 263. Over time, the 
accepted definition of TRALI has evolved, with the current working definition; “Acute dyspnoea 
with hypoxia and pulmonary infiltrates within 6 hours of transfusion, with no other apparent 
cause” 264.  
 
The 10-year prospective study of serious transfusion related complications in the United 
Kingdom 202 has provided the most detailed data on reported adverse events in children with a 
pooled epidemiologic estimate of adverse outcome rates in 18:100 000 red cell transfusions 
for children <18 years of age  and an overall incidence of 37 000 for infants <1 month of age  
265. While rare, rates of TRALI were 6% which, not-withstanding its relative rarity, does support 
it being a significant cause of transfusion-related mortality. The current data, as for TACO, fails 
to support transfusion associated acute respiratory decompensation consistent with TRALI as 
defined in other patient populations in the extremely preterm infant.  The SHOT childhood 
study authors themselves concluded that “transfusion-related acute lung injury is difficult to 
diagnose in any patient and may pose particular diagnostic problems in children” 265. Equally 
important is the concern that an unreliable definition for TRALI, especially for specific patient 
populations, may draw false conclusions about its risk factors and biology 266. 
 
TRALI, in particular, has been proposed to have an inflammatory aetiology with a temporal 
relationship to alternative risk factors for acute respiratory distress syndrome such as sepsis or 
pneumonia central to its development 267. Biomarkers have increasingly been utilised in clinical 
diagnosis and decision making. For example, the use of biomarkers such as troponin and brain 
natriuretic peptide (BNP) has been investigated in the setting of transfusion-related adverse 
outcomes although any additional diagnostic value appears limited 268. More recently 
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inflammatory biomarkers have been found to predict the onset and underlying pathogenesis 
of nonhydrostatic (e.g., permeability) pulmonary oedema 269, 270. Importantly, pre-transfusion 
and post-transfusion alterations in these inflammatory cytokines have also been recognised in 
patients who develop TRALI and TACO 271-273. However, the association between post-
transfusion plasma pro-inflammatory cytokine concentrations and alterations in clinical 
markers of cardio-respiratory function in the extremely preterm infant has not been reported.  
 
There are a number of limitations to the current study. It is important to note that the 
physiological data was only collected for the first transfusion exposure. This is an important 
consideration given that numerous studies have demonstrated immunomodulation following 
exposure to 3 to 4 PRBC transfusions 49, 50, 166, 168.  While there is evidence for alterations in pro-
inflammatory cytokine production and endothelial activation in response to single transfusion 
exposure 63, no studies have specifically investigated if repeat transfusion exposure results in 
similar adverse responses.  There is, however, circumstantial evidence that repeat transfusion 
may indeed lead to endothelial activation and increased morbidity with an association between 
repeat PRBC transfusion exposure and increased ischemic damage reported in adult cardiac 
patients 168. Therefore, it is possible that the magnitude of any physiological response to 
transfusion may increase with repeat transfusion exposure if TRIM is a significant contributor 
to the underlying pathophysiologic processes. Further, measuring post-transfusion cytokine 
concentrations at a single time point does not capture differences in the timing of peak cytokine 
responses known to occur after an inflammatory stimulus such as transfusion exposure. 
However, we were constrained within the design of the current study with respect to the 
number and timing of blood sampling in this vulnerable patient group. Similarly, we could not 
perform a chest x-ray following transfusion exposure, as required for the current diagnostic 
criteria for TRALI and TACO, without a clear clinical indication. Finally, given the very high 
incidence of respiratory and cardiovascular instability in this patient group, with evolving 
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clinical signs and symptoms, it may simply be impossible to delineate additional physiologic 
burden imposed by transfusion exposure. 
 
In summary, the current data focusing on the first transfusion exposure in the extremely 
preterm infant supports both changes over time and in response to the type of PRBCs 
transfused. However, the alterations in CO, SVR, DBP, MAP and respiratory rate do not meet 
the current accepted definitions for either TRALI or TACO employed in other critically ill 
populations and while statistically significant their clinical significance remains unknown. This 
is likely due to the unique clinical presentation of the extremely preterm infant. Specifically, 
transfusion-related alterations in cardio-respiratory stability may be masked by the evolution 
of significant morbidities such as neonatal respiratory distress syndrome and cardiovascular 
instability secondary to poor cardiac function and the influence of a significant PDA which 
complicate the early postnatal period. Interestingly, we observed an association between 
transfusion-related changes in the pro-inflammatory cytokine IL-6 and CO and SVR, despite a 
failure to meet TACO or TRALI diagnostic definitions. Therefore, while the potential harmful 
consequences of transfusion secondary to acute adverse physiological responses analogous 
with TACO and TRALI cannot be ruled out, these findings suggest a potential for an interaction 
between transfusion-related immunomodulation and organ dysfunction which warrants 
further investigation. Whether any adverse effect is modifiable through an alteration in RBC 




























The proposed mechanisms underlying the association between PRBC and the spectrum of post-
transfusion multi-organ morbidity and mortality, remain poorly understood. One potential 
contributing pathway may be the transfusion recipient’s immune response to the transfusion 
itself. Numerous pre-clinical studies demonstrate that RBC products can directly modulate 
immune cell function 59. For instance, leukodepleted PRBCs have been shown to prime 
mononuclear cells resulting in significant increases in pro-inflammatory cytokines 104. This 
effect has been termed TRIM and describes both adverse pro-inflammatory and 
immunosuppressive responses.  
 
TRIM has been proposed to be a “two-insult” process 97. Initial sensitisation to inflammatory 
processes results in priming of host neutrophils (first insult). Applying this model to the preterm 
infant, the first ‘hit’ may be the pathophysiologic process resulting in preterm birth. Subsequent 
exposure to biological response mediators passively transfused along with the PRBCs then 
results in a pro-inflammatory immune response (second insult) 98. While these pathological 
processes are yet to be fully characterised, biological response mediators that may be 
implicated in the second “hit” include donor antibodies, bioactive lipids, free haemoglobin, red 
cell membrane fragments and cytokines that accumulate during blood product storage 95.  
 
In vitro data supports the ability of the supernatant from stored PRBCs to “prime” unstimulated  
allogeneic neutrophils, inducing the release of IL-8 and altering the cells chemotactic properties 
99. Further, TRIM appears to be characterised by activation of vascular endothelial cells and 
platelets. These cells are highly sensitive to inflammatory signals and may release toxic 
bioactive mediators following activation by donor blood 98. While TRIM has not been 
definitively proven in preterm infants, this patient population are potentially at the greatest 
risk of immunomodulation due to their immature immune system. As a result, it may represent 
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one of the central processes underlying TRALI; associated with an increase in BPD and TRAGI; 
linked to an increase in the occurrence of NEC 95, morbidities characterised by inflammation 
and endothelial activation 274, 275. 
 
While modifications in red blood cell processing, such as pre-storage leukodepletion, have 
resulted in reduction in the incidence of common neonatal morbidities such as ROP, BPD, and 
NEC, as well as a trend towards a reduction in bacteraemia and IVH 129, they have not 
completely abrogated the immunomodulatory effect of PRBC transfusions. Specifically, 
transfusion with leukodepleted PRBCs is still associated with post-transfusion increases in pro-
inflammatory cytokines (IL-1ß, IL-8, TNF) and markers of endothelial activation 63 37. Recent pre-
clinical evidence, however, has suggested that pre-transfusion washing of PRBCs removes 
proteins, extracellular potassium, inflammatory cytokines and chemokines, as well as RBC 
microparticles 172, reducing the immunomodulatory potential. Therefore, the aim of this 
chapter was to investigate whether transfusion with washed leukodepleted red blood cells in 
the extremely preterm infant would result in an ameliorated post-transfusion pro-
inflammatory cytokine response and reduced endothelial activation compared to transfusion 
with standard, unwashed leukodepleted PRBCs.  
6.2 Methods 
Parents of extremely preterm infants <29 weeks’ gestation were approached and consented 
prior to their child’s first elective transfusion. Randomisation was completed by the SA 
Pathology transfusion laboratory, with each infant being randomised to either unwashed PRBCs 
or washed PRBCs for their first and all subsequent PRBC transfusions they required during their 
primary NICU admission. Within each study arm, infants were stratified by gestational age, 23+0 
to 25+6 and 26+0 to 28+6 weeks. All transfusions used leukodepleted, O Rh negative PRBCs, with 
a fixed volume of 15mL/kg transfused over 3 hours. The Australian Red Cross Blood Service 
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washed PRBC packs 3 days post collection as per standard processing protocols. The SA 
Pathology transfusion laboratory were unblinded to pack allocation to comply with all other 
current ordering and safety protocols. However, study investigators, attending clinicians, 
nursing staff and parents were blinded to product allocation.  
 
As described in Chapter 3, prior to the transfusion, infants had 0.4 mL whole blood collected, 
with a post-transfusion sample collected 4-6 hours following transfusion completion. A 1 mL 
sample was also collected from the red cell pack. Samples were centrifuged and plasma 
aliquoted for analysis of cytokines and markers of endothelial activation analysis. Plasma 
cytokine levels for each transfusion sample were analysed using the Human High Sensitivity T-
Cell Magnetic Bead panel multiplex ELISA (see 3.4.1 High Sensitivity T-Cell Multiplex Assay). 
Markers of endothelial activation were measured using human sepsis bead panel multiplex 
ELISA (see 3.4.2 Neonatal Sepsis Assay). 
6.2.1 Statistical Analysis 
Extremely preterm infants will have a median number of 3-5 transfusion exposures during their 
primary hospital admission. Therefore, we made an a priori decision to determine transfusion 
associated changes in circulating cytokines and markers of endothelial activation for the first 4 
transfusions in our population of 154 extremely preterm infants. Clinical characteristics are 
presented as median (IQR) or number (%) where appropriate. Demographic data were 
compared using ANOVA or Mann-Whitney U depending on distribution and differences in 
frequencies for categorical variables tested using the χ2 test or Fisher's Exact.  
 
As the plasma cytokine concentrations were not normally distributed, the Friedman test was 
used to assess differences between baseline cytokine concentrations prior to each transfusion 
exposure, with the alpha level set at 0.01 to adjust for multiple comparisons.  Pre- and post-
transfusion levels of plasma cytokines are presented as median (interquartile range), with 
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differences assessed using Wilcoxon Signed Rank test with a p value <0.05 considered 
significant. Within subject temporal changes, in the pre- to post-transfusion change in plasma 
cytokines and markers of endothelial activation, in each group across the three transfusion 
exposures were analysed using a Linear Mixed Model. Heterogenous compound symmetry was 
used as the repeated covariance type and LSD as the confidence interval adjustment, to 
compare changes within treatment groups. To investigate whether transfusion related changes 
in cytokines and markers of endothelial activation were influenced by gestational age, sex, age 
at first transfusion, and pre-transfusion haemoglobin, these variables were included as co-
variates. Data were analysed using the Statistical Package for the Social Sciences (SPSS v26; IBM 
SPSS, Chicago, IL). 
6.3 Results 
Baseline clinical characteristics are shown in Table 6.1. No differences were seen for gestational 
age at birth, sex, birth weight or other common antenatal characteristics across transfusion 
exposure. Postnatal age at transfusion, pre-transfusion Hb and Hb response to transfusion were 
similar between the unwashed and washed groups for each.  
 
Transfusion pack concentrations of cytokines and markers or endothelial activation 
A random selection of transfusion pack samples across the four transfusion exposures were 
selected (n=36 per study group) to determine if detectable levels of cytokines and markers of 
endothelial activation were present before transfusion into the recipient. IFNγ, IL-1b, IL-10, IL-
12, and IL-17A were undetectable in both the unwashed and washed packs. While IL-6 was 
detectable in the unwashed packs (median 1.46 (IQR 0.8-7.3) pg/ml), it was undetectable in the 
washed packs. IL-8 and TNF were present in detectable concentrations in both the unwashed 
and washed packs, with levels not significantly different (Fig 6.1A and 6.1B). Neither sFas or 
sFasL were detectable in the unwashed or washed packs. While sICAM1 was only detectable in 
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11% of the washed packs, it was present in a significantly greater proportion of the unwashed 
packs (92%, π2=55.0, p=0.01), with a median concentration of 83.4 (52.9-116.2) pg/ml. 
Similarly, sVCAM1 and PAI1 were detectable in more unwashed packs than washed PRBC packs, 
although this difference did not reach significance. However, the detectable concentrations in 
the unwashed packs were significantly higher than in the washed packs (p<0.001 for both, Fig 
6.1C and 6.1D). MIF was detectable in all packs, with levels higher in the washed compared to 

























Figure 6.1 Plasma cytokines and markers of endothelial activation within the PRBC pack. A IL-
8, B TNF, C sVCAM1, D PAI1, and E MIF. Median (IQR) *p<0.05 **p<0.01. 
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Data presented as median (IQR) or N (%). Fisher’s Exact Test or Pearson Chi-Square used for comparison between groups. UW- unwashed PRBCs, 
W- washed PRBCs.
Table 6.1 Antenatal characteristics across transfusion exposure   



















































































IUGR 9 (12) 15 (19) 6 (10) 13 (21) 4 (9) 10 (20) 4 (11) 9 (24) 





































Chorioamnionitis 30 (39) 23 (30) 26 (44) 21 (34) 21 (45) 16 (32) 17 (46) 12 (32) 
Magnesium Sulphate 48 (62) 52 (68) 38 (64) 41 (66) 30 (64) 32 (64) 24 (65) 25 (66) 
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The baseline concentrations of cytokines and markers of endothelial activation in plasma of 
newborn infants in the unwashed and washed PRBC treatment groups at transfusion 1, 2, 3 and 
4 are shown in Table 6.2 and 6.3. Baseline concentrations were compared prior to the 1st, 2nd, 
3rd and 4th transfusions, both within group and between the unwashed and washed groups. For 
those infants receiving unwashed blood, the pre-transfusion cytokine concentrations did not 
vary between the 1st and 4th transfusion exposures. However, for infants transfused with 
washed PRBCs, significant overall changes in baseline cytokine concentrations were seen for 
IFNγ (p<0.001), IL-12 (p=0.012), IL-17A (p=0.002) and IL-1β (p=0.008). Post-hoc tests 
demonstrated increases in baseline IFNγ concentrations from transfusion 1 to 3 (p=0.002) and 
1 to 4 (p=0.004), while IL-12 and IL-17A baseline concentrations increased between transfusion 
1 and 3 alone (p<0.001 and p=0.01 respectively). Pre-transfusion concentrations of markers of 
endothelial activation did not differ between the 1st and 4th transfusion for either the unwashed 
or washed groups.  
 
No baseline differences were seen in cytokine concentrations or endothelial markers between 
the unwashed and washed groups for the first transfusion exposure. However, infants receiving 
washed PRBCs had increased concentrations of IL-1β (p=0.03), IL-6 (p=0.01), IFNγ (p=0.05), in 
addition to increased concentrations of MIF (p=0.004) and sFas (p=0.05) prior to their second 
transfusion when compared to those infants in the unwashed group. Likewise, infants in the 
washed group had higher concentrations of IL-1β (p=0.03) and IL-6 (p=0.01) prior to the third 
transfusion exposure.  
 




























Data presented as median (IQR). UW – unwashed PRBCs, W – washed PRBCs. Mann-Whitney U used to compare unwashed vs washed.     
*p<0.05 **p<0.01 
 
Table 6.2 Baseline cytokine concentrations (pg/ml)   
 Transfusion 1 Transfusion 2 Transfusion 3 Transfusion 4 
 UW W UW W UW W UW W 
IFNγ 0.9 
(0 – 13.9) 
1.32 
(0 – 4.9) 
0  
(0 – 15.2) 
4.2* 
(0.4 – 6.7) 
2.58  
(0 – 15.4) 
5.5  






(1.4 – 40.1) 
16 
(4 – 32.1) 
11.9  
(1.7 – 66.3) 
12.8  
(3.6 – 49.8) 
11.3  
(1.7 – 25.1) 
12 






(0 – 8.8) 
1.7 
(0.8 – 6.4) 
3.5  
(0 – 9) 
2.7  
(1 – 8) 
2.7  
(0 – 6.3) 
4  






(0 – 14.8) 
2.1 
(0.1 – 7) 
5.1  
(0 – 11.9) 
3.4  
(0.4 – 9.6) 
7.4  
(1.2 – 16.7) 
5.9  






(0 – 6.4) 
0.5 
(0 – 2.8) 
0  
(0 – 1.2) 
0.8*  
(0 – 5.4) 
0  
(0 – 2.1) 
1.2*  






(0 – 54.6) 
28.1 
(6.4 – 103) 
10.9  
(0 – 42.8) 
29.9**  
(7.4 – 87.2) 
8.2  
(0 – 29.3) 
23.8** 






(64 – 314) 
252 
(118 – 527) 
75.4  
(37.5 – 242.5) 
259.6  
(97.5 – 455) 
89.2  
(35.3 – 274.4) 
285.3  






(31.8 – 81) 
40.2 
(28.5 – 66) 
40.8  
(26 – 93.9) 
44.2  
(30.2 – 71.6) 
46.5  
(29.9 – 66.9) 
55.5  
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Table 6.3 Baseline concentrations of markers of endothelial activation (pg/ml unless otherwise stated)   
 Transfusion 1 Transfusion 2 Transfusion 3 Transfusion 4 
 UW W UW W UW W UW W 
MIF  126.5 
(61.7 – 296.2) 
149  
(62 – 349) 
121.8 
(98.9 – 210.2) 
237.3** 
(126.5 – 628.2) 
132.8 
(70.2 – 332.9) 
126.8 





sICAM1 (ng/ml) 19.8 
(14.3 – 31.4) 
20.4 
(10.9 – 32.6) 
22.9 
(16.0 – 34.7) 
26.4 
(13.3 – 41.7) 
29.0 
(23.8 – 42.9) 
23.6 





sFasL  17.2  
(6.7 – 28.7) 
15.1  
(8.6 – 30.6) 
15.4 
(7.1 – 25.6) 
17.4 
(11.3 – 37.2) 
15.2 
(8.5 – 26.5) 
18.9 





sFas  245  
(173 – 380) 
322 
(261 – 442) 
257.8 
(168.7 – 392) 
343* 
(242 – 439) 
247 
(194 – 506) 
318 





sVCAM1 (ng/ml) 227 
(171 – 389) 
226 
(19 – 446) 
251 
(160 – 367) 
246 
(184 – 420) 
190 
(113 – 375) 
259 





PAI1 (ng/ml) 12.2  
(7.0 – 16.6) 
9.3 
(4.2 – 17.1) 
9.5 
(4.3 – 13.0) 
14.1 
(4.1 – 25.5) 
6.9 
(3.8 – 13.9) 
10.5 





Data presented as median (IQR). UW – unwashed PRBCs, W – washed PRBCs. Mann-Whitney U used to compare unwashed vs washed. *p<0.05 **p<0.01 
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Transfusion associated changes in plasma cytokine and markers of endothelial activation  
Neither unwashed or washed PRBCs resulted in significant post-transfusion changes in IL-1β, 
IL-12, IL-17A, IFNγ or TNF at the first transfusion exposure. However, transfusion with washed 
PRBCs was associated with a significant fall in post-transfusion IL-6 (p=0.008, Figure 6.2A) and 
IL-10 (p=0.014, Figure 6.2B), with transfusion of both unwashed and washed PRBCs resulting in 
a reduction in circulating IL-8 (unwashed p=0.024, washed p=0.027, Figure 6.2C). No changes 
were observed for any markers of endothelial activation. 
 
At the second transfusion exposure, no post-transfusion alterations were seen for IL-1β, IL-6 
and IL-17A for either unwashed or washed PRBCs. However, transfusion with washed PRBCs 
resulted in a reduction in IFNγ (p=0.043, Figure 6.3A), TNF (p=0.041, Figure 6.3B), IL-8 
(p=0.004, Figure 6.3C), and IL-10 (p=0.003, Figure 6.3D) and an increase in IL-12 (p=0.01, 
Figure 6.3E). No change was observed for MIF, sVCAM1, sFasL and PAI1. However, 
transfusion with unwashed PRBCs was associated with an increase in sICAM1 (p=0.023, Figure 




Figure 6.2 Plasma cytokine response to 1st transfusion exposure (    unwashed     washed). A IL-
6, B IL-10 and C IL-8. Median (IQR) *p<0.05**p<0.01.  
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Figure 6.3 Plasma cytokine response to 2nd transfusion exposure (    unwashed     washed). A 









Figure 6.4 Markers of endothelial activation response to 2nd transfusion(    unwashed     washed).  
A sICAM1 and B sFas. Median (IQR) *p<0.05 **p<0.01. 
 
By the 3rd transfusion significant post-transfusion increases were seen for IL-17A (p=0.05) and 
TNF (p=0.007) in those infants transfused with unwashed blood. Conversely, transfusion with 
washed PRBCs was associated with a decrease in IL-17A (p=0.013, Figure 6.5A), TNF (p=0.05, 
Figure 6.5B), IL-6 (p=0.001, Figure 6.5C), IL-8 (p=0.037, Figure 6.5D), IL-12 (p=0.001, Figure 
6.5E) and IFNγ (p=0.001, Figure 6.5F). No transfusion-related changes were seen for markers 
of endothelial activation for those infants receiving washed blood. However, in those 
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transfused with unwashed PRBCs, there was an increase in MIF (p=0.005, Figure 6.6A) and PAI1 
(p=0.05, Figure 6.6B). Finally, no differences were seen for either unwashed or washed PRBCs 
at the fourth transfusion exposure for any of the circulating cytokines or markers of endothelial 
activation. 
 
Figure 6.5 Plasma cytokine response to 3rd transfusion exposure (    unwashed     washed). A IL-







Figure 6.6 Markers of endothelial activation response to 3rd transfusion(    unwashed     washed). 




Differential effect of transfusion with unwashed versus washed PRBCs on plasma cytokines  
Within subject temporal changes in the pre- to post-transfusion changes in plasma cytokines 
and markers of endothelial activation in each group across the three transfusion exposures 
were analysed using a Linear Mixed Model with gestational age, sex, age at first transfusion, 
and pre-transfusion haemoglobin included as co-variates. As the number of infants who went 
on to receive a 4th transfusion was significantly reduced in both the unwashed and washed 
PRBC groups this analysis was confined to the first three transfusion exposures.  
Table 6.4 Fixed effects values for transfusion exposure 
Cytokine Pack-type x transfusion exposure 
IL12 (F(1, 307)= 4.0, p=0.04) 
IL17A (F(1, 307)= 4.9, p=0.03) 
TNF (F(1, 206)= 2.4, p=0.046) 
 
Tests for fixed effects demonstrated a significant interaction effect between PRBC transfusion 
pack type and transfusion exposure for IL12, IL17A, and TNF (Table 6.4). For infants transfused 
with washed PRBCs, the post-transfusion change in fell between the 3 transfusion exposures 
for IL12 (F(1, 151)= 10.5, p=0.001), IL17A (F(1, 151)= 6.9, p=0.01) and TNF (F(1, 156)= 4.4, p=0.03) while 
no change in the magnitude of the transfusion related change was observed in infants 
transfused with unwashed blood  (Fig 6.7 A, B and C). Further, a fixed effect for transfusion 
exposure was demonstrated for IFN (F(1, 236)= 4.9, p=0.028) with the change greatest after 
the third transfusion irrespective of the type of PRBCs transfused. 
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Figure 6.7 Mean (SEM) change in cytokine concentrations with repeated transfusion 
exposure. A IL-12, B IL-17A and C TNF. *p<0.05 **p<0.01 
6.4 Discussion  
There is a paucity of studies addressing potential mechanistic pathways underlying the 
association between PRBC transfusion exposure and adverse neonatal outcome. The most 
recent meta-analysis of the literature focusing on neonatal transfusion and adverse outcome 
has recognised this as a clear knowledge gap 60. Recently, attention has shifted to investigating 
the recipient’s inflammatory response to transfusion. These studies report increases in 
circulating plasma concentrations of pro-inflammatory cytokines and markers of endothelial 



























































birth 37, 63. This inflammatory response occurs despite modifications to PRBC processing such 
as leukodepletion which are proposed to reduce their inflammatory potential and therefore 
the incidence of transfusion associated neonatal morbidity and mortality 129.  
 
There are even fewer studies addressing the potential for transfusion with washed 
leukodepleted PRBCs to further ameliorate this unwanted consequence of transfusion 
exposure in the critically ill. In the current study, transfusion with washed PRBCs resulted in 
significant post-transfusion decreases in plasma pro-inflammatory cytokines and chemokines, 
while transfusion with unwashed PRBCs resulted in the opposite, with significant increases in 
IL-17A and TNF. By the 3rd transfusion exposure this response to unwashed blood was also 
associated with an increase in markers of endothelial activation, specifically MIF and PAI1, an 
effect not seen with washed PRBCs. This data suggests that not only is the potential for 
transfusion-related immunomodulation present in the initial days following extremely preterm 
birth, changes with on-going repeated transfusion exposure and critically can be modified by 
transfusion with washed PRBCs. If transfusion-related immunomodulation does constitute a 
critical process linking PRBC exposure to morbidity and mortality in this high-risk patient group, 
the current data suggests that the use of washed PRBCs could reduce the adverse impact of 
TRIM and ultimately result in improved clinical outcomes. 
 
Extremely preterm infants represent a particularly heavily transfused population receiving on 
average 3-5 blood transfusions during their hospital admission most commonly early in their 
admission to NICU 48. Despite this, previous studies have focused on single exposures often 
weeks after preterm birth 37, 63. A strength of the current study was that repeated transfusion 
exposure rather than a single transfusion event was investigated. For infants transfused with 
washed PRBCs lower post-transfusion plasma concentrations of pro-inflammatory cytokines 
were seen after the 1st, 2nd, and 3rd transfusion exposures, an effect not observed with 
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unwashed PRBCs. The most striking difference in response to unwashed and washed PRBCs 
was observed following the 3rd transfusion, specifically opposite effects on plasma 
concentrations of IL-12, IL-17A and TNF, with transfusion with washed PRBCs eliciting a 
significantly reduced pro-inflammatory response. This appears to be independent of 
gestational age, sex, and degree of pre-transfusion anaemia. The pro-inflammatory response 
to repeat transfusion exposure with unwashed PRBCs is analogous with observational data 
suggesting a relationship between increasing transfusion exposure and/or cumulative volume 
of blood transfused and risk of overall mortality 170 and morbidities such as BPD, ROP, and NEC 
193, 276, 277. However, whether the observed differences in recipient immune responses between 
those transfused with washed versus unwashed PRBC translates to clinically meaningful 
outcomes remains unknown.  
 
The interaction between pro-inflammatory cytokines and the endothelium may play an 
important role linking transfusion exposure to adverse clinical outcomes. For instance, TNF and 
IL-1β activate endothelial cells resulting in the recruitment of leukocytes to sites of cellular 
damage 278 and IL-8 promotes leukocyte emigration from the vasculature 279. Central to these 
processes is MIF, which promotes the expression of endothelial P-selectin and the arrest of 
leukocyte rolling 280. MIF is important in the regulation of host inflammatory and immune 
responses and is produced by monocytes/macrophages upon stimulation with various pro-
inflammatory stimuli, including TNF and interferon 281. PRBC type specific alterations in PAI1 
were also observed. PAI1 is not commonly associated with the preterm morbidities, however 
it has recently been proposed to play a role in the pathogenesis of BPD 282. It is produced by a 
number of cells such as macrophages, adipocytes and cardiac myocytes and increased 
expression is associated with tissue and vascular damage 283. PAI-1 is thought to be part of the 
acute phase response and is strongly influenced by inflammatory cytokines such as TNF and IL-
6. The current data supports a link between TRIM and endothelial activation or damage, with 
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the 3rd transfusion exposure to unwashed but not washed PRBCs associated with post-
transfusion increases in TNF, MIF and PAI1. This transfusion related effect could contribute to 
organ dysfunction and morbidity, for instance post-transfusion lung injury 78.  
 
While a “two-insult” hypothesis has been proposed to underlie TRIM the exact mechanism/s 
remains poorly understood. It has been suggested that TRIM results in long term or permanent 
alteration to immune function 167 which is then compounded by repeat transfusion exposure 
50. While the volume needed to induce TRIM is likely highly patient specific 49, previous studies 
have demonstrated immunomodulation following exposure to 3-4 PRBC transfusions 49, 50, 166, 
168. This is in agreement with the current data where the most marked transfusion-related 
changes in cytokines and markers of endothelial activation occurred following the third 
transfusion exposure. However, the lower post-transfusion cytokine concentrations seen 
following transfusion with washed PRBCs was surprising. One possible explanation is that 
anaemia per se is known to be pro-inflammatory with the paediatric and adult literature 
reporting elevated concentrations of IFNγ, IL-6 and TNF in iron deficiency anaemia 284, 285 and 
elevated IL-2, IL-6 and TNF in aplastic anaemia 286. Further, in a murine model of acute blood 
loss, the resultant pro-inflammatory response is blunted by subsequent transfusion with 
reductions in IFNγ, IL-6, and IL-10 287. However, it is unknown what effect, if any, anaemia of 
prematurity in the extremely preterm infant has on basal production of pro-inflammatory 
cytokines. Nonetheless, if similar increases in circulating cytokines did occur, transfusion with 
washed PRBCs may result in a dampened inflammatory response in the recipient resulting in a 
net reduction in post-transfusion cytokine concentrations. Transfusion with unwashed PRBCs, 
resulting in greater transfusion-associated immunomodulation and pro-inflammatory cytokine 
production, may conversely result in comparable or greater concentrations of post-transfusion 
circulating cytokines despite correction of the initial pro-inflammatory anaemic state. 
Interestingly, when degree of pre-transfusion anaemia was included as a co-variate in the 
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mixed linear models’ analysis of the temporal pattern of change in cytokine and markers of 
endothelial activation concentration following the first 3 transfusion exposures, it did not exert 
a significant effect.  
 
We know that washing PRBCs alters their immunomodulatory potential 254. In addition to 
residual leukocytes, PRBC units also contain non-polar lipids and a mixture of pro-inflammatory 
lysophosphatidylcholines (lyso-PCs) 288. Lyso-PC modulates the activity of NKT and T cells 289, 
acts as an NK cell chemoattractant 290, induces dendritic cell maturation 291, and stimulates the 
production of pro-inflammatory cytokines 292. In addition, ecosanoids (prostaglandins and 
thromboxanes) can also accumulate in PRBCs 293. PRBC washing removes these bioactive 
substances along with extracellular potassium, inflammatory cytokines and chemokines, as well 
as cell-free haemoglobin and PRBC microparticles 172. These reductions occur not only when 
packs are washed at the initial storage time but also following storage for a number of days. 
Importantly, in vivo studies have shown that incubation of pulmonary endothelial cells with 
supernatant from washed PRBC transfusion packs is not associated with the increased 
endothelial permeability or pro-inflammatory cytokine and chemokine release observed 
following incubation with supernatant from unwashed PRBCs 172, 174.  The sole study comparing 
the effect of transfusion with unwashed PRBCs to washed PRBCs in a paediatric population 
demonstrates a reduction in the post-transfusion increases in IL-6 and IL-10 in the washed 
group 163. The current data suggests that PRBC washing is associated with a similar effect in the 
transfused extremely preterm infant, with a different response to that observed with 
unwashed PRBC characterised by less pronounced effect on circulating cytokines and no impact 
on markers of endothelial activation. This finding suggests the TRIM response is different to 
washed PRBCs which, in this high risk, heavily transfused population, warrants further detailed 
investigation linking altered immune responses with subsequent morbidity and mortality.   
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While baseline pre-transfusion cytokine concentrations did not alter between the 1st and 4th 
transfusion for those infants who received unwashed PRBCs, pre-transfusion concentrations of 
IFNγ, IL-1β, IL-12 and IL-17A increased in those who received washed PRBCs. This was not due 
to differences in clinical characteristics such as postnatal age, degree of anaemia, requirement 
for invasive respiratory support (as a proxy for severity of lung disease) or proportion receiving 
antibiotics for suspected or proven sepsis at the time of transfusion exposure, all of which could 
alter circulating concentrations of pro-inflammatory cytokines.  While these findings may 
reflect the influence of a reduction in the sample size with each subsequent transfusion and 
inherent biological variability in the recipient’s response to PRBC exposure, data on temporal 
changes in cytokine concentrations in the first weeks of life in preterm infants are very limited 
294, 295 and frequently conflicting. For some of the cytokines and chemokines an increase after 
birth is found, while for others, a decrease is observed 296, 297. Data from extremely preterm 
infants is even more limited and confounded by small sample sizes 298, the influence of an 
increased incidence of intra-uterine exposure to inflammation 299 or a focus on characterising 
patterns of change in post-natal cytokine concentrations as a predictor of neonatal morbidity 
such as BPD or brain injury 300. With TRIM proposed to result in long-term alterations in immune 
function (ref 167) and compromising both pro-inflammatory and immunosuppressive 
components, the lack of a post-natal age dependent change in baseline cytokine 
concentrations in the unwashed PRBC group may represent an aberrant developmental 
response. Despite unchanged baseline levels the magnitude of the post-transfusion increases 
in cytokines grew with subsequent transfusion exposure. Conversely, in the washed group, for 
those cytokines where the baseline increased between the 1st and subsequent transfusions, 
the post-transfusion concentration progressively fell. Further, while the changes in baseline 
concentrations in the unwashed group did not reach significance, the pattern of change 
between the 1st and 4th transfusions were similar. This may reflect the influence of a reduction 
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in the sample size with each subsequent transfusion and inherent biological variability in the 
recipient’s response to PRBC exposure.   
 
Previous studies, focusing solely on unwashed leukodepleted PRBC packs, have reported 
conflicting evidence regarding the presence of detectable levels of pro-inflammatory cytokines 
and markers of endothelial activation in the supernatant of the transfusion units 37, 63, 162. In the 
current study, IL-6 was detectable in the unwashed PRBC transfusion packs alone, while IL-8 
and TNF were present in comparable concentrations in the supernatant of pack samples from 
both unwashed and washed PRBCs. Further, the markers of endothelial activation sICAM1, 
sVCAM1 and PAI1 were detectable in more unwashed PRBC packs than washed PRBC packs, 
and in higher concentrations. Conversely, while MIF was detectable in both pack types, levels 
were higher in the washed PRBC units. Firstly, due to methodological constraints, the pack 
concentrations where only measured in 72 samples selected at random. However, the findings 
are consistent with those previously reported by Keir and colleagues in unwashed 
leukodepleted PRBCs used for transfusion in preterm infants 63. However, they contradict the 
findings of Dani 37 and Locke 162 who report no detectable cytokine levels. While the age of the 
PRBCs transfused and the multiplex assay approach employed to measure the concentration 
of multiple analytes were similar between the current study and that of Dani and colleagues 37, 
there are significant methodological differences that deserve consideration. The most 
significant difference is related to the blood pack additive solution used. Studies by Dani and 
Locke using unwashed PRBCs containing AS-5 Optisol  37, 162. The PRBC packs in the current 
study and that of Keir and colleagues contained SAG-M 63. While some studies have failed to 
show a difference in cytokine content of PRBC units stored in different solutions 301, others 
have reported marked differences with the media used having a significant impact on pack 
cytokine levels 302 and on inherent properties of the stored PRBCs, such as microparticle 
production and endothelial adhesion, effects greater with SAG-M 303.   
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Irrespective of the inconsistencies in the published data, the biological significance of the 
presence of cytokines and markers of endothelial activation in the unwashed and washed PRBC 
remains unknown. We observed an increase in IL-12 and IL-17A following the second and third 
transfusions respectively, neither of which were detected in the transfusion packs, post-
transfusion concentrations of MIF where greater in the unwashed group despite this group 
exhibiting lower pack levels. Further, if any increase was solely the result of infusion of 
cytokines along with the PRBCs, one would expect a consistent post-transfusion change in 
cytokine concentration following the 1st, 2nd and 3rd transfusions, rather than specific changes 
that differed.  
 
The current study has a number of strengths and limitations. The requirement for transfusion 
and age of PRBCs transfused was controlled through the use of a transfusion threshold defined 
a priori and a maximal shelf life of 14 days. These measures limit the impact of difference in the 
age of the PRBC pack, therefore storage lesion, and the potential for differences in the degree 
of anaemia to confound the transfusion related changes in cytokines and markers of 
endothelial activation.  As previously stated, a strength of the current study was that repeated 
transfusion exposure, rather than a single transfusion event, was investigated. This makes the 
data more clinically relevant, with extremely preterm infants receiving on average 3-5 blood 
transfusions during their hospital admission 48. However, post-transfusion concentrations of 
cytokines and markers of endothelial activation were measured at a single time point; 
therefore, it is not known whether these changes were sustained or transient. This is an 
important consideration, with some data supporting time related changes in specific cytokines 
and adhesion molecules 37. Indeed, these changes may be the result of alterations in immune 
cell phenotype and therefore cytokine production, an effect that can only be conclusively 
proven through more detailed immune profiling which extends beyond measurement of 
circulating cytokines and markers of endothelial activation.  
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While baseline, pre-transfusion cytokine concentrations were higher in the current study in 
comparison to other studies reporting responses to single transfusion later in the post-natal 
period 37, 38, this is likely due to samples being collected earlier in the post-natal period. 
Importantly, the baseline cytokine concentrations observed in the current study are consistent 
with previous studies characterising the temporal changes in plasma cytokines in extremely 
preterm infants over the first weeks of postnatal life 298, 300, with the post-transfusion increases 
observed following exposure to unwashed blood higher than those reported across the 
neonatal period.  However, it is important to acknowledge that temporal changes in plasma 
cytokines are likely confounded by many other inflammatory signals, both pathological and 
related to intensive care therapies such as on-going mechanical ventilation experienced by the 
extremely preterm infant in the first weeks of life 304. Finally, the number of infants receiving 
multiple transfusions decreased as transfusion exposure increased. This may have resulted in 
a loss of power and ability to accurately detect true differences between pre- and post-
transfusion concentrations of cytokines and markers of endothelial activation in response to 
unwashed versus washed PRBC exposure. As a result, the mixed linear models’ analysis, which 
controlled for the contribution of gestational age, sex, postnatal age at first transfusion and 
degree of pre-transfusion anaemia on the change in cytokines and markers of endothelial 
activation across the exposures, was limited to the first three transfusions. 
 
In summary, the current data supports the potential for transfusion-related 
immunomodulation to be present early following preterm birth at a time when the 
pathophysiologic processes that potentially contribute to the development of the major 
morbidities associated with extremely preterm birth are likely to be initiated. Further, the 
recipient response to transfusion exposure appears to be influenced by the number of 
transfusions they receive. Most importantly, the data suggests that inflammatory responses 
following transfusion exposure in the extremely preterm infant differ between those receiving 
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unwashed PRBCs compared to those receiving washed PRBCs. These data add to our growing 
understanding of TRIM in the extremely preterm infant and highlight the need to further 
characterise the mechanisms linking PRBC transfusion with increased pro-inflammatory 
cytokine production and endothelial activation, a biologically plausible link between transfusion 
exposure and increased incidence of neonatal morbidity and mortality. Ultimately, to 
determine if the adoption of transfusion with washed PRBCs translates into improved survival 
free of significant neonatal morbidity in extremely preterm infants requires an adequately 
powered randomised controlled trial comparing washed with unwashed PRBC transfusion with 
clinically important outcomes.






































7.1 Introduction  
It is clear that transfusion exposure increases the risk of death in critically ill adult patients 49 
with the risk of both short and long-term mortality increasing in proportion to total number of 
transfusions received 49 50. While historically this has been thought to be explained by co-
morbidities in the transfused recipient, a growing body of literature suggests that 
characteristics of the blood donor impact a recipient’s prognosis 228, 305. In particular, emerging 
evidence supports a role for female donor sex to negatively influence the recipient’s response 
198. As a result, the role of blood donor demographics on transfusion efficacy and safety is an 
emerging area of interest in transfusion medicine research 306-308. As discussed previously, 
morbidity in the transfusion recipient may be the result of adverse physiological responses, 
aberrant immunological reactions, or perhaps both. Indeed, while there is emerging evidence 
focusing on donor sex-related differences in haemoglobin increment in the recipient, there is 
very little data examining the effect of donor sex on other physiological biomarkers, immune 
function or outcomes assessing transfusion effectiveness and safety 309. 
 
Specifically, female donor sex has been proposed to contribute to adverse outcomes for 
transfusion recipients. Research to do date has primarily focused on plasma and platelet 
transfusions. Data from retrospective observational studies suggests significantly greater risks 
of adverse outcomes, in particular the diagnosis of TRALI 202, following transfusion of plasma or 
platelets from female donors compared to male donors. However, there is increasing 
awareness that exposure to PRBCs from a female donor may pose a similar risk 199. Whether 
similar effects occur in the preterm infant in response to exposure to blood products from 
female donors has received little attention. A single retrospective study of extremely preterm 
infants who received a transfusion of either exclusively male or mixture of male and female 
donor PRBCs reported significantly higher rates of mortality, significant morbidity and 
prolonged hospital stay in those infants exposed to any female blood 234. While the underlying 
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mechanism linking the sex of the donor to higher rates of adverse outcome remains unknown, 
HLA antibodies are one potential candidate 202. Approximately 20% of multiparous women have 
circulating HLA antibodies 207. These antibodies are known to stimulate circulating leukocytes, 
neutrophils and other cytotoxic cells, initiating a cascade of inflammatory events and 
widespread inflammation 205, 210.  
 
The aim of this chapter is to investigate whether the sex of the donor contributes to immune 
response to PRBC transfusion exposure in the extremely preterm infant. Specifically, this 
analysis will explore whether sex of the donor contributes to any of the changes in circulating 
plasma cytokines observed in the extremely preterm infant following transfusion with 
unwashed and washed PRBCs.  
7.2 Methods 
As described in Chapter 6, the number of cytokines and markers of endothelial activation that 
exhibited significant post-transfusion changes increased with each transfusion exposure with 
the greatest differences seen after the third transfusion. Therefore, the donor sex for each of 
the first 3 PRBC packs the infant received was obtained from The Australian Red Cross Blood 
Service. Briefly, transfusion pack identification numbers were recorded from each pack and 
sent to the New South Wales branch of the Australian Red Cross. The identification number 
revealed the characteristics of the pack’s donor. For the purpose of this study only the sex of 
the donor was required. Study groups were defined by the donor sex (those who received 
PRBCs from only male donors for the first three transfusions or those who received any PRBCs 
from a female donor) and whether they received unwashed or washed PRBCs. Cytokines and 
markers of endothelial activation data were therefore analysed as 4 groups: unwashed PRBCs 
male only donors; unwashed PRBCs any female donor; washed PRBCs male only donors; and 
washed PRBCs any female donor. While all FFP was obtained from male donors, platelets may 
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be from either male or female. As data on the donor sex for platelet transfusions the infants 
received was not available, those infants who received a platelet transfusion before any of the 
3 PRBC transfusion exposures were excluded from analysis.  
 
 Inflammatory cytokines and markers of endothelial activation were analysed using the 
methods described in Chapter 3. Briefly, prior to the transfusion, infants had 0.4mL whole blood 
collected with a post-transfusion sample collected 4-6 hours following transfusion completion. 
Samples were centrifuged and plasma aliquoted for cytokine and markers of endothelial 
activation analysis. Circulating cytokine levels for each transfusion sample were analysed using 
the Human High Sensitivity T-Cell Magnetic Bead panel multiplex ELISA (see 3.4.1 High 
Sensitivity T-Cell Multiplex Assay). Markers of endothelial activation were measured using 
human sepsis bead panel multiplex ELISA (see 3.4.2 Neonatal Sepsis Assay). 
7.2.1 Statistical Analysis  
Demographic data is presented as median (IQR) or N (%). Fisher’s Exact Test or Pearson Chi-
Square was used for comparison between groups. As the cytokine and endothelial markers 
were not normally distributed the Kruskal-Wallis test was used to compare differences 
between pre- and post-transfusion concentrations for the 4 groups with a p<0.05 considered 
statistically significant. Where the pre- post-transfusion change was significant for more than 
one of the groups, the magnitude of the difference (∆change) was compared by the Kruskal-
Wallis test with Dunn’s post hoc test to investigate differences between the individual groups, 
with a p<0.01 used to correct for multiple comparisons. Further, hierarchical multiple 
regression was used to assess the impact of exposure of the four transfusion exposure groups 
(unwashed PRBCs male only donors; unwashed PRBCs any female donor; washed PRBCs male 
only donors; and washed PRBCs any female donor) on the magnitude of the change, after 
controlling for gestational age, newborn sex, and age at first transfusion. 
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7.3 Results  
Baseline antenatal characteristics are shown in Table 7.1. Groups were defined by type of PRBC 
transfusion (unwashed versus washed) and donor sex. While there were no significant 
differences in major clinical characteristics including gestational age, exposure to antenatal 
inflammation, mode of delivery or birthweight, infants who received more than one transfusion 
with washed blood from a male donor were more likely to be growth restricted and from a pre-
eclamptic pregnancy. No differences in any of the groups was observed with transfusion 
characteristics. The three transfusion exposures occurred within the first three weeks of 
postnatal life. Unsurprisingly, as transfusion exposure increased, the number of newborns 
transfused with only blood from a male donor decreased. 
There was no significant difference between the groups in pre-transfusion cytokines prior to 
any of the three transfusion exposures and the baseline pre-transfusion concentrations of the 
individual cytokines was not significantly different between the 1st and 3rd transfusion 
exposure.  
 











n 40 30 55 14  
Gestation 25 (24-27) 26 (25-27) 26 (25-27) 25 (25-26) ns 









IUGR 6 (13) 4 (13) 13 (22) 1 (6) ns 

























28 (62) 20 (65) 40 (68) 12 (67) ns 
Chorioamnionitis 19 (42) 10 (32) 19 (32) 5 (28) ns 
Preeclampsia  1 (2) 1 (3) 5 (8) 0 (0) ns 



















n 17 35 31 24  
Gestation 25 (23-26) 25 (24-27) 26 (24-27) 26 (25-26) ns 









IUGR 1 (5) 5 (14) 10 (29) * 2 (7) 0.05 

























15 (75) 21 (57) 24 (69) 18 (67) ns 
Chorioamnionitis 11 (55) 14 (38) 13 (37) 9 (33) ns 
Preeclampsia  1 (5) 1 (3) 4 (11) 0 (0) ns 


















n 10 32 16 28  
Gestation 25 (24-26) 25 (24-26) 25 (23-26) 25 (24-26) ns 









IUGR 0 (0) 5 (15) 6 (35) * 3 (9) 0.04 

























8 (73) 21 (62) 13 (76) 20 (61) ns 
Chorioamnionitis 7 (64) 14 (41) 4 (24) 14 (42) ns 
Preeclampsia  0 (0) 0 (0) 4 (24) * 0 (0) <0.001 

















Data presented as median (IQR) or n (%) 
 
Following the first transfusion IL-10 decreased in those infants in the  washed blood male only 
donors group (17.1 (3.1-30.5) to 10.6 (3.4-17.1) pg/ml, p=0.02), an effect also seen following 
the second transfusion exposure (14.4 (3.1-58.3) to 12.7 (5.4-28.6) pg/ml, p=0.022). At the 
second transfusion exposure IL-8 fell in infants transfused with washed blood male only donors 
group (350.5 (95.5-484.5) to 130.1 (86.5-233.4) pg/ml, p=0.049) and washed blood any females 
group (231.5 (64.3-370.6) to 88.6 (32.0-172.3) pg/ml, p=0.017).  
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Table 7.2 Pre-post third transfusion exposure cytokine concentrations  
 Unwashed Male 
(n=10) 




Washed any Female 
(n=28) 








































































































































Table 7.3 Change in plasma cytokine concentration pre- to post third transfusion exposure (pg/ml) 
 Unwashed Male 
(n=10) 




Washed any Female 
(n=28) 
p 
IFNγ -7.7 (-13.3- 0.8) 0 (-0.6- 10.39) -4.2 (-21.7—0.1) -1.5 (-6.3—0.1) 0.01 
IL-10 -3.8 (-34.7-3.1) 3.4 (0-19.33) -7.4 (-13.5- -4.4) -1.6 (-16.2- 2.5) 0.01 
IL-12 -1.7 (-1.9- -0.8) 0.4 (0- 5) -1.5 (-30- -0.7) -2.3 (-8.2- 0.03) 0.001 
IL-17A  0.6 (-1.3- 1.2) 4.8 (-0.6- 12.5) -4.5 (-21.7- -1) -1.7 (-10.4- 2.1) 0.002 
IL-1β 0 (-0.3- 2.2) 0 (-0.3- 6) -8.1 (-21.5-0) -0.1 (-1.4- 1.7) ns 
IL-6 -1.2 (-8.2- 10.8) 0 (-1- 6) -3.7 (-30- -2.4) -5.6 (-15.7- -0.2) 0.008 
IL-8 -65 (-132.2- 23) 54 (-13.5- 78.3) -168.1 (-216.4- -33.7) -40.6 (-258.7- 53.7) ns 
TNF 7 (-3.2- 31.45) 14.5 (-0.8- 43.5) -13.6 (-18.6- 5.3) -15.4 (-28.1- 11.9) ns 
Data presented as median (IQR) 
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The third transfusion exposure was associated with the greatest number of post-transfusion 
changes in circulating cytokine concentration (Table 7.2). While the 1st and 2nd transfusion 
exposures only resulted in significant changes in those groups receiving washed blood, the 3rd 
transfusion exposure also resulted in significant changes in those infants in the unwashed 
PRBCs any female donor group, with no differences observed in the unwashed PRBCs male only 
donor group. For those infants receiving washed PRBCs, IFNγ and IL-12 decreased, while IL-6 
increased, but only in the washed male donor only group. For the infants receiving unwashed 
PRBCs, IL-17A and TNF increased. Interestingly, post-transfusion IL-10 concentrations 
decreased in those newborns transfused with unwashed PRBCs from both males and females 






















Figure 7.1 ∆change of inflammatory cytokine response to 3rd transfusion exposure ( Male  
Female). A IL-10, B IL-12, C IL-6, D IL-17A, Median (IQR) *p<0.05 **p<0.01 †p<0.001.  
 
To determine if the magnitude of the observed post-transfusion changes in cytokines that 
occurred in 2 or more of the groups differed the ∆change between the pre- and post-
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transfusion concentrations was calculated. A significant difference in the ∆change was seen for 
IFNγ, IL-6, IL-10, IL-12, and IL-17A (Table 7.3). On post-hoc comparison, the post-transfusion 
increases in the unwashed PRBCs any female donor group was significantly different from the 
observed decrease in the washed PRBCs any female donor group (p=0.02) (Figure 7.1A). A 
similar effect was also seen for IL-12 (p=0.002) (Figure 7.1B) and IL-6 (p=0.02) (Figure 7.1C), 
with the differences between these two groups for IL-17A close to significance (p=0.07) (Figure 
7.1D). Significant differences were also seen between the post-transfusion increases in the 
unwashed PRBCs any female donor group and decreases in the washed PRBCs male only donor 
group for IL-12 (p=0.001), IL-6 (p=0.05) and IL-17A (p=0.003).   
 
Where significant post-transfusion differences between pre- to post-transfusion cytokine 
concentrations observed following the third transfusion, hierarchical multiple regression was 
used to assess the impact of exposure of the four transfusion exposure groups (unwashed 
PRBCs male only donors; unwashed PRBCs any female donor; washed PRBCs male only donors; 
and washed PRBCs any female donor) on the magnitude of the change, after controlling for 
gestational age, newborn sex, age at first transfusion and degree of pre-transfusion anaemia. 
Preliminary analyses were conducted to ensure no violation of the assumptions of normality, 
linearity, multi-collinearity and homoscedasticity. Gestational age, newborn sex, and age at first 
transfusion were entered at Step 1 with transfusion exposure group entered at Step 2.  
 
For IL-12, gestation, sex, age at first transfusion and degree of pre-transfusion anaemia 
accounted for 10.6% of the variance in Change in plasma IL-12 concentration. After entry of 
transfusion exposure group at Step 2 the total variance explained by the model as a whole was 
26.2%, F(5, 55)=4.878, p=0.002. Transfusion exposure group explained an additional 16% of the 
variance in Change in IL-12, after controlling for gestation, sex, age at first transfusion and 
degree of pre-transfusion anaemia, R squared change = .16, F change (1, 55) = 11.64, p=0.001. 
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In the final model gestational age and transfusion exposure group were statistically significant, 
with transfusion exposure group recording a higher  value ( = .41, p=0.001) than gestational 
age (( = -.26, p=0.04). 
 
For IL-17A, gestation, sex, age at first transfusion and degree of pre-transfusion anaemia 
accounted for 14.4% of the variance in Change in plasma IL-17A concentration. After entry of 
transfusion exposure group at Step 2 the total variance explained by the model as a whole was 
29.4%, F(4, 54)=5.63, p=0.001. Transfusion exposure group explained an additional 15% of the 
variance in Change in IL-17A, R squared change = .16, F change (1, 54) = 11.46, p=0.001. Again, 
in the final model gestational age and transfusion exposure group were statistically significant, 
with transfusion exposure group recording a higher  value ( = .4, p=0.001) than gestational 
age (( = -.25, p=0.049). 
7.4 Discussion 
The impact of donor sex on recipient outcome has been demonstrated in a number of areas of 
transfusion / transplantation medicine. Blood product donor sex is a well-recognised risk factor 
for TRALI 310, 311, donor-recipient sex mismatch is a recognised risk factor for decreased survival 
post-cardiac transplant 312, and stem cell recipients show better outcome when cells are 
donated by men 313. However, the evidence for an effect of PRBC donor sex on adverse 
outcomes in the preterm neonatal population has only recently gained attention. A single 
retrospective observational study has reported an association between exposure to female 
PRBC transfusion with morbidity and prolonged length of hospital stay 234. Further analysis 
comparing exclusively female donor blood with male donor blood demonstrated a dose 
response effect with a significant interaction of female donor blood and the number of 
transfusions and morbidity 234.  
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To date, critically, the biological mechanisms that might explain why donor sex could result in 
harm in the transfusion recipient remain poorly understood 198. In the current study we focused 
on the potential for donor sex to influence TRIM in response to both unwashed and washed 
PRBCs. The post-transfusion changes in circulating cytokines differed significantly in those 
infants who received unwashed PRBCs from both male and female donors, compared to those 
transfused with washed PRBCs. Specifically, by the 3rd transfusion exposure, infants transfused 
with unwashed PRBCs from both male and female donors had a significant increase in 
circulating IL-10, IL-12, IL-6 and IL-17A. The opposite was observed for infants transfused with 
washed PRBCs from only male donors and those transfused with washed PRBCs from both 
sexes. This data suggests that not only the type of blood, whether unwashed or washed, but 
also donor characteristics are important. Further, transfusion related changes in immune 
responses appear central to the recipient’s response to PRBC exposure highlighting the 
complexity of transfusion associated morbidities and mortality. 
 
Some differences between PRBCs from male compared to female donors are fundamental. For 
instance, PRBCs from male donors are known to have higher total haemoglobin content than 
those from females, while rates of storage haemolysis are higher 308, 314. Further, larger 
increments in haemoglobin concentration are seen in recipients of PRBCs from male donors 
compared to female donors 308. In addition, differences in haemoglobin increment in sex-
mismatched versus same sex donors have been reported with male recipients of female 
derived PRBCs having significantly smaller increases in haemoglobin concentration than female 
recipients of male derived PRBCs 308. Pre-menopausal women lose blood monthly through 
menses and therefore their red cell mass is comprised of a higher proportion of young red cells 
with greater rigidity and better oxygen carrying capacity 307. Further, a difference in iron status 
between female and male donors, particularly those female donors who have previously been 
pregnant, has been proposed to be important, with donor iron deficiency resulting in iron-
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deficient erythropoiesis, associated with worse recovery of red blood cells post-transfusion in 
animal models 315. 
 
Specific attention has been given to a potential role for antibody-mediated immune cell 
activation by donor HLA-antibodies 310. HLA molecules are part of the human major 
histocompatibility system (MHC) and are a family of cell surface glycoproteins that bind to 
intracellular and extracellular peptides 203. The HLA family is separated into two distinct 
functional and structural groups; HLA Class I and HLA Class II 205. Class I HLA antigens are carried 
in varying degrees on almost all nucleated cells, whereas Class II antigens are carried on 
immune cells, such as activated T cells, B cells, macrophages, dendritic cells, cells of the thymus 
and in certain other cell lineages, such as epithelial and endothelial cells, after exposure to 
interferon-γ 204.  The overall role of the HLA proteins is induction and regulation of immune 
responses 205. However,  in the setting of an inappropriate immune response, such as with a 
sex-mismatched transfusion, the immune response produced by the HLA proteins may be rapid 
and extremely robust 206.  
 
Anti-HLA antibodies are more common in women than men, even if previously transfused. 
Importantly, the rates of sensitisation increase significantly in those women with a history of 
any pregnancy increasing with the total number of pregnancies 316. The rates of antibody 
reactivity with MHC Class I and Class II are very similar, ranging from 20-50% detected in those 
with a history of pregnancy 317. The most compelling evidence linking anti-HLA antibodies and 
donor sex to clinical outcomes centres on TRALI where plasma containing blood products from 
female donors is a well-established risk factor for this major transfusion related morbidity 311. 
It has been proposed that HLA class II antibodies activate neutrophils in the pulmonary 
vasculature by binding to monocytes causing release of pro-inflammatory cytokines and 
resulting in end-organ damage 218. Implicated pro-inflammatory cytokines and chemokines 
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include IFNγ, IL-6 and IL-8 318, 319, inflammatory mediators which were found to change in a 
donor sex and PRBC transfusion product specific manner in the current study. 
 
Previously, platelets and plasma products have been the only blood products thought to have 
a role in the mechanisms by which HLA-antibodies cause an adverse immune reaction 212. With 
the surface bound HLA antigen easily detached and shed during storage 205, universal 
leukodepletion and storage time limits were thought to be the solution to the risk posed by 
HLA antibodies 207. However, this is not the case with HLA antibodies detectable in transfused 
packs 207. While HLA Class I antigens are carried in varying degrees on erythrocytes 205, the role 
of PRBCs in antibody-mediated transfusion reactions has been largely overlooked. It has been 
suggested that a single RBC carries around 100 to 2000 HLA Class I antigens and, as there are 
1000 times more red blood cells to leukocytes, the potential for HLA mediated adverse immune 
responses may, in fact, be more significant than for plasma and platelets 212.  
 
Our observation of significant changes in pro-inflammatory cytokines in relation to exposure to 
female donor PRBCs after repeat transfusion is consistent with the HLA-antibody hypothesis. 
Even after leukodepletion HLA antibodies are detectable in transfused packs 207. In addition, 
the preterm infant is capable of developing anti-HLA antibodies in response to repeat 
transfusion exposure 320 despite the assumption that the preterm infant has a functionally 
immature capacity to secrete immunoglobulins 321. Finally, washing of transfusion products has 
been shown to eliminate residual antigens 322-324. This may explain the potentially beneficial 
effect seen in those infants receiving blood from female donors, with post-transfusion pro-
inflammatory cytokine concentrations significantly lower in those transfused with washed 
PRBCs compared to those receiving unwashed PRBCs. It is also likely that the relative exposure 
to plasma elements after a 15ml/kg PRBC transfusion in the extremely preterm infant is greater 
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than that for a 1-2 unit PRBC transfusion in an adult 234, an exposure that would be reduced 
following PRBC washing. 
 
The current data represents an exploratory analysis focusing on potential causal pathways 
underlying the association between PRBC transfusion related adverse outcomes and donor sex. 
As such, clinical outcomes are not reported. Murphy and colleagues have recently reported a 
large retrospective observational study on the impact of donor sex on clinical outcomes in a 
population of preterm infants of similar gestational age. In addition to demonstrating an 
increased incidence of BPD, NEC and death or any morbidity in those infants who received any 
PRBC transfusion from a female donor, the odds ratio for any morbidity increased for each 
additional female donor transfusion 234. Our finding of greater transfusion related changes in 
immune function with increasing transfusion exposure would seem consistent with this later 
finding. There are, however, some important differences between the studies. Obviously, 
Murphy et al did not investigate the additional contribution of transfusion with unwashed 
versus washed blood with all PRBC transfusions leukodepleted PRBCs although transfusion 
volume and duration were similar. In addition, we chose to investigate alterations in circulating 
pro-inflammatory cytokines in infants who received up to 3 PRBC transfusions. On the contrary, 
Murphy at el did not control for transfusion exposure and as a result, a significantly higher 
number of transfusions was received by those in the “female donor” group. This is a potential 
source of bias with the association between the treatment and the outcome both impacted by 
the indication. Unfortunately, this is well recognised in transfusion studies and only partially 
controlled for by attempts to compare illness severity scores between groups. Finally, the 
studies differ with regard to exposure to other transfusion products. In the current study, we 
excluded from analysis any infant who received platelets prior to any PRBC transfusion 
exposure, although we did include infant who had FFP which in our institution is derived solely 
from male donors. This was principally due to the sex of the platelet donor being unknown due 
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to the use of pooled platelet units in some. Conversely, Murphy at el excluded infants who 
received both platelets and FFP.  
 
An important strength of the current study was our approach to classifying donor exposure. As 
transfusion exposure increases the likelihood of receiving a mixture of male donor only and 
sex-mis-matched PRBC transfusions increases making it increasingly difficult to define exposure 
status. By limiting the current study to the first three PRBC transfusions and excluding those 
who received platelet transfusions we were able to define a simple binary variable (at least one 
transfusion that was mis-matched versus exclusively male donor only). However, there a 
number of limitations. The aim of the current study was to determine the effect of exposure to 
PRBCs from a female donor on immune responses in the transfusion recipient. Unfortunately, 
due to our sample size, we were unable to recruit a group of extremely preterm, female infants 
transfused with exclusively female donor blood. Further, we did not investigate the effect of 
sex mismatched transfusions in females, that is female transfusion recipients transfused with 
PRBCs from male donors. However, adult data reports a significant increase in the hazard ratio 
for death for male recipients receiving PRBCs from both female donors with and without a 
history of pregnancy, while no significant effect was seen in female recipients receiving either 
sex-matched PRBCs from donor females or sex-mismatched PRBCs from males 228, 233. Due to 
limitations in the data collected at the time of blood product donation, we also have no 
information of the pregnancy status of the female donors nor the HLA status or previous 
transfusion history for donors of either sex. Finally, as per Chapter 6, post-transfusion 
concentrations of cytokines were measured at a single time point; therefore, it is not known 
whether these changes were sustained or transient.  
 
The results of this study highlight the complexity of transfusion responses in a high risk, heavily 
transfused population. While an area of increasing interest in adults, studies focussing on the 
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preterm infant remain rare. The current data emphasises the importance of specifically 
investigating the role of donor characteristics, and particularly sex, in this relatively unexplored 
area of transfusion research. However, the clinical implications are potentially wide ranging 
particularly if borne out in follow up studies. If future studies confirm the adverse impact of 
female sex of donor this would impact not only blood banking processes but also the general 
donor pool. While the current data suggests that donor sex influences TRIM in the extremely 
preterm infant, clearly the mechanisms that contribute to these changes remain incompletely 
characterised. Further, there remains a disconnect between studies with an emphasis on major 
clinical outcomes and those with a mechanistic focus. As we do not know the sex of the donor 
when PRBCs are requested for transfusion current practice results in quasi-randomisation of 
donor sex exposure. However, this apparently random allocation of PRBCs is not a replacement 
for a randomised trial, one specifically designed to conclusively address the impact of donor 
sex on both underlying pathophysiologic pathways and clinically relevant outcomes. Clearly, 
this represents a significant knowledge gap. Any future randomised trial of unwashed versus 
washed PRBCs transfusion in the extremely preterm infant warrants consideration of donor sex 
in the study design. It will be also important for future studies that detailed records of the 
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8.1 Final Discussion  
A tailored approach to PRBC transfusion in the extremely preterm newborn would represent a 
significant step forward in perinatal medicine. We have reached a point where decades of 
studies in this heavily transfused population have left the field in an on-going state of 
uncertainty with recent international surveys confirming that, with respect to transfusion 
practices, widespread clinical variation continues 325. The current data provides important 
foundational information upon which on-going research into the consequences of PRBC 
transfusion in the preterm newborn can be built. It is clear that allogeneic leukodepleted PRBCs 
are not an inert product, rather they are biologically active. It is clear that the extremely 
preterm newborn presents unique challenges. From the current data it could be concluded that 
exposure to PRBCs represents one of the commonest iatrogenic inflammatory signals in the 
preterm newborn. If this is the case, a logical response would be to avoid PRBC transfusion if 
at all possible. It is therefore unsurprising that a fundamental unanswered question in this high-
risk group is when to transfuse in addition to what to transfuse with to reduce the risk of 
unwanted adverse transfusion related complications 326. 
 
Specifically addressing the first question, the relatively small number of high-quality 
randomised trials comparing liberal versus restrictive transfusion thresholds is a significant 
problem 136. While RCTs are generally accepted to be the highest level of evidence it is not 
infrequent, particularly in perinatal trials, that the available evidence to be derived from trials 
are too limited in sample size to accurately and therefore convincingly profile efficacy and 
particularly risk  327. It is anticipated that upcoming publications of the TOP 328 and ETTNO 329 
large-scale randomised trials of transfusion thresholds to guide practice in the preterm 
newborn may finally provide clarity on when to transfuse. In particular, it is hoped that, when 
synthesised with the existing evidence which is now over 10-15 years old, there will no longer 
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be any ambiguity over the effect of liberal versus restrictive transfusion thresholds on death or 
neurodevelopmental impairment in the extremely preterm newborn.   
 
Are we any closer to accurately reporting the risks associated with transfusion? This is a critical 
first step for subsequent studies investigating approaches to transfusion that might ameliorate 
adverse consequence of PRBC exposure. To date, there has been a reliance on observational 
data as most of the risks associated with transfusion are rare and therefore impossible to 
accurately evaluate in trials with small sample sizes 265. Even meta-analysis is inconclusive as 
potential transfusion-related risks are invariably secondary outcomes with trial based data 
therefore inconclusive due to lack of power 136. Indeed, in a recent systematic review focusing 
on potential adverse outcomes associated with transfusion exposure, in the third of the studies 
which were randomised the sample sizes were considered inadequate to thoroughly address 
harm 60. Further, the authors reported that failure to control for potential confounding factors 
such as indication bias or a lack of clear, consistent definitions of the different adverse effects 
related to RBC transfusion in the nonrandomised studies was a recurrent finding 60.  
 
As is the case for defining the correct transfusion threshold, several studies are currently 
underway which may provide more information on the proposed link between transfusion 
exposure and neonatal morbidity. These include large observational studies investigating the 
link between transfusion and ROP 330, 331 and a large multi-national randomised trial 
investigating the link between PRBC transfusion exposure and NEC specifically focusing on the 
contribution of withholding feeding prior to, during and immediately after transfusion 236. What 
remains a pressing need, as highlighted in this thesis, are clinical trials that incorporate a 




Physiological Response to Transfusion  
With a sample size of 154 extremely preterm newborns, the aims of the current thesis were 
restricted to potential mechanistic explanations for the association between transfusion 
exposure with unwashed versus washed PRBCs rather than the impact on clinical outcomes. 
However, physiological responses to transfusion were investigated with a focus on peri- and 
post-transfusion changes in cardio-respiratory variables. While changes over time and in 
response to the type of PRBCs transfused were observed, none met the current agreed criteria 
for the accepted definitions for either TRALI or TACO employed in other critically ill populations. 
What does this finding of no transfusion-related physiologic instability mean for this 
population? One possibility is that clinical correlates of TRALI and TACO do not exist in this high-
risk group. However, this seems counter-intuitive given that the volume of each transfusion 
received by the extremely preterm newborn comparatively far exceeds that in an older child or 
adult in which both these conditions, although rare, definitely exist. Another possibility is that 
given the degree of physiological instability common in this group early in the neonatal course, 
the period in which exposure to PRBCs is greatest, any additional adverse effects on cardio-
respiratory function are obscured by the biological noise of extreme prematurity.  Finally, the 
unique nature of the preterm infant’s cardiovascular system may cope far superiorly to those 
of adults and older children.  
 
There was some evidence of inter-play between transfusion associated immune responses and 
alterations in cardio-respiratory function. Specifically, an association between post-transfusion 
IL-6 concentrations and decreased systemic vascular resistance and increased cardiac output 
was seen suggesting a compensatory response to maintain blood pressure and end-organ 
perfusion in the setting of an increase in pro-inflammatory mediators. However, it is clear that 
the interaction between physiological and immune responses to transfusion remains to be fully 
characterised. Indeed, it is likely that the relative contribution of each varies between individual 
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newborns, influenced by degree of anaemia, illness severity at time of transfusion, and inherent 
characteristics of the PRBCs transfused. It is also important, when considering the potential for 
interaction between immune and physiological responses, to consider observations from 
numerous studies that suggest immunomodulation appears to be “greatest” following 
exposure to 3 or 4 PRBC transfusions 49, 50, 166, 168. It is important to highlight that the relationship 
between physiological responses to transfusion and transfusion related changes in circulating 
cytokines was investigated for the first exposure to PRBCs in transfusion naïve newborns alone. 
The possibility that the magnitude of any physiological response to transfusion increases with 
repeat transfusion exposure, if TRIM is indeed a significant contributor to the underlying 
pathophysiologic processes, warrants further investigation. 
 
Immune Responses to PRBC Transfusion and are Washed PRBCs the Answer? 
The principle focus of this thesis was transfusion-related alterations in immune responses 
focusing on differences in recipient reactions to unwashed and washed PRBCs. However, 
exactly how TRIM manifests itself in the extremely preterm newborn is poorly characterised. 
Indeed, the original observations of decreased helper T-cell count, decreased 
helper/suppressor T-lymphocyte ratio, decreased natural killer (NK) cell function, defective 
antigen presentation, decreased cytokine (IL-2, interferon-γ) production, and decreased 
monocyte/macrophage phagocytic function, led to TRIM being thought of as 
immunosuppressive 332. However, a greater awareness that transfusion-related tissue injury is 
mediated by reactive oxygen species and proteolytic enzymes released from activated 
neutrophils with endothelial activation highlights a pro-inflammatory component 333.  As a 
result, it has been proposed that the reported association between PRBC transfusion exposure 
and short-term morbidity and mortality more likely reflects a ‘‘pro-inflammatory’’ rather than 
an ‘‘immunomodulatory’’ effect 100. 
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Numerous pre-clinical studies demonstrate that RBC products directly modulate immune cell 
function 59. This has led to the concept of TRIM as “two-insult” process 97 in the transfusion 
recipient mediated by biological response mediators, such as donor antibodies, bioactive lipids, 
free haemoglobin, red cell membrane fragments and cytokines that accumulate during blood 
product storage 95. This has led to a focus on modifying the transfusion product through 
leukodepletion and more recently washing 173. However, research into the effect of RBCs on 
immune cell function is still preliminary. The current data suggests that not only is the potential 
for transfusion-related effects of immune function present in the initial days following 
extremely preterm birth, but changes with ongoing repeated transfusion exposure. Critically, 
these changes are different in response to transfusion with unwashed versus washed PRBCs. 
As a result, the use of washed PRBCs could reduce the adverse impact of TRIM, whether this 
translates to improved clinical outcomes remains unknown and therefore warrant further 
investigation. Further work needs to be done to accurately classify TRIM in the preterm 
newborn with evidence from the adult literature suggesting the effects vary between different 
critically ill populations 100. 
 
In the current study, as for the majority of previous pre-clinical and clinical studies investigating 
the immune response to transfusion, the cellular components of the blood are removed with 
the analysis of the responses focusing on bioactive mediators in plasma or serum. While 
valuable, emerging evidence indicates this represents an incomplete profile of the relevant 
markers. Until recently red blood cells have been relatively understudied and thought to only 
be important for respiratory gas exchange. However, recent data suggests they are 
multifunctional and have more complex functions than previously understood 334, 335. As a 
result, red blood cells like other blood products should be considered a complex, living tissue 
capable of signalling or receiving signals from other cell types with the potential to elicit or 
participate in the immune response after transfusion. This highlights the importance of 
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developing a better understanding of TRIM, which may be even more incomplete than 
previously thought. 
 
Do these new insights contribute to the potentially beneficial effects of transfusion of washed 
PRBCs on recipient immune function in the extremely preterm newborn? Darbonne and 
colleagues described a receptor on the surface of red blood cells that binds IL-8 336. This was 
subsequently found to also bind C-X-C (GRO-α, NAP-2) and CeC (RANTES, MCP-1) chemokines 
337. Later identified as Duffy Antigen Receptor for Chemokines (DARC), this receptor was 
originally identified in 1950 338 and is known to also be present on endothelial cells 339. DARC is 
involved with both binding and releasing cytokines and as a result the RBC has been proposed 
to act both as a sink for excess circulating inflammatory markers 336, 340 while also acting as a 
reservoir of these cytokines to release when they are needed 341. This is an important function, 
as previously, increases in secreted cytokines from stored RBCs were attributed to WBCs. 
Intriguingly, washing RBCs significantly attenuates the release of a number of pro-inflammatory 
cytokines including IL-1β, IL-6, IL-8, MIP-1α, MIP-1β, and TNF 342. As this data is consistent with 
our observations of the effect of transfusion with washed PRBCs on post-transfusion cytokine 
concentrations, it is tempting to speculate that the washing process results in the release of 
RBC bound cytokines prior to transfusion resulting in reduced capacity to release cytokines and 
potentially contributing to the altered inflammatory response in the recipient. It would also be 
consistent with our observation of lower cytokine concentrations in the supernatant of the 
washed compared to the unwashed transfusion packs. To our knowledge, no detailed analysis 
of cytokine and chemokine concentrations in the lysate and/or cytosol of washed 
leukodepleted PRBCs in comparison to unwashed leukodepleted PRBCs has been conducted. 
This warrants future investigation.   
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The processes through which RBC release bound cytokines remain unknown. RBCs are devoid 
of the classic secretion pathways that are well documented for other cell types due to the lack 
of organelles. However, other mechanisms have been proposed that may have a role in this 
process including release of microparticles 336, 343, 344. Microparticles, produced as RBCs age, 
stimulate a variety of disease processes including immunomodulation 345 103. Although various 
mechanisms of action have been investigated, such as the activation of antigen presenting cells 
103, the cytokine contribution from these microparticles has been largely overlooked 346. DARC 
is known to be present on the surface of RBC microparticles 347 and retains its capacity to bind 
cytokines and chemokines 348. What is not known is its function in cytokine release. 
Interestingly, not only are microparticles significantly reduced in paediatric washed PRBC 
transfusion units but washing also alters the microparticle GPA phenotype 172. Although a 
number of inflammatory proteins have been identified on RBCs the knowledge of the molecular 
processes behind the binding and release of many of these cytokines from RBCs remains 
superficial. Specifically, if washing also alters the expression of DARC on microparticles, does 
this simple processing step also alter the immunomodulatory effect of microparticles in the 
transfusion recipient? 
 
The interaction between pro-inflammatory cytokines and the endothelium may also play an 
important role linking transfusion exposure to adverse clinical outcomes. By the 3rd transfusion 
exposure, the pro-inflammatory response to unwashed blood was also associated with an 
increase in markers of endothelial activation, specifically MIF and PAI1, an effect not seen with 
washed PRBCs. Clearly, inflammatory stimuli directly impact on the endothelium with pro-
inflammatory cytokines such as TNF and IL-1β activating endothelial cells and resulting in the 
recruitment of leukocytes to sites of cellular damage 278. Central to these processes is the 
increased expression of several adhesion molecules and chemokines, including MIF, which 
promotes a number of responses such as the expression of endothelial P-selectin and the arrest 
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of leukocyte rolling 280. Known to be produced by a wide range of endothelial cells including 
both the vascular 349 and pulmonary endothelium 350,  MIF has been shown to play a critical 
role in a wide range of inflammatory conditions 335. As a result, we chose to investigate the 
effects of exposure to unwashed and washed PRBCs on this marker of endothelial function. 
However, it has recently become apparent that RBCs are actually the largest reservoir for this 
protein in blood, contributing 25μg of this protein per millilitre, a level 1000-fold higher than 
the average levels detected in plasma 335. Secreted or free MIF has a primary role as a pro-
inflammatory cytokine which modulates the migration of inflammatory cells 351. However, MIF 
may also be released following RBC haemolysis, an effect proposed to contribute to the 
significantly elevated concentrations observed in the plasma of septic patients where high 
levels of this protein have been correlated with early death 352. This likely explains the higher 
levels of MIF in the supernatant of the washed packs with washing known to increase the 
degree of haemolysis in PRBC pedi-packs up to 14 days of storage, although levels remain well 
below safety limits 254. It does, however, highlight the complexity of the interplay between the 
transfused blood product and the transfusion recipient. 
 
The Contribution of Donor Characteristics to Transfusion-Related Adverse Outcomes 
The impact of donor sex on transfusion recipient outcomes has been demonstrated in a 
number of areas of transfusion / transplantation medicine. However, the evidence for an effect 
of PRBC donor sex on adverse outcomes in the preterm neonatal population has only recently 
gained attention. Further, despite increasing attention, the biological mechanisms that might 
explain why donor sex could cause harm in the transfusion recipient remain poorly understood 
198. The current data demonstrates that the post-transfusion changes in circulating cytokines 
differ significantly in those newborns who received unwashed PRBCs from both male and 
female donors compared to those transfused with washed PRBCs. In light of the 
epidemiological data from the study by Murphy et al which reported higher rates of mortality, 
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significant morbidity and prolonged hospital stay in those infants exposed to any female blood 
234, these findings have significant consequences for both the neonatal and transfusion 
communities. Further, if these findings are confirmed, likely in the setting of a large-scale 
randomised trial, they broaden the potential of alterations in blood banking policy to reduce 
the risk of transfusion associated adverse outcomes in the extremely preterm newborn. Rather 
than limiting available PRBCs to those solely from male donors, a restriction with wide ranging 
implications for blood product availability, PRBC washing may represent a single, simple 
intervention which reduces transfusion associated morbidity and mortality. Clearly, these 
findings may have significant consequences for transfusion studies already underway and those 
in the planning stage. The significant impact of donor sex also has implications for other 
transfusion product exposures. This is particularly important for those pooled products derived 
from multiple donors such as FFP and particularly platelets. This question was out of the scope 
of the current thesis and warrants more in-depth investigation.  
 
Future Directions and Translation into Clinical Practice 
Given the current data, what are the implications for clinical practice in the field of perinatal 
medicine? While it is hoped we are about to finally answer the question, “when to transfuse”, 
many more questions remain unanswered.  In light of our findings of differing effects on 
circulating pro-inflammatory cytokines with increasing transfusion exposure, the impact of 
total volume or number of PRBC transfusion events an individual extremely preterm newborn 
is exposed to requires attention. For instance, the current data may suggest that fewer, larger 
volume transfusions may result in a differed inflammatory response following transfusion. 
Further, an extremely preterm newborn in the first days or weeks of life is likely to be very 
different from one further along the neonatal journey. If we assume the inflammatory milieu 
of prematurity is most complex and potentially harmful soon after birth, should all early 
transfusions be not only washed but also from only male donors? Outside this high-risk period, 
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could PRBCs from either male or female donors be used or even unwashed leukodepleted 
PRBCs?  Other important considerations which may impact upon future trials include the role 
of irradiation, transfusion of O negative versus cross match blood and other novel processing 
steps for instance supernatant reduction 353. All add to the complexity of clinical trial design in 
the field of transfusion medicine.  
 
While not designed to demonstrate a clinical advantage of transfusion of washed compared 
with unwashed PRBCs, the observation of significantly different inflammatory responses in the 
washed group represents a biologically plausible mechanism by which transfusion with washed 
PRBCs may be beneficial. Further, epidemiological and observational evidence supports an 
association between transfusion of washed RBCs and fewer post-transfusion complications in 
cardiac patients, improved survival in acute leukaemia patients 354 and reduced transfusion-
related pro-inflammatory cytokine production in paediatric cardiac surgical patients 355. 
Significantly, the potential for clinical benefit in the extremely preterm newborn remains a 
significant knowledge gap.  
 
Due to the number of transfusions a preterm newborn is exposed to during their primary 
hospital admission, any improvement in outcome related to a modification in transfusion 
practice is rapidly translated into clinical practice. To date, the only intervention associated with 
a clinically important reduction in morbidity in the preterm newborn in relation to PRBC 
transfusion practice, was the introduction of pre-storage leukodepletion 129. This led to 
adoption of this simple processing step world-wide. The current data adds to the growing in 
vitro and ex vivo mechanistic literature supporting a different inflammatory response to 
washed PRBCs compared to unwashed PRBCs. However, an adequately powered randomised 
trial with a meaningful clinical outcome is the critical next step in order to prove or disprove 
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whether this intervention has the potential to result in a similar wholesale change in transfusion 
practice, to achieve improvements in survival free of significant neonatal morbidity. 
 
PRBC washing is already a readily available, standardised process provided by The Australian 
Red Cross. However, due to greater manufacturing costs incurred with the washing process 
($426.94 for a washed leukodepleted RBC pack versus $399.25 for an equivalent unwashed 
leukodepleted RBC pack) and more importantly shortened shelf life, unwashed leukodepleted 
PRBCs remain the product of choice in Australia. The data in this thesis not only establishes the 
clinical feasibility of a randomised trial of unwashed versus washed PRBCs in the NICU 
environment but provides hypothesis generating evidence focusing on the pathophysiologic 
processes that may explain the beneficial effect of exposure to washed PRBCs if a transfusion 
is clinically indicated. 
 
A randomised controlled trial adequately powered with clinically important outcomes and 
associated health economic outcomes is the only way to determine whether washed PRBCs 
compared to unwashed PRBCs improve clinical outcomes in extremely preterm newborns. Such 
an approach would effectively bridge the gap between research into transfusion-related 
adverse outcomes and translation into practice with clinical and economic evaluation. The 
current economic burden placed on the individual and the healthcare system of each surviving 
extremely preterm newborn is immense. For instance, depending on BPD severity, surviving 
newborns may have a life-time projected economic impact of over $1.2 million AUD 356. With 
an additional $30 manufacturing cost for washed PRBCs, even taking into consideration the 
potential for increased overall wastage of this critical resource due to reduced shelf life, the 
avoidance of even a single case of significant long-term neonatal morbidity would make this 





1. Welfare AIoHa. Australia’s mothers and babies 2014—in brief. Canberra: Australian 
Institute of Health and Welfare; 2016. 
2. Leuthner SR. Borderline viability: controversies in caring for the extremely premature 
infant. Clinics in perinatology. 2014;41(4):799-814. 
3. Slattery MM, Morrison JJ. Preterm delivery. Lancet. 2002;360(9344):1489-1497. 
4. Welfare AIoHa. Australia’s mothers and babies 2017—in brief. Canberra: AIHW; 2019. 
5. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth 
throughout childhood in England and Wales. Pediatrics. 2009;123(2):e312-327. 
6. Hall ES, Greenberg JM. Estimating community-level costs of preterm birth. Public 
Health. 2016;141:222-228. 
7. Valieva OA, Strandjord TP, Mayock DE, Juul SE. Effects of transfusions in extremely low 
birth weight infants: a retrospective study. Journal of Pediatrics. 2009;155(3):331-337 
e331. 
8. Iacovidou N, Varsami M, Syggellou A. Neonatal outcome of preterm delivery. Annals of 
the New York Academy of Sciences. 2010;1205:130-134. 
9. Ge WJ, Mirea L, Yang J, Bassil KL, Lee SK, Shah PS, et al. Prediction of neonatal outcomes 
in extremely preterm neonates. Paediatrics. 2013;132(4):e876-885. 
10. Gien J, Kinsella JP. Pathogenesis and treatment of bronchopulmonary dysplasia. Current 
Opinion in Pediatrics. 2011;23(3):305-313. 
11. Hodzic Z, Bolock AM, Good M. The Role of Mucosal Immunity in the Pathogenesis of 
Necrotizing Enterocolitis. Frontiers in Pediatrics. 2017;5:40. 
12. Poralla C, Hertfelder HJ, Oldenburg J, Muller A, Bartmann P, Heep A. Elevated 
interleukin-6 concentration and alterations of the coagulation system are associated 
with the development of intraventricular hemorrhage in extremely preterm infants. 
Neonatology. 2012;102(4):270-275. 
 170 
13. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, et al. Vascular 
endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and 
oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. 
Arterioscler Thromb Vasc Biol. 2007;27(7):1587-1595. 
14. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects 
Research Part A: Clinical and Molecular Teratology. 2014;100(3):145-157. 
15. Zysman-Colman Z, Tremblay GM, Bandeali S, Landry JS. Bronchopulmonary dysplasia - 
trends over three decades. Paediatrics & child health. 2013;18(2):86-90. 
16. Day CL, Ryan RM. Bronchopulmonary dysplasia: new becomes old again! Pediatr Res. 
2017;81(1-2):210-213. 
17. Kevill KA, Bhandari V, Kettunen M, Leng L, Fan J, Mizue Y, et al. A role for macrophage 
migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol. 
2008;180(1):601-608. 
18. Sun H, Choo-Wing R, Fan J, Leng L, Syed MA, Hare AA, et al. Small molecular modulation 
of macrophage migration inhibitory factor in the hyperoxia-induced mouse model of 
bronchopulmonary dysplasia. Respir Res. 2013;14:27. 
19. Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA, Schonberger LB. Necrotising 
enterocolitis hospitalisations among neonates in the United States. Paediatr Perinat 
Epidemiol. 2006;20(6):498-506. 
20. Singh R, Shah BL, Frantz ID, 3rd. Necrotizing enterocolitis and the role of anemia of 
prematurity. Seminars in Perinatology. 2012;36(4):277-282. 
21. Allin BSR, Long AM, Gupta A, Lakhoo K, Knight M, British Association of Paediatric 
Surgeons Congenital Anomalies Surveillance System Necrotising Enterocolitis C. One-
year outcomes following surgery for necrotising enterocolitis: a UK-wide cohort study. 
Arch Dis Child Fetal Neonatal Ed. 2018;103(5):F461-F466. 
 171 
22. Christensen RD, Baer VL, Lambert DK, Ilstrup SJ, Eggert LD, Henry E. Association, among 
very-low-birthweight neonates, between red blood cell transfusions in the week after 
birth and severe intraventricular hemorrhage. Transfusion. 2014;54(1):104-108. 
23. Baer VL, Lambert DK, Henry E, Snow GL, Butler A, Christensen RD. Among very-low-
birth-weight neonates is red blood cell transfusion an independent risk factor for 
subsequently developing a severe intraventricular hemorrhage? Transfusion. 
2011;51(6):1170-1178. 
24. Perlman JM, Volpe JJ. Intraventricular hemorrhage in extremely small premature 
infants. Am J Dis Child. 1986;140(11):1122-1124. 
25. Luu TM, Ment LR, Schneider KC, Katz KH, Allan WC, Vohr BR. Lasting effects of preterm 
birth and neonatal brain hemorrhage at 12 years of age. Pediatrics. 2009;123(3):1037-
1044. 
26. Chow SSW, Creighton, P., Chambers, G.M., Lui, K. Report of the Australian and New 
Zealand Neonatal Network 2017. Sydney: ANZNN; 2019. 
27. Heep A, Behrendt D, Nitsch P, Fimmers R, Bartmann P, Dembinski J. Increased serum 
levels of interleukin 6 are associated with severe intraventricular haemorrhage in 
extremely premature infants. Archives of Disease in Childhood Fetal and Neonatal 
Edition. 2003;88(6):F501-504. 
28. Wang HC, Lin WC, Lin YJ, Rau CS, Lee TH, Chang WN, et al. The association between 
serum adhesion molecules and outcome in acute spontaneous intracerebral 
hemorrhage. Crit Care. 2011;15(6):R284. 
29. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 
1993;11:767-804. 
30. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual 
impairment and estimates of retinopathy of prematurity at regional and global levels 
for 2010. Pediatr Res. 2013;74 Suppl 1:35-49. 
 172 
31. Chow SSW, CreightonP, Kamnder V, Haslam R, Lui K. Report of the Australian and New 
Zealand Neonatal Network 2016. Sydney2018. 
32. Cavallaro G, Filippi L, Bagnoli P, La Marca G, Cristofori G, Raffaeli G, et al. The 
pathophysiology of retinopathy of prematurity: an update of previous and recent 
knowledge. Acta Ophthalmol. 2014;92(1):2-20. 
33. Dani C, Reali MF, Bertini G, Martelli E, Pezzati M, Rubaltelli FF. The role of blood 
transfusions and iron intake on retinopathy of prematurity. Early Hum Dev. 
2001;62(1):57-63. 
34. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14 
Suppl A:S140-144. 
35. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor 
(VEGF) and its receptors. FASEB J. 1999;13(1):9-22. 
36. Crawford TM, Andersen CC, Hodyl NA, Robertson SA, Stark MJ. The contribution of red 
blood cell transfusion to neonatal morbidity and mortality. J Paediatr Child Health. 
2019;55(4):387-392. 
37. Dani C, Poggi C, Gozzini E, Leonardi V, Sereni A, Abbate R, et al. Red blood cell 
transfusions can induce proinflammatory cytokines in preterm infants. Transfusion. 
2017;57(5):1304-1310. 
38. Keir AK, McPhee AJ, Andersen CC, Stark MJ. Plasma cytokines and markers of 
endothelial activation increase after packed red blood cell transfusion in the preterm 
infant. Pediatric Research. 2013;73(1):75-79. 
39. Widness JA. Pathophysiology of Anemia During the Neonatal Period, Including Anemia 
of Prematurity. Neoreviews. 2008;9(11):e520. 
40. Colombatti R, Sainati L, Trevisanuto D. Anemia and transfusion in the neonate. Semin 
Fetal Neonatal Med. 2016;21(1):2-9. 
 173 
41. Strauss RG. Anaemia of prematurity: pathophysiology and treatment. Blood Rev. 
2010;24(6):221-225. 
42. Wardrop CA, Holland BM, Veale KE, Jones JG, Gray OP. Nonphysiological anaemia of 
prematurity. Archives of Disease in Childhood. 1978;53(11):855-860. 
43. Jeon GW, Sin JB. Risk factors of transfusion in anemia of very low birth weight infants. 
Yonsei medical journal. 2013;54(2):366-373. 
44. Aher S, Malwatkar K, Kadam S. Neonatal anemia. Semin Fetal Neonatal Med. 
2008;13(4):239-247. 
45. Stockman JA, 3rd. The anemia of prematurity and the decision when to transfuse. Adv 
Pediatr. 1983;30:191-219. 
46. Collard KJ. Transfusion related morbidity in premature babies: Possible mechanisms and 
implications for practice. World Journal of Clinical Paediatrics. 2014;3(3):19-29. 
47. Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ, et al. Randomized 
trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm 
infants. Pediatrics. 2005;115(6):1685-1691. 
48. Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, et al. The 
Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of 
a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth 
weight infants. J Pediatr. 2006;149(3):301-307. 
49. Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative 
transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day 
mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J 
Am Coll Surg. 2009;208(5):931-937, 937 e931-932; discussion 938-939. 
50. Santos AA, Sousa AG, Piotto RF, Pedroso JC. Mortality risk is dose-dependent on the 
number of packed red blood cell transfused after coronary artery bypass graft. Rev Bras 
Cir Cardiovasc. 2013;28(4):509-517. 
 174 
51. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell 
storage and complications after cardiac surgery. N Engl J Med. 2008;358(12):1229-
1239. 
52. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyren O, et al. 
Survival after blood transfusion. Transfusion. 2008;48(12):2577-2584. 
53. Kneyber MC, Grotenhuis F, Berger RF, Ebels TW, Burgerhof JG, Albers MJ. Transfusion 
of leukocyte-depleted RBCs is independently associated with increased morbidity after 
pediatric cardiac surgery. Pediatr Crit Care Med. 2013;14(3):298-305. 
54. Strauss RG. Red blood cell transfusion practices in the neonate. Clinics in perinatology. 
1995;22(3):641-655. 
55. dos Santos AM, Guinsburg R, de Almeida MF, Procianoy RS, Leone CR, Marba ST, et al. 
Red blood cell transfusions are independently associated with intra-hospital mortality 
in very low birth weight preterm infants. The Journal of pediatrics. 2011;159(3):371-
376 e371-373. 
56. Wang YC, Chan OW, Chiang MC, Yang PH, Chu SM, Hsu JF, et al. Red Blood Cell 
Transfusion and Clinical Outcomes in Extremely Low Birth Weight Preterm Infants. 
Pediatr Neonatol. 2017;58(3):216-222. 
57. Keir A, Aziz K, McMillan D, Monterrosa L, Ojah C, Lee S, et al. Red Blood Cell Transfusions 
at 21 Days of Age or Older in Previously Transfusion-Naive Very Preterm Infants: 
Association with Neonatal Outcomes. Am J Perinatol. 2015;32(12):1139-1144. 
58. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of 
allogeneic blood transfusion and the available strategies for their prevention. Blood. 
2009;113(15):3406-3417. 
59. Remy KE, Hall MW, Cholette J, Juffermans NP, Nicol K, Doctor A, et al. Mechanisms of 
red blood cell transfusion-related immunomodulation. Transfusion. 2018;58(3):804-
815. 
 175 
60. Keir A, Pal S, Trivella M, Lieberman L, Callum J, Shehata N, et al. Adverse effects of red 
blood cell transfusions in neonates: a systematic review and meta-analysis. Transfusion. 
2016;56(11):2773-2780. 
61. Hall N, Ong EGP, Ade-Ajayi N, Fasoli L, Ververidis M, Kiely EM, et al. T cryptantigen 
activation is associated with advanced necrotizing enterocolitis. Journal of Pediatric 
Surgery. 2002;37(5):791-793. 
62. Gephart SM. Transfusion-associated necrotizing enterocolitis: evidence and 
uncertainty. Adv Neonatal Care. 2012;12(4):232-236. 
63. Keir AK, McPhee AJ, Andersen CC, Stark MJ. Plasma cytokines and markers of 
endothelial activation increase after packed red blood cell transfusion in the preterm 
infant. Pediatr Res. 2013;73(1):75-79. 
64. Krimmel GA, Baker R, Yanowitz TD. Blood transfusion alters the superior mesenteric 
artery blood flow velocity response to feeding in premature infants. Am J Perinatol. 
2009;26(2):99-105. 
65. Patel RM, Knezevic A, Shenvi N, Hinkes M, Keene S, Roback JD, et al. Association of Red 
Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight 
Infants. JAMA. 2016;315(9):889-897. 
66. Mohamed A, Shah PS. Transfusion associated necrotizing enterocolitis: a meta-analysis 
of observational data. Pediatrics. 2012;129(3):529-540. 
67. Garg P, Pinotti R, Lal CV, Salas AA. Transfusion-associated necrotizing enterocolitis in 
preterm infants: an updated meta-analysis of observational data. J Perinat Med. 
2018;46(6):677-685. 
68. Hay S, Zupancic JA, Flannery DD, Kirpalani H, Dukhovny D. Should we believe in 
transfusion-associated enterocolitis? Applying a GRADE to the literature. Semin 
Perinatol. 2017;41(1):80-91. 
 176 
69. El Kenz H, Van der Linden P. Transfusion-related acute lung injury. European journal of 
anaesthesiology. 2014;31(7):345-350. 
70. Bianchi M, Vaglio S, Pupella S, Marano G, Facco G, Liumbruno GM, et al. Leucoreduction 
of blood components: an effective way to increase blood safety? Blood Transfusion. 
2016;14(2):214-227. 
71. ISBT Working Party on Haemovigilance. PROPOSED STANDARD DEFINITIONS FOR 
SURVEILLANCE OF NON INFECTIOUS ADVERSE TRANSFUSION REACTIONS International 
Society of Blood Transfusion; 2013. 
72. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al. Transfusion-
related acute lung injury: definition and review. Crit Care Med. 2005;33(4):721-726. 
73. Gauvin F, Robillard P, Hume H, Grenier D, Whyte RK, Webert KE, et al. Transfusion-
related acute lung injury in the Canadian paediatric population. Paediatr Child Health. 
2012;17(5):235-239. 
74. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet. 
2013;382(9896):984-994. 
75. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J 
Haematol. 2007;136(6):788-799. 
76. Zhang H, Fang J, Su H, Chen M. Risk factors for bronchopulmonary dysplasia in neonates 
born at </= 1500 g (1999-2009). Pediatr Int. 2011;53(6):915-920. 
77. Otrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk mitigation: an 
update. Vox sanguinis. 2017;112(8):694-703. 
78. Rashid N, Al-Sufayan F, Seshia MM, Baier RJ. Post transfusion lung injury in the neonatal 
population. J Perinatol. 2013;33(4):292-296. 
79. Grev JE, Stanclova M, Ellsworth MA, Colby CE. Does Red Blood Cell Transfusion-Related 
Acute Lung Injury Occur in Premature Infants? A Retrospective Cohort Analysis. Am J 
Perinatol. 2017;34(1):14-18. 
 177 
80. Cooke RW, Clark D, Hickey-Dwyer M, Weindling AM. The apparent role of blood 
transfusions in the development of retinopathy of prematurity. Eur J Pediatr. 
1993;152(10):833-836. 
81. Englert JA, Saunders RA, Purohit D, Hulsey TC, Ebeling M. The Effect of Anemia on 
Retinopathy of Prematurity in Extremely Low Birth Weight Infants. Journal Of 
Perinatology. 2001;21:21. 
82. Dani C, Reali MF, Bertini G, Martelli E, Pezzati M, Rubaltelli FF. The role of blood 
transfusions and iron intake on retinopathy of prematurity. Early Human Development. 
2001;62(1):57-63. 
83. Englert JA, Saunders RA, Purohit D, Hulsey TC, Ebeling M. The effect of anemia on 
retinopathy of prematurity in extremely low birth weight infants. J Perinatol. 
2001;21(1):21-26. 
84. Brooks SE, Marcus DM, Gillis D, Pirie E, Johnson MH, Bhatia J. The effect of blood 
transfusion protocol on retinopathy of prematurity: A prospective, randomized study. 
Pediatrics. 1999;104(3 Pt 1):514-518. 
85. Stark MJ, Keir AK, Andersen CC. Does non-transferrin bound iron contribute to 
transfusion related immune-modulation in preterms? Archives of Disease in Childhood 
Fetal and Neonatal Edition. 2013;98(5):F424-429. 
86. Stutchfield CJ, Jain A, Odd D, Williams C, Markham R. Foetal haemoglobin, blood 
transfusion, and retinopathy of prematurity in very preterm infants: a pilot prospective 
cohort study. Eye (London, England). 2017;31(10):1451-1455. 
87. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID, 3rd, Shah B, Rubin LP. Variations 
in blood transfusions among newborn intensive care units. SNAP II Study Group. The 
Journal of pediatrics. 1998;133(5):601-607. 
 178 
88. Baer VL, Lambert DK, Henry E, Snow GL, Christensen RD. Red blood cell transfusion of 
preterm neonates with a Grade 1 intraventricular hemorrhage is associated with 
extension to a Grade 3 or 4 hemorrhage. Transfusion. 2011;51(9):1933-1939. 
89. dos Santos AM, Guinsburg R, de Almeida MF, Procianoy RS, Marba ST, Ferri WA, et al. 
Factors associated with red blood cell transfusions in very-low-birth-weight preterm 
infants in Brazilian neonatal units. BMC Pediatrics. 2015;15:113. 
90. Christensen RD. Associations Between “Early” Red Blood Cell Transfusion and Severe 
Intraventricular Hemorrhage, and Between “Late” Red Blood Cell Transfusion and 
Necrotizing Enterocolitis. Seminars in Perinatology. 2012;36(4):283-289. 
91. Rabelo TK, Zeidan-Chulia F, Vasques LM, dos Santos JP, da Rocha RF, Pasquali MA, et al. 
Redox characterization of usnic acid and its cytotoxic effect on human neuron-like cells 
(SH-SY5Y). Toxicology in vitro : an international journal published in association with 
BIBRA. 2012;26(2):304-314. 
92. Tarnow-Mordi W, Morris J, Kirby A, Robledo K, Askie L, Brown R, et al. Delayed versus 
Immediate Cord Clamping in Preterm Infants. N Engl J Med. 2017;377(25):2445-2455. 
93. Fogarty M, Osborn DA, Askie L, Seidler AL, Hunter K, Lui K, et al. Delayed vs early 
umbilical cord clamping for preterm infants: a systematic review and meta-analysis. 
American Journal of Obstetrics and Gynecology. 2018;218(1):1-18. 
94. Sparrow RL. Red blood cell storage and transfusion-related immunomodulation. Blood 
transfusion = Trasfusione del sangue. 2010;8 Suppl 3:s26-30. 
95. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute 
gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red 
blood cell transfusion. Journal of Paediatrics. 2011;158(3):403-409. 
96. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of 
blood transfusions. N Engl J Med. 1978;299(15):799-803. 
 179 
97. Karam O, Tucci M, Toledano BJ, Robitaille N, Cousineau J, Thibault L, et al. Length of 
storage and in vitro immunomodulation induced by prestorage leukoreduced red blood 
cells. Transfusion. 2009;49(11):2326-2334. 
98. Sparrow RL. Red blood cell storage and transfusion-related immunomodulation. Blood 
Transfusion. 2010;8 Suppl 3:s26-30. 
99. Sparrow RL, Patton KA. Supernatant from stored red blood cell primes inflammatory 
cells: influence of prestorage white cell reduction. Transfusion. 2004;44(5):722-730. 
100. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an 
update. Blood Rev. 2007;21(6):327-348. 
101. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune 
responses. J Allergy Clin Immunol. 2002;110(5):693-702. 
102. Tissot JD, Rubin O, Canellini G. Analysis and clinical relevance of microparticles from red 
blood cells. Curr Opin Hematol. 2010;17(6):571-577. 
103. Danesh A, Inglis HC, Jackman RP, Wu S, Deng X, Muench MO, et al. Exosomes from red 
blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-
cell responses in vitro. Blood. 2014;123(5):687-696. 
104. Collard KJ, White DL. On the source of the non-transferrin-bound iron which 
accumulates in packed red blood cell units during storage. Blood Transfus. 
2014;12(4):527-532. 
105. Dani C, Martelli E, Bertini G, Pezzati M, Rossetti M, Buonocore G, et al. Effect of blood 
transfusions on oxidative stress in preterm infants. Archives of disease in childhood. 
2004;89(5):F408-411. 
106. Lawrence SM, Corriden R, Nizet V. Age-Appropriate Functions and Dysfunctions of the 
Neonatal Neutrophil. Front Pediatr. 2017;5:23. 
107. Walker WA. Development of the intestinal mucosal barrier. J Pediatr Gastroenterol 
Nutr. 2002;34 Suppl 1:S33-39. 
 180 
108. Strunk T, Currie A, Richmond P, Simmer K, Burgner D. Innate immunity in human 
newborn infants: prematurity means more than immaturity. J Matern Fetal Neonatal 
Med. 2011;24(1):25-31. 
109. Goenka A, Kollmann TR. Development of immunity in early life. J Infect. 2015;71 Suppl 
1:S112-120. 
110. Black A, Bhaumik S, Kirkman RL, Weaver CT, Randolph DA. Developmental regulation of 
Th17-cell capacity in human neonates. Eur J Immunol. 2012;42(2):311-319. 
111. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and 
inflammatory diseases. Autoimmun Rev. 2014;13(6):668-677. 
112. Caron JE, La Pine TR, Augustine NH, Martins TB, Kumanovics A, Hill HR. Severely 
depressed interleukin-17 production by human neonatal mononuclear cells. Pediatr 
Res. 2014;76(6):522-527. 
113. Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-producing 
effector and regulatory human T cells from lineage-committed naive precursors. J 
Immunol. 2014;193(3):1047-1054. 
114. Mikacenic C, Hansen EE, Radella F, Gharib SA, Stapleton RD, Wurfel MM. Interleukin-
17A Is Associated With Alveolar Inflammation and Poor Outcomes in Acute Respiratory 
Distress Syndrome. Crit Care Med. 2016;44(3):496-502. 
115. Gleditsch DD, Shornick LP, Van Steenwinckel J, Gressens P, Weisert RP, Koenig JM. 
Maternal inflammation modulates infant immune response patterns to viral lung 
challenge in a murine model. Pediatr Res. 2014;76(1):33-40. 
116. Chen T, Liu HX, Yan HY, Wu DM, Ping J. Developmental origins of inflammatory and 
immune diseases. Mol Hum Reprod. 2016;22(8):858-865. 
117. Fergusson D, Hutton B, Hogan DL, LeBel L, Blajchman MA, Ford JC, et al. The age of red 
blood cells in premature infants (ARIPI) randomized controlled trial: study design. 
Transfus Med Rev. 2009;23(1):55-61. 
 181 
118. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, et al. 
Double-blind, randomized controlled trial on the effect of leukocyte-depleted 
erythrocyte transfusions in cardiac valve surgery. Circulation. 2004;109(22):2755-2760. 
119. Alkalay AL, Galvis S, Ferry DA, Simmons CF, Krueger RC, Jr. Hemodynamic changes in 
anemic premature infants: are we allowing the hematocrits to fall too low? Pediatrics. 
2003;112(4):838-845. 
120. Fredrickson LK, Bell EF, Cress GA, Johnson KJ, Zimmerman MB, Mahoney LT, et al. Acute 
physiological effects of packed red blood cell transfusion in preterm infants with 
different degrees of anaemia. Arch Dis Child Fetal Neonatal Ed. 2011;96(4):F249-253. 
121. Whyte RK. Neurodevelopmental outcome of extremely low-birth-weight infants 
randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. 
Seminars in Perinatology. 2012;36(4):290-293. 
122. Bifano EM, Curran TR. Minimizing donor blood exposure in the neonatal intensive care 
unit. Current trends and future prospects. Clin Perinatol. 1995;22(3):657-669. 
123. National Blood Authority. Patient Blood Management Guidelines: Module 6, in 
Neonatal and Paediatrics. Canberra, Australia2015. 
124. Murphy GJ, Pike K, Rogers CA, Wordsworth S, Stokes EA, Angelini GD, et al. Liberal or 
restrictive transfusion after cardiac surgery. N Engl J Med. 2015;372(11):997-1008. 
125. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, et al. Lower 
versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 
2014;371(15):1381-1391. 
126. Palmieri TL, Holmes JHt, Arnoldo B, Peck M, Potenza B, Cochran A, et al. Transfusion 
Requirement in Burn Care Evaluation (TRIBE): A Multicenter Randomized Prospective 
Trial of Blood Transfusion in Major Burn Injury. Ann Surg. 2017;266(4):595-602. 
 182 
127. Rygard SL, Holst LB, Wetterslev J, Johansson PI, Perner A, group Tt, et al. Higher vs. lower 
haemoglobin threshold for transfusion in septic shock: subgroup analyses of the TRISS 
trial. Acta Anaesthesiol Scand. 2017;61(2):166-175. 
128. Bergamin FS, Almeida JP, Landoni G, Galas F, Fukushima JT, Fominskiy E, et al. Liberal 
Versus Restrictive Transfusion Strategy in Critically Ill Oncologic Patients: The 
Transfusion Requirements in Critically Ill Oncologic Patients Randomized Controlled 
Trial. Crit Care Med. 2017;45(5):766-773. 
129. Fergusson D, Hebert PC, Lee SK, Walker CR, Barrington KJ, Joseph L, et al. Clinical 
outcomes following institution of universal leukoreduction of blood transfusions for 
premature infants. JAMA. 2003;289(15):1950-1956. 
130. Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion 
strategies for patients in pediatric intensive care units. N Engl J Med. 
2007;356(16):1609-1619. 
131. Karam O, Tucci M, Ducruet T, Hume HA, Lacroix J, Gauvin F, et al. Red blood cell 
transfusion thresholds in pediatric patients with sepsis. Pediatr Crit Care Med. 
2011;12(5):512-518. 
132. Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, et al. 
Neurodevelopmental outcome of extremely low birth weight infants randomly assigned 
to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics. 
2009;123(1):207-213. 
133. Hack M, Taylor HG, Drotar D, Schluchter M, Cartar L, Wilson-Costello D, et al. Poor 
predictive validity of the Bayley Scales of Infant Development for cognitive function of 
extremely low birth weight children at school age. Pediatrics. 2005;116(2):333-341. 
134. Nopoulos PC, Conrad AL, Bell EF, Strauss RG, Widness JA, Magnotta VA, et al. Long-term 
outcome of brain structure in premature infants: effects of liberal vs restricted red 
blood cell transfusions. Arch Pediatr Adolesc Med. 2011;165(5):443-450. 
 183 
135. Jelkmann W. Effects of erythropoietin on brain function. Curr Pharm Biotechnol. 
2005;6(1):65-79. 
136. Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood 
transfusion for preventing morbidity and mortality in very low birth weight infants. 
Cochrane database of systematic reviews (Online). 2011(11):Cd000512. 
137. Tinmouth A, Fergusson D, Yee IC, Hebert PC, Investigators A, Canadian Critical Care 
Trials G. Clinical consequences of red cell storage in the critically ill. Transfusion. 
2006;46(11):2014-2027. 
138. Baumgartner JM, Silliman CC, Moore EE, Banerjee A, McCarter MD. Stored red blood 
cell transfusion induces regulatory T cells. Journal of the American College of Surgeons. 
2009;208(1):110-119. 
139. Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman LH, Ahn YS. Microparticles in 
stored red blood cells as potential mediators of transfusion complications. Transfusion. 
2011;51(4):886-893. 
140. Burnouf T, Chou ML, Goubran H, Cognasse F, Garraud O, Seghatchian J. An overview of 
the role of microparticles/microvesicles in blood components: Are they clinically 
beneficial or harmful? Transfusion and apheresis science : official journal of the World 
Apheresis Association : official journal of the European Society for Haemapheresis. 
2015;53(2):137-145. 
141. Kostova EB, Beuger BM, Klei TR, Halonen P, Lieftink C, Beijersbergen R, et al. 
Identification of signalling cascades involved in red blood cell shrinkage and 
vesiculation. Biosci Rep. 2015;35(2):e00187. 
142. Lelubre C, Vincent JL. Relationship between red cell storage duration and outcomes in 
adults receiving red cell transfusions: a systematic review. Crit Care. 2013;17(2):R66. 
143. Straat M, Boing AN, Tuip-De Boer A, Nieuwland R, Juffermans NP. Extracellular Vesicles 
from Red Blood Cell Products Induce a Strong Pro-Inflammatory Host Response, 
 184 
Dependent on Both Numbers and Storage Duration. Transfus Med Hemother. 
2016;43(4):302-305. 
144. Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody 
mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 
2015;29(1):51-61. 
145. Rubin O, Crettaz D, Tissot JD, Lion N. Microparticles in stored red blood cells: submicron 
clotting bombs? Blood transfusion = Trasfusione del sangue. 2010;8 Suppl 3:s31-38. 
146. Hod EA, Zhang N, Sokol SA, Wojczyk BS, Francis RO, Ansaldi D, et al. Transfusion of red 
blood cells after prolonged storage produces harmful effects that are mediated by iron 
and inflammation. Blood. 2010;115(21):4284-4292. 
147. Bal SH, Heper Y, Kumas LT, Guvenc F, Budak F, Goral G, et al. Effect of storage period of 
red blood cell suspensions on helper T-cell subpopulations. Blood Transfusion. 2017:1-
11. 
148. Baumgartner JM, Silliman CC, Moore EE, Banerjee A, McCarter MD. Stored red blood 
cell transfusion induces regulatory T cells. J Am Coll Surg. 2009;208(1):110-119. 
149. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC. Increased rate of infection 
associated with transfusion of old blood after severe injury. Arch Surg. 2002;137(6):711-
716; discussion 716-717. 
150. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood 
transfused in septic ICU patients. Can J Anaesth. 1997;44(12):1256-1261. 
151. Silliman CC, Thurman GW, Ambruso DR. Stored blood components contain agents that 
prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. 
Vox Sang. 1992;63(2):133-136. 
152. Weinberg JA, McGwin G, Jr., Marques MB, Cherry SA, 3rd, Reiff DA, Kerby JD, et al. 
Transfusions in the less severely injured: does age of transfused blood affect outcomes? 
J Trauma. 2008;65(4):794-798. 
 185 
153. Heddle NM, Cook RJ, Arnold DM, Liu Y, Barty R, Crowther MA, et al. Effect of Short-Term 
vs. Long-Term Blood Storage on Mortality after Transfusion. N Engl J Med. 
2016;375(20):1937-1945. 
154. Gauvin F, Spinella PC, Lacroix J, Choker G, Ducruet T, Karam O, et al. Association 
between length of storage of transfused red blood cells and multiple organ dysfunction 
syndrome in pediatric intensive care patients. Transfusion. 2010;50(9):1902-1913. 
155. Fergusson DA, Hebert P, Hogan DL, LeBel L, Rouvinez-Bouali N, Smyth JA, et al. Effect of 
fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-
weight infants: the ARIPI randomized trial. JAMA. 2012;308(14):1443-1451. 
156. Cardo LJ, Wilder D, Salata J. Neutrophil priming, caused by cell membranes and 
microvesicles in packed red blood cell units, is abrogated by leukocyte depletion at 
collection. Transfusion and apheresis science : official journal of the World Apheresis 
Association : official journal of the European Society for Haemapheresis. 
2008;38(2):117-125. 
157. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, et al. 
Beneficial effects of leukocyte depletion of transfused blood on postoperative 
complications in patients undergoing cardiac surgery: a randomized clinical trial. 
Circulation. 1998;97(6):562-568. 
158. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al. Clinical 
outcomes following institution of the Canadian universal leukoreduction program for 
red blood cell transfusions. JAMA. 2003;289(15):1941-1949. 
159. Watkins TR, Rubenfeld GD, Martin TR, Nester TA, Caldwell E, Billgren J, et al. Effects of 
leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. 
Crit Care Med. 2008;36(5):1493-1499. 
 186 
160. Nathens AB, Nester TA, Rubenfeld GD, Nirula R, Gernsheimer TB. The effects of 
leukoreduced blood transfusion on infection risk following injury: a randomized 
controlled trial. Shock. 2006;26(4):342-347. 
161. van Hilten JA, van de Watering LM, van Bockel JH, van de Velde CJ, Kievit J, Brand R, et 
al. Effects of transfusion with red cells filtered to remove leucocytes: randomised 
controlled trial in patients undergoing major surgery. BMJ. 2004;328(7451):1281. 
162. Locke R, Paul D, Touch S, Mackley A, Maduskuie V, Fawcett P. Cytokine load in 
prestorage leukoreduced PRBC transfusions in premature infants. J Perinatol. 
2005;25(8):526-530. 
163. Cholette JM, Henrichs KF, Alfieris GM, Powers KS, Phipps R, Spinelli SL, et al. Washing 
red blood cells and platelets transfused in cardiac surgery reduces postoperative 
inflammation and number of transfusions: results of a prospective, randomized, 
controlled clinical trial. Pediatric Critical Care Medicine. 2012;13(3):290-299. 
164. Leng L, Bucala R. Macrophage migration inhibitory factor. Critical care medicine. 
2005;33(12 Suppl):S475-477. 
165. Grimshaw K, Sahler J, Spinelli SL, Phipps RP, Blumberg N. New frontiers in transfusion 
biology: identification and significance of mediators of morbidity and mortality in stored 
red blood cells. Transfusion. 2011;51(4):874-880. 
166. Scott BH, Seifert FC, Grimson R. Blood transfusion is associated with increased resource 
utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth. 
2008;11(1):15-19. 
167. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C. Impact of 
allogenic packed red blood cell transfusion on nosocomial infection rates in the critically 
ill patient. Crit Care Med. 2002;30(10):2249-2254. 
 187 
168. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, 
postoperative morbidity, and cost after red blood cell transfusion in patients having 
cardiac surgery. Circulation. 2007;116(22):2544-2552. 
169. Jaime-Perez JC, Colunga-Pedraza PR, Gomez-Almaguer D. Is the number of blood 
products transfused associated with lower survival in children with acute lymphoblastic 
leukemia? Pediatr Blood Cancer. 2011;57(2):217-223. 
170. dos Santos AM, Guinsburg R, de Almeida MF, Procianoy RS, Leone CR, Marba ST, et al. 
Red blood cell transfusions are independently associated with intra-hospital mortality 
in very low birth weight preterm infants. Journal of Pediatrics. 2011;159(3):371-
376.e371-373. 
171. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet 
transfusions in adult acute leukemia BMC Blood Disorders. 2004;4(1):6. 
172. Loh YS, Tan S, Kwok M, Stark MJ, Marks DC. Reduction of biological response modifiers 
in the supernatant of washed paediatric red blood cells. Vox Sanguinis. 
2016;111(4):365-373. 
173. Biffl WL, Moore EE, Offner PJ, Ciesla DJ, Gonzalez RJ, Silliman CC. Plasma from aged 
stored red blood cells delays neutrophil apoptosis and primes for cytotoxicity: 
abrogation by poststorage washing but not prestorage leukoreduction. The Journal of 
Trauma. 2001;50(3):426-431; discussion 432. 
174. Rao RS, Howard CA, Teague TK. Pulmonary endothelial permeability is increased by fluid 
from packed red blood cell units but not by fluid from clinically-available washed units. 
The Journal of Trauma. 2006;60(4):851-858. 
175. Wozniak MJ, Sullo N, Qureshi S, Dott W, Cardigan R, Wiltshire M, et al. Randomized trial 
of red cell washing for the prevention of transfusion-associated organ injury in cardiac 
surgery. British Journal of Anaesthesia. 2017;118(5):689-698. 
 188 
176. Weisbach V, Riego W, Strasser E, Zingsem J, Ringwald J, Zimmermann R, et al. The in 
vitro quality of washed, prestorage leucocyte-depleted red blood cell concentrates. Vox 
Sanguinis. 2004;87(1):19-26. 
177. de Vroege R, Wildevuur WR, Muradin JA, Graves D, van Oeveren W. Washing of stored 
red blood cells by an autotransfusion device before transfusion. Vox Sanguinis. 
2007;92(2):130-135. 
178. Scott KL, Lecak J, Acker JP. Biopreservation of red blood cells: past, present, and future. 
Transfusion Medicine Reviews. 2005;19(2):127-142. 
179. Thomas S, Hancock V, Cardigan R. Repeated short-term warming of red blood cell 
concentrates has minimal effect on their quality. Vox Sanguinis. 2012;103(2):113-121. 
180. Warner MA, Welsby IJ, Norris PJ, Silliman CC, Armour S, Wittwer ED, et al. Point-of-care 
washing of allogeneic red blood cells for the prevention of transfusion-related 
respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical 
trial in patients undergoing cardiac surgery. BMJ Open. 2017;7(8):e016398. 
181. Keir AK, Wilkinson D, Andersen C, Stark MJ. Washed versus unwashed red blood cells 
for transfusion for the prevention of morbidity and mortality in preterm infants. 
Cochrane database of systematic reviews (Online). 2016;1:CD011484. 
182. Rocha G, Pereira S, Antunes-Sarmento J, Flor-de-Lima F, Soares H, Guimaraes H. Early 
anemia and neonatal morbidity in extremely low birth-weight preterm infants. Journal 
of Maternal-Fetal Neonatal Medicine. 2019:1-7. 
183. Cambonie G, Matecki S, Milesi C, Voisin M, Guillaumont S, Picaud JC. Myocardial 
adaptation to anemia and red blood cell transfusion in premature infants requiring 
ventilation support in the 1st postnatal week. Neonatology. 2007;92(3):174-181. 
184. Kanmaz HG, Sarikabadayi YU, Canpolat E, Altug N, Oguz SS, Dilmen U. Effects of red cell 
transfusion on cardiac output and perfusion index in preterm infants. Early Human 
Development. 2013;89(9):683-686. 
 189 
185. Yu CW, Sung RY, Fok TF, Wong EM. Effects of blood transfusion on left ventricular 
output in premature babies. Journal of Paediatrics and Child Health. 1998;34(5):444-
446. 
186. Sortica da Costa C, Cardim D, Molnar Z, Kelsall W, Ng I, Czosnyka M, et al. Changes in 
hemodynamics, cerebral oxygenation and cerebrovascular reactivity during the early 
transitional circulation in preterm infants. Pediatric Research. 2019:247-253. 
187. Nelle M, Hocker C, Zilow EP, Linderkamp O. Effects of red cell transfusion on cardiac 
output and blood flow velocities in cerebral and gastrointestinal arteries in premature 
infants. Archives of Disease in Childhood. 1994;71(1):F45-48. 
188. Quante M, Pulzer F, Blaser A, Gebauer C, Kluge J, Robel-Tillig E. Effects of anaemia on 
haemodynamic and clinical parameters in apparently stable preterm infants. Blood 
transfusion = Trasfusione del sangue. 2013;11(2):227-232. 
189. Ramaekers VT, Casaer P, Marchal G, Smet M, Goossens W. The effect of blood 
transfusion on cerebral blood-flow in preterm infants: a Doppler study. Developmental 
medicine and child neurology. 1988;30(3):334-341. 
190. Dani C, Pezzati M, Martelli E, Prussi C, Bertini G, Rubaltelli FF. Effect of blood 
transfusions on cerebral haemodynamics in preterm infants. Acta Paediatr. 
2002;91(9):938-941. 
191. Dani C, Pratesi S, Fontanelli G, Barp J, Bertini G. Blood transfusions increase cerebral, 
splanchnic, and renal oxygenation in anemic preterm infants. Transfusion. 
2010;50(6):1220-1226. 
192. Liem KD, Hopman JC, Oeseburg B, de Haan AF, Kollee LA. The effect of blood transfusion 
and haemodilution on cerebral oxygenation and haemodynamics in newborn infants 
investigated by near infrared spectrophotometry. Eur J Pediatr. 1997;156(4):305-310. 
 190 
193. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute 
gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red 
blood cell transfusion. Journal of Pediatrics. 2011;158(3):403-409. 
194. Bailey SM, Hendricks-Munoz KD, Mally PV. Variability in splanchnic tissue oxygenation 
during preterm red blood cell transfusion given for symptomatic anaemia may reveal a 
potential mechanism of transfusion-related acute gut injury. Blood Transfus. 
2015;13(3):429-434. 
195. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients 
with sepsis. JAMA. 1993;269(23):3024-3029. 
196. Havranek T, Thompson Z, Carver JD. Factors that influence mesenteric artery blood flow 
velocity in newborn preterm infants. J Perinatol. 2006;26(8):493-497. 
197. Chasse M, Tinmouth A, English SW, Acker JP, Wilson K, Knoll G, et al. Association of 
Blood Donor Age and Sex With Recipient Survival After Red Blood Cell Transfusion. 
JAMA Internal Medicine. 2016;176(9):1307-1314. 
198. Heddle NM, Cook RJ, Liu Y, Zeller M, Barty R, Acker JP, et al. The association between 
blood donor sex and age and transfusion recipient mortality: an exploratory analysis. 
Transfusion. 2019;59(2):482-491. 
199. Jones AR, Brown MR, Vance DE. From Donor to Recipient: Considerations for Blood 
Transfusion Outcomes Research. Biol Res Nurs. 2017;19(5):491-498. 
200. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated 
with passive transfer of antileukocyte antibodies. Am Rev Respir Dis. 1983;128(1):185-
189. 
201. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-
related acute lung injury. Transfusion. 1985;25(6):573-577. 
202. Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al. Ten years of 
hemovigilance reports of transfusion-related acute lung injury in the United Kingdom 
 191 
and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-
452. 
203. Bontadini A. HLA techniques: typing and antibody detection in the laboratory of 
immunogenetics. Methods. 2012;56(4):471-476. 
204. Klein J, Sato A. The HLA system. First of two parts. The New England Journal of Medicine. 
2000;343(10):702-709. 
205. Mosaad YM. Clinical Role of Human Leukocyte Antigen in Health and Disease. 
Scandinavian Journal of Immunology. 2015;82(4):283-306. 
206. Turner D. The human leucocyte antigen (HLA) system. Vox Sanguinis. 2004;87 
Suppl1:87-90. 
207. Brown CJ, Navarrete CV. Clinical relevance of the HLA system in blood transfusion. Vox 
Sanguinis. 2011;101(2):93-105. 
208. Klein J, Sato A. The HLA system. Second of two parts. The New England Journal of 
Medicine. 2000;343(11):782-786. 
209. McCaughan JA, Tinckam KJ. Donor specific HLA antibodies & allograft injury: 
mechanisms, methods of detection, manifestations and management. Transplant 
International. 2018;31(10):1059-1070. 
210. Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox 
Sanguinis. 2011;100(1):122-128. 
211. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. 
Transfus Med Rev. 2004;18(3):184-188. 
212. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: 
mechanisms of sensitization and implications for prevention. American Journal of 
Transplantation. 2011;11(9):1785-1791. 
213. Rogers TS, Fung MK, Harm SK. Recent Advances in Preventing Adverse Reactions to 
Transfusion. F1000Res. 2015;4. 
 192 
214. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization 
in female apheresis donors. Transfusion. 1999;39(1):103-106. 
215. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, et al. Transfusion-related 
acute lung injury surveillance (2003-2005) and the potential impact of the selective use 
of plasma from male donors in the American Red Cross. Transfusion. 2007;47(4):599-
607. 
216. Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): 
anti-leukocyte antibodies. Crit Care Med. 2006;34(5 Suppl):S118-123. 
217. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in 
transfusion-related acute lung injury and results of leucocyte antibody screening of 
blood donors. Vox Sanguinis. 2008;95(4):313-317. 
218. Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role of anti-
human leucocyte antigen class II alloantibody and monocytes in development of 
transfusion-related acute lung injury. Transfus Med. 2007;17(2):129-134. 
219. Australia NBA. Australian Haemovigilance Report2016. 
220. Tynell E, Andersson TM, Norda R, Edgren G, Nyren O, Shanwell A, et al. Should plasma 
from female donors be avoided? A population-based cohort study of plasma recipients 
in Sweden from 1990 through 2002. Transfusion. 2010;50(6):1249-1256. 
221. Gajic O, Yilmaz M, Iscimen R, Kor DJ, Winters JL, Moore SB, et al. Transfusion from male-
only versus female donors in critically ill recipients of high plasma volume components. 
Critical Care Medicine. 2007;35(7):1645-1648. 
222. Ray S, Rogers L, Pagel C, Raman S, Peters MJ, Ramnarayan P. PaO2/FIO2 Ratio Derived 
From the SpO2/FIO2 Ratio to Improve Mortality Prediction Using the Pediatric Index of 
Mortality-3 Score in Transported Intensive Care Admissions. Pediatr Crit Care Med. 
2017;18(3):e131-e136. 
 193 
223. Gajic O, Rana R, Mendez JL, Rickman OB, Lymp JF, Hubmayr RD, et al. Acute lung injury 
after blood transfusion in mechanically ventilated patients. Transfusion. 
2004;44(10):1468-1474. 
224. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial oftransfusion-related 
acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion. 
2001;41(3):317-322. 
225. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings 
of a consensus conference: towards an understanding of TRALI. Transfusion Medicine 
Reviews. 2005;19(1):2-31. 
226. Middelburg RA, Van Stein D, Zupanska B, Uhrynowska M, Gajic O, Muniz-Diaz E, et al. 
Female donors and transfusion-related acute lung injury: A case-referent study from 
the International TRALI Unisex Research Group. Transfusion. 2010;50(11):2447-2454. 
227. Desmarets M, Bardiaux L, Benzenine E, Dussaucy A, Binda D, Tiberghien P, et al. Effect 
of storage time and donor sex of transfused red blood cells on 1-year survival in patients 
undergoing cardiac surgery: an observational study. Transfusion. 2016;56(5):1213-
1222. 
228. Bjursten H, Dardashti A, Bjork J, Wierup P, Algotsson L, Ederoth P. Transfusion of sex-
mismatched and non-leukocyte-depleted red blood cells in cardiac surgery increases 
mortality. J Thorac Cardiovasc Surg. 2016;152(1):223-232 e221. 
229. Chasse M, McIntyre L, English SW, Tinmouth A, Knoll G, Wolfe D, et al. Effect of Blood 
Donor Characteristics on Transfusion Outcomes: A Systematic Review and Meta-
Analysis. Transfusion medicine reviews. 2016;30(2):69-80. 
230. Jordan A, Chen D, Yi QL, Kanias T, Gladwin MT, Acker JP. Assessing the influence of 
component processing and donor characteristics on quality of red cell concentrates 
using quality control data. Vox Sanguinis. 2016;111(1):8-15. 
 194 
231. Hilario S, Saldanha C, Martins e Silva J. An in vitro study of adrenaline effect on human 
erythrocyte properties in both gender. Clinical Hemorheology and Microcirculation. 
2003;28(2):89-98. 
232. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, et al. Nitric oxide scavenging by 
red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell 
storage lesion. Circulation. 2011;124(4):465-476. 
233. Caram-Deelder C, Kreuger AL, Evers D, de Vooght KMK, van de Kerkhof D, Visser O, et 
al. Association of Blood Transfusion From Female Donors With and Without a History of 
Pregnancy With Mortality Among Male and Female Transfusion Recipients. JAMA. 
2017;318(15):1471-1478. 
234. Murphy T, Chawla A, Tucker R, Vohr B. Impact of Blood Donor Sex on Transfusion-
Related Outcomes in Preterm Infants. The Journal of Pediatrics. 2018;201:215-220. 
235. Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on 
red cell post-transfusion outcomes. Transfusion Medicine Reviews. 2018;32(1):28-35. 
236. Gale C, Modi N, Jawad S, Culshaw L, Dorling J, Bowler U, et al. The WHEAT pilot trial-
WithHolding Enteral feeds Around packed red cell Transfusion to prevent necrotising 
enterocolitis in preterm neonates: a multicentre, electronic patient record (EPR), 
randomised controlled point-of-care pilot trial. BMJ Open. 2019;9(9):e033543. 
237. Koenig J, Hill LK, Williams DP, Thayer JF. Estimating cardiac output from blood pressure 
and heart rate: the liljestrand & zander formula. Biomed Sci Instrum. 2015;51:85-90. 
238. Iyer NP, Mhanna MJ. Non-invasively derived respiratory severity score and oxygenation 
index in ventilated newborn infants. Pediatr Pulmonol. 2013;48(4):364-369. 
239. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal 
and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 
gm. J Pediatr. 1978;92(4):529-534. 
 195 
240. Patz A. New international classification of retinopathy of prematurity. Pediatrics. 
1984;74(1):160-161. 
241. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal 
necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 
1978;187(1):1-7. 




Published 2020. Accessed 10/06/2020, 2020. 
243. Panel ACCPG. Antenatal corticosteroids given to women prior to birth to improve fetal, 
infant, child and adult health: Clinical Practice Guidelines.: Liggins Institute, The 
University of Auckland, Auckland. New Zealand.; 2015. 
244. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and 
transfusion-related acute lung injury. Blood. 2019;133(17):1840-1853. 
245. Keir AK, New H, Robitaille N, Crighton GL, Wood EM, Stanworth SJ. Approaches to 
understanding and interpreting the risks of red blood cell transfusion in neonates. 
Transfus Med. 2019;29(4):231-238. 
246. Muszynski JA, Spinella PC, Cholette JM, Acker JP, Hall MW, Juffermans NP, et al. 
Transfusion-related immunomodulation: review of the literature and implications for 
pediatric critical illness. Transfusion. 2017;57(1):195-206. 
247. Jung YH, Jang J, Kim HS, Shin SH, Choi CW, Kim EK, et al. Respiratory severity score as a 
predictive factor for severe bronchopulmonary dysplasia or death in extremely preterm 
infants. BMC Pediatr. 2019;19(1):121. 
 196 
248. Askie LM, Darlow BA, Davis PG, Finer N, Stenson B, Vento M, et al. Effects of targeting 
lower versus higher arterial oxygen saturations on death or disability in preterm infants. 
Cochrane database of systematic reviews (Online). 2017;4:CD011190. 
249. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus 
arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr. 
1995;127(5):774-779. 
250. Alverson DC, Eldridge M, Dillon T, Yabek SM, Berman W, Jr. Noninvasive pulsed Doppler 
determination of cardiac output in neonates and children. The Journal of pediatrics. 
1982;101(1):46-50. 
251. Bard H, Fouron JC, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic 
adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. The 
Journal of pediatrics. 1998;132(4):630-634. 
252. Kanmaz HG, Sarikabadayi YU, Canpolat E, Altug N, Oguz SS, Dilmen U. Effects of red cell 
transfusion on cardiac output and perfusion index in preterm infants. Early Hum Dev. 
2013;89(9):683-686. 
253. Yu CW, Sung RY, Fok TF, Wong EM. Effects of blood transfusion on left ventricular 
output in premature babies. J Paediatr Child Health. 1998;34(5):444-446. 
254. Loh YS, Tan S, Kwok M, Stark MJ, Marks DC. Reduction of biological response modifiers 
in the supernatant of washed paediatric red blood cells. Vox sanguinis. 
2016;111(4):365-373. 
255. Giesinger RE, McNamara PJ. Hemodynamic instability in the critically ill neonate: An 
approach to cardiovascular support based on disease pathophysiology. Semin Perinatol. 
2016;40(3):174-188. 
256. Rios DR, Bhattacharya S, Levy PT, McNamara PJ. Circulatory Insufficiency and 
Hypotension Related to the Ductus Arteriosus in Neonates. Front Pediatr. 2018;6:62. 
 197 
257. Plummer NS. Blood Transfusion: A Report of Six Fatalities. Br Med J. 1936;2(3962):1186-
1189. 
258. Popovsky MA, Audet AM, Andrzejewski C, Jr. Transfusion-associated circulatory 
overload in orthopedic surgery patients: a multi-institutional study. 
Immunohematology. 1996;12(2):87-89. 
259. De Cloedt L, Emeriaud G, Lefebvre E, Kleiber N, Robitaille N, Jarlot C, et al. Transfusion-
associated circulatory overload in a pediatric intensive care unit: different incidences 
with different diagnostic criteria. Transfusion. 2018;58(4):1037-1044. 
260. Network. TISoBTWPoHicwTIH. The Transfusion-associated Circulatory Overload 
Definition (2011 revision)  www.isbtweb. Published 2011. Accessed 31/01/2020, 2020. 
261. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. 
Lancet. 1967;2(7511):319-323. 
262. Khemani RG, Smith LS, Zimmerman JJ, Erickson S, Pediatric Acute Lung Injury Consensus 
Conference G. Pediatric acute respiratory distress syndrome: definition, incidence, and 
epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. 
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and 
the World Federation of Pediatric Intensive and Critical Care Societies. 2015;16(5 Suppl 
1):S23-40. 
263. De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The 
Montreux definition of neonatal ARDS: biological and clinical background behind the 
description of a new entity. The Lancet Respiratory medicine. 2017;5(8):657-666. 
264. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward 
an understanding of transfusion-related acute lung injury: statement of a consensus 
panel. Transfusion. 2004;44(12):1774-1789. 
 198 
265. Stainsby D, Jones H, Wells AW, Gibson B, Cohen H, Group SS. Adverse outcomes of 
blood transfusion in children: analysis of UK reports to the serious hazards of 
transfusion scheme 1996-2005. Br J Haematol. 2008;141(1):73-79. 
266. Vande Vusse LK, Caldwell E, Tran E, Hogl L, Dinwiddie S, Lopez JA, et al. The 
Epidemiology of Transfusion-related Acute Lung Injury Varies According to the Applied 
Definition of Lung Injury Onset Time. Ann Am Thorac Soc. 2015;12(9):1328-1335. 
267. Popovsky MA. Pulmonary consequences of transfusion: TRALI and TACO. Transfusion 
and apheresis science : official journal of the World Apheresis Association : official 
journal of the European Society for Haemapheresis. 2006;34(3):243-244. 
268. Li G, Daniels CE, Kojicic M, Krpata T, Wilson GA, Winters JL, et al. The accuracy of 
natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in 
the differentiation between transfusion-related acute lung injury and transfusion-
related circulatory overload in the critically ill. Transfusion. 2009;49(1):13-20. 
269. Agrawal A, Zhuo H, Brady S, Levitt J, Steingrub J, Siegel MD, et al. Pathogenetic and 
predictive value of biomarkers in patients with ALI and lower severity of illness: results 
from two clinical trials. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L634-639. 
270. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, et al. Plasma 
angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir 
Crit Care Med. 2013;187(7):736-742. 
271. Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. Transfusion-
related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-1767. 
272. Vlaar AP, Hofstra JJ, Determann RM, Veelo DP, Paulus F, Levi M, et al. Transfusion-
related acute lung injury in cardiac surgery patients is characterized by pulmonary 
inflammation and coagulopathy: a prospective nested case-control study. Crit Care 
Med. 2012;40(10):2813-2820. 
 199 
273. Roubinian NH, Looney MR, Kor DJ, Lowell CA, Gajic O, Hubmayr RD, et al. Cytokines and 
clinical predictors in distinguishing pulmonary transfusion reactions. Transfusion. 
2015;55(8):1838-1846. 
274. Menden H, Tate E, Hogg N, Sampath V. LPS-mediated endothelial activation in 
pulmonary endothelial cells: role of Nox2-dependent IKK-beta phosphorylation. Am J 
Physiol Lung Cell Mol Physiol. 2013;304(6):L445-455. 
275. Yazji I, Sodhi CP, Lee EK, Good M, Egan CE, Afrazi A, et al. Endothelial TLR4 activation 
impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-
nitrite signaling. Proceedings of the National Academy of Sciences of the United States 
of America. 2013;110(23):9451-9456. 
276. Collard KJ. Is there a causal relationship between the receipt of blood transfusions and 
the development of chronic lung disease of prematurity? Medical hypotheses. 
2006;66(2):355-364. 
277. Valieva OA, Strandjord TP, Mayock DE, Juul SE. Effects of transfusions in extremely low 
birth weight infants: a retrospective study. The Journal of pediatrics. 2009;155(3):331-
337 e331. 
278. Petri B, Phillipson M, Kubes P. The physiology of leukocyte recruitment: an in vivo 
perspective. J Immunol. 2008;180(10):6439-6446. 
279. Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation. 
2009;16(1):31-42. 
280. Cheng Q, McKeown SJ, Santos L, Santiago FS, Khachigian LM, Morand EF, et al. 
Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in 
human endothelial cells via promotion of expression of adhesion molecules. J Immunol. 
2010;185(2):1238-1247. 
281. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory 
bowel diseases. Mol Nutr Food Res. 2008;52(8):885-897. 
 200 
282. Ince DA, Atac FB, Ozkiraz S, Dilmen U, Gulcan H, Tarcan A, et al. The role of plasminogen 
activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in 
bronchopulmonary dysplasia. Genet Test Mol Biomarkers. 2010;14(5):643-647. 
283. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor 
linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 
2010;28(5):e72-91. 
284. Jason J, Archibald LK, Nwanyanwu OC, Bell M, Jensen RJ, Gunter E, et al. The effects of 
iron deficiency on lymphocyte cytokine production and activation: preservation of 
hepatic iron but not at all cost. Clin Exp Immunol. 2001;126(3):466-473. 
285. Askar S, Deveboynu SN, Er H, Askar TK, Hismiogullari AA. Changes in pro-inflammatory 
cytokines and antimicrobial proteins in elderly women with iron deficiency anemia. Pak 
J Med Sci. 2019;35(2):298-301. 
286. Dutta A, De R, Dolai TK, Mitra PK, Halder A. Changes in Different Cytokines (IL-2, TNF-
alpha, and IFN-gamma) Profile in Acquired Aplastic Anemia Patients: A Study From 
Eastern India. J Pediatr Hematol Oncol. 2020;42(3):185-192. 
287. Jackman RP, Utter GH, Muench MO, Heitman JW, Munz MM, Jackman RW, et al. Distinct 
roles of trauma and transfusion in induction of immune modulation after injury. 
Transfusion. 2012;52(12):2533-2550. 
288. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of 
lipids that develop during the routine storage of blood and prime the neutrophil NADPH 
oxidase. J Lab Clin Med. 1994;124(5):684-694. 
289. Fox LM, Cox DG, Lockridge JL, Wang X, Chen X, Scharf L, et al. Recognition of lyso-
phospholipids by human natural killer T lymphocytes. PLoS Biol. 2009;7(10):e1000228. 
290. Jin Y, Damaj BB, Maghazachi AA. Human resting CD16-, CD16+ and IL-2-, IL-12-, IL-15- 
or IFN-alpha-activated natural killer cells differentially respond to 
 201 
sphingosylphosphorylcholine, lysophosphatidylcholine and platelet-activating factor. 
European journal of immunology. 2005;35(9):2699-2708. 
291. Coutant F, Perrin-Cocon L, Agaugue S, Delair T, Andre P, Lotteau V. Mature dendritic 
cell generation promoted by lysophosphatidylcholine. J Immunol. 2002;169(4):1688-
1695. 
292. Olofsson KE, Andersson L, Nilsson J, Bjorkbacka H. Nanomolar concentrations of 
lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine 
production in macrophages. Biochem Biophys Res Commun. 2008;370(2):348-352. 
293. Jacobi KE, Wanke C, Jacobi A, Weisbach V, Hemmerling TM. Determination of 
eicosanoid and cytokine production in salvaged blood, stored red blood cell 
concentrates, and whole blood. J Clin Anesth. 2000;12(2):94-99. 
294. Rizos D, Protonotariou E, Malamitsi-Puchner A, Sarandakou A, Trakakis E, Salamalekis E. 
Cytokine concentrations during the first days of life. Eur J Obstet Gynecol Reprod Biol. 
2007;131(1):32-35. 
295. Matoba N, Yu Y, Mestan K, Pearson C, Ortiz K, Porta N, et al. Differential patterns of 27 
cord blood immune biomarkers across gestational age. Pediatrics. 2009;123(5):1320-
1328. 
296. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage 
in the preterm newborn. Pediatric research. 1997;42(1):1-8. 
297. Schelonka RL, Maheshwari A, Carlo WA, Taylor S, Hansen NI, Schendel DE, et al. T cell 
cytokines and the risk of blood stream infection in extremely low birth weight infants. 
Cytokine. 2011;53(2):249-255. 
298. Lusyati S, Hulzebos CV, Zandvoort J, Sauer PJ. Levels of 25 cytokines in the first seven 
days of life in newborn infants. BMC Res Notes. 2013;6:547. 
 202 
299. Nishimaki S, Shima Y, Sato M, An H, Kadota K, Yokota S. Postnatal changes of cytokines 
in premature infants with or without funisitis. J Matern Fetal Neonatal Med. 
2014;27(15):1545-1549. 
300. Paananen R, Husa AK, Vuolteenaho R, Herva R, Kaukola T, Hallman M. Blood cytokines 
during the perinatal period in very preterm infants: relationship of inflammatory 
response and bronchopulmonary dysplasia. J Pediatr. 2009;154(1):39-43 e33. 
301. Weisbach V, Wanke C, Zingsem J, Zimmermann R, Eckstein R. Cytokine generation in 
whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates. 
Vox sanguinis. 1999;76(2):100-106. 
302. Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R. The influence of platelet 
additive solutions on cytokine levels and complement activation in platelet 
concentrates during storage. Vox sanguinis. 2003;84(1):28-35. 
303. Veale MF, Healey G, Sparrow RL. Effect of additive solutions on red blood cell (RBC) 
membrane properties of stored RBCs prepared from whole blood held for 24 hours at 
room temperature. Transfusion. 2011;51 Suppl 1:25s-33s. 
304. Bose CL, Laughon MM, Allred EN, O'Shea TM, Van Marter LJ, Ehrenkranz RA, et al. 
Systemic inflammation associated with mechanical ventilation among extremely 
preterm infants. Cytokine. 2013;61(1):315-322. 
305. Middelburg RA, Briet E, van der Bom JG. Mortality after transfusions, relation to donor 
sex. Vox sanguinis. 2011;101(3):221-229. 
306. Edgren G, Murphy EL, Brambilla DJ, Westlake M, Rostgaard K, Lee C, et al. Association 
of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell 
Transfusion Recipients. JAMA. 2019;321(22):2183-2192. 
307. Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on 
red cell post-transfusion outcomes. Transfusion medicine reviews. 2018;32(1):28-35. 
 203 
308. Roubinian NH, Plimier C, Woo JP, Lee C, Bruhn R, Liu VX, et al. Effect of donor, 
component, and recipient characteristics on hemoglobin increments following red 
blood cell transfusion. Blood. 2019;134(13):1003-1013. 
309. Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M, et al. Effects of red-
cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 
2015;372(15):1419-1429. 
310. Lieberman L, Petraszko T, Yi QL, Hannach B, Skeate R. Transfusion-related lung injury in 
children: a case series and review of the literature. Transfusion. 2014;54(1):57-64. 
311. Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention 
measures and their impact at Canadian Blood Services. Transfusion. 2012;52(3):567-
574. 
312. Weiss ES, Allen JG, Patel ND, Russell SD, Baumgartner WA, Shah AS, et al. The impact of 
donor-recipient sex matching on survival after orthotopic heart transplantation: 
analysis of 18 000 transplants in the modern era. Circ Heart Fail. 2009;2(5):401-408. 
313. Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, et al. Risks and benefits of 
sex-mismatched hematopoietic cell transplantation differ according to conditioning 
strategy. Haematologica. 2015;100(11):1477-1485. 
314. Kanias T, Lanteri MC, Page GP, Guo Y, Endres SM, Stone M, et al. Ethnicity, sex, and age 
are determinants of red blood cell storage and stress hemolysis: results of the REDS-III 
RBC-Omics study. Blood Adv. 2017;1(15):1132-1141. 
315. Bandyopadhyay S, Brittenham GM, Francis RO, Zimring JC, Hod EA, Spitalnik SL. Iron-
deficient erythropoiesis in blood donors and red blood cell recovery after transfusion: 
initial studies with a mouse model. Blood transfusion = Trasfusione del sangue. 
2017;15(2):158-164. 
316. Peters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung 
injury; from discovery to prevention. Br J Haematol. 2015;170(5):597-614. 
 204 
317. Weinstock C, Schnaidt M. Human Leucocyte Antigen Sensitisation and Its Impact on 
Transfusion Practice. Transfus Med Hemother. 2019;46(5):356-369. 
318. Vlaar AP, Wolthuis EK, Hofstra JJ, Roelofs JJ, Boon L, Schultz MJ, et al. Mechanical 
ventilation aggravates transfusion-related acute lung injury induced by MHC-I class 
antibodies. Intensive Care Med. 2010;36(5):879-887. 
319. Reinisch W, Lichtenberger C, Steger G, Tillinger W, Scheiner O, Gangl A, et al. Donor 
dependent, interferon-gamma induced HLA-DR expression on human neutrophils in 
vivo. Clin Exp Immunol. 2003;133(3):476-484. 
320. Bedford Russell AR, Rivers RP, Davey N. The development of anti-HLA antibodies in 
multiply transfused preterm infants. Arch Dis Child. 1993;68(1 Spec No):49-51. 
321. Lucivero G, Dell'Osso A, Iannone A, Selvaggi L, Antonaci S, Bettocchi S, et al. Phenotypic 
immaturity of T and B lymphocytes in cord blood of full-term normal neonates. Analysis 
of cell surface markers by using conventional techniques and monoclonal antibodies. 
Biol Neonate. 1983;44(5):303-308. 
322. Gruber M, Breu A, Frauendorf M, Seyfried T, Hansen E. Washing of banked blood by 
three different blood salvage devices. Transfusion. 2013;53(5):1001-1009. 
323. Smith T, Riley W, Fitzgerald D. In vitro comparison of two different methods of cell 
washing. Perfusion. 2013;28(1):34-37. 
324. Bennett-Guerrero E, Kirby BS, Zhu H, Herman AE, Bandarenko N, McMahon TJ. 
Randomized study of washing 40- to 42-day-stored red blood cells. Transfusion. 
2014;54(10):2544-2552. 
325. Guillen U, Cummings JJ, Bell EF, Hosono S, Frantz AR, Maier RF, et al. International 
survey of transfusion practices for extremely premature infants. Semin Perinatol. 
2012;36(4):244-247. 
326. Kirpalani H, Whyte RK. What Is New about Transfusions for Preterm Infants? An Update. 
Neonatology. 2019;115(4):406-410. 
 205 
327. DeMauro SB, Giaccone A, Kirpalani H, Schmidt B. Quality of reporting of neonatal and 
infant trials in high-impact journals. Pediatrics. 2011;128(3):e639-644. 
328. NICHD Neonatal Research Network. Transfusion of Prematures Trial (TOP). 
https://clinicaltrials.gov/ct2/show/NCT01702805. Published 2012. Accessed July, 2017. 
329. ETTNO Investigators. The “effects of transfusion thresholds on neurocognitive outcome 
of extremely low birth-weight infants (ETTNO)” study: Background, aims and study 
protocol. Neonatology. 2012;101:301-305. 
330. Lundgren P, Athikarisamy SE, Patole S, Lam GC, Smith LE, Simmer K. Duration of anaemia 
during the first week of life is an independent risk factor for retinopathy of prematurity. 
Acta Paediatr. 2018;107(5):759-766. 
331. Slidsborg C, Jensen A, Forman JL, Rasmussen S, Bangsgaard R, Fledelius HC, et al. 
Neonatal Risk Factors for Treatment-Demanding Retinopathy of Prematurity: A Danish 
National Study. Ophthalmology. 2016;123(4):796-803. 
332. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. 
Transfusion. 1990;30(7):651-658. 
333. Vedder NB, Winn RK, Rice CL, Harlan JM. Neutrophil-mediated vascular injury in shock 
and multiple organ failure. Prog Clin Biol Res. 1989;299:181-191. 
334. Fredriksson K, Lundahl J, Palmberg L, Romberger DJ, Liu XD, Rennard SI, et al. Red blood 
cells stimulate human lung fibroblasts to secrete interleukin-8. Inflammation. 
2003;27(2):71-78. 
335. Karsten E, Hill CJ, Herbert BR. Red blood cells: The primary reservoir of macrophage 
migration inhibitory factor in whole blood. Cytokine. 2018;102:34-40. 
336. Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, et al. Red blood 
cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991;88(4):1362-
1369. 
 206 
337. Neote K, Mak JY, Kolakowski LF, Jr., Schall TJ. Functional and biochemical analysis of the 
cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood. 
1994;84(1):44-52. 
338. Cutbush M, Mollison PL. The Duffy blood group system. Heredity (Edinb). 
1950;4(3):383-389. 
339. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, et al. The Duffy 
antigen receptor for chemokines transports chemokines and supports their 
promigratory activity. Nat Immunol. 2009;10(1):101-108. 
340. Novitzky-Basso I, Rot A. Duffy antigen receptor for chemokines and its involvement in 
patterning and control of inflammatory chemokines. Front Immunol. 2012;3:266. 
341. Fukuma N, Akimitsu N, Hamamoto H, Kusuhara H, Sugiyama Y, Sekimizu K. A role of the 
Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem 
Biophys Res Commun. 2003;303(1):137-139. 
342. Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. Sci 
Rep. 2018;8(1):3101. 
343. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, et al. Duffy antigen 
receptor for chemokines (Darc) polymorphism regulates circulating concentrations of 
monocyte chemoattractant protein-1 and other inflammatory mediators. Blood. 
2010;115(26):5289-5299. 
344. Oonishi T, Sakashita K, Ishioka N, Suematsu N, Shio H, Uyesaka N. Production of 
prostaglandins E1 and E2 by adult human red blood cells. Prostaglandins Other Lipid 
Mediat. 1998;56(2-3):89-101. 
345. Said AS, Rogers SC, Doctor A. Physiologic Impact of Circulating RBC Microparticles upon 
Blood-Vascular Interactions. Frontiers in physiology. 2017;8:1120. 
346. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signalling and 
modulating immune cells. Blood Rev. 2019:100644. 
 207 
347. Canellini G, Rubin O, Delobel J, Crettaz D, Lion N, Tissot JD. Red blood cell microparticles 
and blood group antigens: an analysis by flow cytometry. Blood transfusion = 
Trasfusione del sangue. 2012;10 Suppl 2:s39-45. 
348. Xiong Z, Cavaretta J, Qu L, Stolz DB, Triulzi D, Lee JS. Red blood cell microparticles show 
altered inflammatory chemokine binding and release ligand upon interaction with 
platelets. Transfusion. 2011;51(3):610-621. 
349. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor 
(MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. 
Cytokine. 1998;10(3):199-205. 
350. Le Hiress M, Tu L, Ricard N, Phan C, Thuillet R, Fadel E, et al. Proinflammatory Signature 
of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage 
Migration Inhibitory Factor/CD74 Complex. Am J Respir Crit Care Med. 
2015;192(8):983-997. 
351. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a 
noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell 
recruitment. Nat Med. 2007;13(5):587-596. 
352. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, et 
al. Association between high levels of blood macrophage migration inhibitory factor, 
inappropriate adrenal response, and early death in patients with severe sepsis. Clin 
Infect Dis. 2007;44(10):1321-1328. 
353. Serrano K, Pambrun C, Levin E, Devine DV. Supernatant reduction of stored gamma-
irradiated red blood cells minimizes potentially harmful substances present in 
transfusion aliquots for neonates. Transfusion. 2017;57(12):3009-3018. 
354. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet 
transfusions in adult acute leukemia [ISRCTN76536440]. BMC blood disorders. 
2004;4(1):6. 
 208 
355. Cholette JM, Henrichs KF, Alfieris GM, Powers KS, Phipps R, Spinelli SL, et al. Washing 
red blood cells and platelets transfused in cardiac surgery reduces postoperative 
inflammation and number of transfusions: results of a prospective, randomized, 
controlled clinical trial. Pediatric critical care medicine : a journal of the Society of 
Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care 
Societies. 2012;13(3):290-299. 
356. van Katwyk S, Augustine S, Thebaud B, Thavorn K. Lifetime patient outcomes and 
healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm 



















































Appendix 1: Clinical Characteristics of Infants Consented but not Transfused 
  
 211 
Table 1.  Antenatal characteristics of babies consented but not transfused  
Gestation, weeks 28 (25 – 29)  
Male  35 (61) 
Birthweight, grams 1060 (446 – 1625) 
IUGR  4 (7) 











Chorioamnionitis  8 (14) 











Necrotising Enterocolitis 2 (4) 
Periventricular Leukomalacia  0 (0) 
Interventricular Haemorrhage  3 (5) 
Retinopathy of Prematurity  0 (0) 
Bronchopulmonary Dysplasia  16 (28) 
Blood culture positive sepsis  4 (7) 
Length of Ventilation   1 (0 – 9) 
Length of Nursery Stay 59 (4 – 112) 
Death 2 (4) 
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Lay Title:  
 
Does washing blood for transfusion make a difference to pre-term babies? 
 
Scientific Title:  
Effect of Pre-Transfusion Washing of Red Blood Cells on Neonatal Outcome: A Randomised 
Controlled Trial 
Investigators 
A/Prof Michael Stark, & Dr Chad Andersen (Department of Neonatal Medicine, Women’s and 
Children’s Hospital), Dr Ben Saxon (Australian Red Cross Blood Transfusion Service & 
Department of Hematology, Women’s and Children’s Hospital) Dr Denese Marks (Australian 
Red Cross Blood Transfusion Service) 
 
Introduction 
You are invited to take part in this research project because you are the parent / guardian of a 
preterm baby who may require a blood transfusion.  
 
Preterm babies often receive a blood transfusion (where blood is administered because the 
blood count falls) during their stay in the nursery. This is partly because of the small amounts 
of blood normally taken for monitoring but also because preterm babies make new red blood 
cells slower. As a result of these factors, the majority of very preterm babies receive a blood 
transfusion.  
 
The blood used for transfusion is extensively screened by the Australian Red Blood Cross service 
and is very safe. Washing of blood for transfusion is normally done by the Red Cross for a variety 
of conditions, is a standard approved blood product and is safe. In sick adults and children 
research suggests washing may reduce illness. If this benefit applies to very preterm babies it 
would make a big difference.  
 
What is the purpose of this research project? 
It is the aim of this study to work out if washing blood for transfusion makes a difference in 
preterm babies.  
 
The study will investigate how the washed blood affects problems related to preterm birth but 
also the type and pattern of very small proteins in the blood stream. These very small proteins 
act as messengers and are a way of measuring the baby’s response to transfusion. 
 
What Does the Study Involve? 
Babies born less than 29 weeks will be eligible if the nursery staff caring for your baby decide 
a red blood cell transfusion is needed. 
Babies will have a 50 / 50 chance of receiving either standard blood from the Red Cross or an 
identical pack of washed blood from the Red Cross. Blood will be prepared in a similar way if 
further transfusions are required.  
 
WOMEN'S & CHILDREN’S HEALTH NETWORK 




In addition, a small blood sample (approximately 6 drops) will be collected before and 2-4 
hours after the transfusion. Every effort will be made to collect these blood samples at the 
same time as routine blood tests ordered by the nursery staff. The specimens will be stored in 
a special freezer and thawed at a later date to be analysed. Every effort will be made to use 
the morning blood specimen which is usually discarded after measurement.  
 
Apart from this additional test, your baby’s participation in this study will not result in any 
other change. Your baby will have data collected from their bedside chart and medical history 
including any clinical problems diagnosed during their stay in the neonatal nursery. None of this 
information will identify you or your baby in any way. 
 
What are the possible benefits? 
We do not expect that your baby will receive any additional benefit from this research. 
Rather, the results of the study may be important in helping us to look after preterm babies 
who require a blood transfusion in the future. 
 
What are the possible risks? 
The study involves taking a small (6 drops) additional amount of blood from your baby. 
Whenever possible this will be done at the same time as blood tests ordered by the nursery 
staff caring for your baby. Further, sucrose will be used to reduce the pain for your baby 
should an extra heel prick be needed to collect the blood sample. Washed blood for 
transfusion is a standard, clinically approved blood product for preterm babies and its use 
does not present any additional risks. 
 
Do I have to take part in this research project? 
No, your baby’s participation in this research project is voluntary. If you do not wish your 
baby to take part they don’t have to. If you decide your baby can take part and later change 
your mind, you are free to withdraw your baby from the project at any stage. This will not 
change your relationship with the medical or nursing teams involved in your babies care. 
 
What if I withdraw from this project? 
If you decide to withdraw, please notify a member of the research team. If you decide to 
leave the project, the researchers will ask you if personal and health information that has 
already been collected can be kept. Please inform the research team if you would like this 
information discarded. 
 
How will I be informed of the results of this research project? 
The results of this research project will be submitted for publication in a medical journal. This 
will be made available to the public. A plain language summary of group results will also be 
made available to you at the end of the study if you request it. 
 
What will happen to information about my baby and I? 
The information obtained from you and your baby will be stored under a study number and 
will be non-identifiable to those outside the research team. The information will be retained 
for a minimum of 30 years. At the end of this period, the hard copy will be shredded, and the 
electronic data will be deleted in a secure manner. The data will be stored in locked filing 
cabinets in the Women’s and Children’s Hospital. Only the principal and co-investigators will 
have access to this information. 
Any information obtained in connection with this research project that can identify you will 
remain confidential and will only be used for the purpose of this research project. It will only 
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be disclosed with your permission, except as required by law. In any publication and / or 
presentation, information will be provided in such a way that you cannot be identified, except 
with your permission. Information about your baby’s participation will be recorded in their 
health record.  
 
How can I access my baby’s information? 
In accordance with relevant laws, you have the right to access the information collected and 
stored by the researchers about you. You also have the right to request that any information, 
with which you disagree, be corrected. Please contact one of the researchers if you would like 
to access your information. 
 
Is this research project approved? 
The ethical aspects of this research project have been approved by the Human Research and 
Ethics Committee of the Women’s and Children’s Hospital – REC2498/9/15. This project will 
be carried out according to the National Statement on Ethical Conduct in Human Research 
(2007) produced by the National Health and Medical Research Council of Australia. This 
statement has been developed to protect the interests of people who agree to participate in 
human research studies. Further, this project is registered as a clinical trial with 
www.clinicaltrials.gov and is publically accessible. 
 
What if I Have a Complaint About the Study? 
Should you wish to discuss the approval process or have concerns about your rights as a 
participant in this research, or you have a complaint about the manner in which the research 
is conducted, it may be given to the researcher, or if an independent person is preferred, Villis 
Marshall, Director, Office for Research, (08) 8204 6453 or 0466393503, email: 
Health.SALHNOfficeforResearch@sa.gov.au. Alternatively you may wish to contact local 
Human Research Ethics Officer, Research Governance Officer, Southern Adelaide Local Health 





















Title: Pre-transfusion washing of red blood cells for preterm infants  
SCIENTIFIC TITLE: Effect of pre-transfusion washing of red blood cells on neonatal outcome: A 
randomised controlled trial 
 
I   _________________________________________________________________hereby consent to 
my child's involvement in the research project entitled: Pre-transfusion washing of red blood cells for 
preterm infants 
 
1. The nature and purpose of the research project described on the attached Information Sheet 
has been explained to me. I understand it and agree to my child taking part. 
 
2. I understand that my child may not directly benefit by taking part in this study. 
 
3. I acknowledge that the possible risks and/or side effects, discomforts and inconveniences, as 
outlined in the Information Sheet, have been explained to me. 
 
4. I understand that I can withdraw my child from the study at any stage and that this will not 
affect medical care or any other aspects of my child's relationship with this healthcare service. 
 
5. I understand that there will be no payment to my child for taking part in this study. 
 
6. I have had the opportunity to discuss taking part in this research project with a family member 
or friend, and/or have had the opportunity to have a family member or friend present whilst 
the research project was being explained by the researcher. 
 
7. I am aware that I should retain a copy of the Consent Form, when completed, and the 
Information Sheet. 
  
8. I understand that I am free to withdraw from the research project, without giving any reason, 
at any time and that my action will not affect the care my child will receive. 
  
9. I agree to the accessing of my child’s medical records. 
 
10. I understand that my child’s information will be kept confidential as explained in the 
information sheet except where there is a requirement by law for it to be divulged. 
 









Signed:.........................................Title:  ..................................................................  
 
Dated:  .............................. 
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Appendix 3: Participant Information Sheet and Consent Form (Flinders Medical Centre 




Lay Title:  
Does washing blood for transfusion make a difference to pre-term babies? 
 
Scientific Title:  
Effect of Pre-Transfusion Washing of Red Blood Cells on Neonatal Outcome: A Randomised 
Controlled Trial 
 
Site Specific Investigator 
Dr Scott Morris (Neonatal Unit, Flinders Medical Centre) 
Investigators 
A/Prof Michael Stark, & Dr Chad Andersen (Department of Neonatal Medicine, Women’s and 
Children’s Hospital), Dr Ben Saxon (Australian Red Cross Blood Transfusion Service & 
Department of Hematology, Women’s and Children’s Hospital) Dr Denese Marks (Australian 
Red Cross Blood Transfusion Service) 
 
Introduction 
You are invited to take part in this research project because you are the parent / guardian of a 
preterm baby who may require a blood transfusion.  
 
Preterm babies often receive a blood transfusion (where blood is administered because the 
blood count falls) during their stay in the nursery. This is partly because of the small amounts 
of blood normally taken for monitoring but also because preterm babies make new red blood 
cells slower. As a result of these factors, the majority of very preterm babies receive a blood 
transfusion.  
 
The blood used for transfusion is extensively screened by the Australian Red Blood Cross service 
and is very safe. Washing of blood for transfusion is normally done by the Red Cross for a variety 
of conditions, is a standard approved blood product and is safe. In sick adults and children 
research suggests washing may reduce illness. If this benefit applies to very preterm babies it 
would make a big difference.  
 
What is the purpose of this research project? 
It is the aim of this study to work out if washing blood for transfusion makes a difference in 
preterm babies.  
 
The study will investigate how the washed blood affects problems related to pre term birth but 
also the type and pattern of very small proteins in the blood stream. These very small proteins 
act as messengers and are a way of measuring the baby’s response to transfusion. 
 
What Does the Study Involve? 
Babies born less than 28+6 weeks will be eligible if the nursery staff caring for your baby 
decide a red blood cell transfusion is needed.  
Babies will have a 50 / 50 chance of receiving either standard blood from the Red Cross or an 
identical pack of washed blood from the Red Cross. Blood will be prepared in a similar way if 
further transfusions are required.  
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In addition, a small blood sample (approximately 6 drops) will be collected before and 2-4 
hours after the transfusion. Every effort will be made to collect these blood samples at the 
same time as routine blood tests ordered by the nursery staff. The specimens will be stored in 
a special freezer and thawed at a later date to be analysed. Every effort will be made to use 
the morning blood specimen which is usually discarded after measurement.  
 
Apart from this additional test, your baby’s participation in this study will not result in any 
other change. Your baby will have data collected from their bedside chart and medical history 
including any clinical problems diagnosed during their stay in the neonatal nursery. None of this 
information will identify you or your baby in any way. 
 
What are the possible benefits? 
We do not expect that your baby will receive any additional benefit from this research. 
Rather, the results of the study may be important in helping us to look after preterm babies 
who require a blood transfusion in the future. 
 
What are the possible risks? 
The study involves taking a small (6 drops) additional amount of blood from your baby. 
Whenever possible this will be done at the same time as blood tests ordered by the nursery 
staff caring for your baby. Further, sucrose will be used to reduce the pain for your baby 
should an extra heel prick be needed to collect the blood sample. Washed blood for 
transfusion is a standard, clinically approved blood product for preterm babies and its use 
does not present any additional risks. 
 
Do I have to take part in this research project? 
No, your baby’s participation in this research project is voluntary. If you do not wish your 
baby to take part they don’t have to. If you decide your baby can take part and later change 
your mind, you are free to withdraw your baby from the project at any stage. This will not 
change your relationship with the medical or nursing teams involved in your babies care. 
 
What if I withdraw from this project? 
If you decide to withdraw, please notify a member of the research team. If you decide to 
leave the project, the researchers will ask you if personal and health information that has 
already been collected can be kept. Please inform the research team if you would like this 
information discarded. 
 
How will I be informed of the results of this research project? 
The results of this research project will be submitted for publication in a medical journal. This 
will be made available to the public. A plain language summary of group results will also be 
made available to you at the end of the study if you request it. 
 
What will happen to information about my baby and I? 
The information obtained from you and your baby will be stored under a study number and 
will be non-identifiable to those outside the research team. The information will be retained 
for a minimum of 30 years. At the end of this period, the hard copy will be shredded and the 
electronic data will be deleted in a secure manner. The data will be stored in locked filing 
cabinets in the Women’s and Children’s Hospital. Only the principal and co-investigators will 
have access to this information.  
Any information obtained in connection with this research project that can identify you will 
remain confidential and will only be used for the purpose of this research project. It will only 
be disclosed with your permission, except as required by law. In any publication and / or 
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presentation, information will be provided in such a way that you cannot be identified, except 
with your permission. Information about your baby’s participation will be recorded in their 
health record.  
 
How can I access my baby’s information? 
In accordance with relevant laws, you have the right to access the information collected and 
stored by the researchers about you. You also have the right to request that any information, 
with which you disagree, be corrected. Please contact one of the researchers if you would like 
to access your information. 
 
Is this research project approved? 
The ethical aspects of this research project have been approved by the Human Research and 
Ethics Committee of the Women’s and Children’s Hospital – REC2498/9/15. This project will 
be carried out according to the National Statement on Ethical Conduct in Human Research 
(2007) produced by the National Health and Medical Research Council of Australia. This 
statement has been developed to protect the interests of people who agree to participate in 
human research studies. Further, this project is registered as a clinical trial with 
www.clinicaltrials.gov and is publically accessible. 
 
What if I Have a Complaint About the Study? 
Should you wish to discuss the approval process or have concerns about your rights as a 
participant in this research, or you have a complaint about the manner in which the research 
is conducted, it may be given to the researcher, or if an independent person is preferred, Villis 
Marshall, Director, Office for Research, (08) 8204 6453 or 0466393503, email: 
Health.SALHNOfficeforResearch@sa.gov.au. Alternatively you may wish to contact local 
Human Research Ethics Officer, Research Governance Officer, Southern Adelaide Local Health 































Title: Pre-transfusion washing of red blood cells for preterm infants  
 
SCIENTIFIC TITLE: Effect of pre-transfusion washing of red blood cells on neonatal outcome: A 




I hereby consent to my child's involvement in the research project entitled: Pre-transfusion washing of 
red blood cells for preterm infants 
 
1. The nature and purpose of the research project described on the attached Information Sheet 
has been explained to me. I understand it and agree to my child taking part. 
 
2. I understand that my child may not directly benefit by taking part in this study. 
 
3. I acknowledge that the possible risks and/or side effects, discomforts and inconveniences, as 
outlined in the Information Sheet, have been explained to me. 
 
4. I understand that I can withdraw my child from the study at any stage and that this will not 
affect medical care or any other aspects of my child's relationship with this healthcare service. 
 
5. I understand that there will be no payment to my child for taking part in this study. 
 
6. I have had the opportunity to discuss taking part in this research project with a family member 
or friend, and/or have had the opportunity to have a family member or friend present whilst 
the research project was being explained by the researcher. 
 
7. I am aware that I should retain a copy of the Consent Form, when completed, and the 
Information Sheet. 
  
8. I understand that I am free to withdraw from the research project, without giving any reason, 
at any time and that my action will not affect the care my child will receive. 
  
9. I agree to the accessing of my child’s medical records. 
 
10. I understand that my child’s information will be kept confidential as explained in the 
information sheet except where there is a requirement by law for it to be divulged. 
 




I certify that I have explained the study to the parent and consider that he/she understands what is 
involved. 
 
Signed:.........................................Title:  .................................................................. 
 
Dated:  .............................. 
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Australian Red Cross Blood Service 
17 O’Riordan Street 
 Alexandria | NSW | 2015 
 P: +61 2 9234 2368 | F: +61 2 9234 2411 
 Web: www.donateblood.com.au 
 
12 November 2019 
A/Prof Michael Stark 
Senior Staff Specialist 
Department of Neonatal Medicine 
Women’s and Children’s Hospital Adelaide 
Theme Leader (Early Origins of Health) 
The Robinson Research Institute 
The University of Adelaide 
 
  
Dear A/Prof Stark, 
 
Reference number: 2013#06 
Project title: Effect of pre-transfusion red cell washing on neonatal outcome: A randomised 
controlled trial  
 
Thank you for submitting the above research project for ethical review. The extension to this project 
submitted on 12 November 2019 was approved by the Secretary on behalf of the Blood Service Ethics 
Committee.  The ethical approval for this project will now lapse on 31 December 2020. 
Please note that all requirements of the original ethical approval for this project still apply.  The Blood 
Service Ethics Committee wishes you every continued success in your research. 




Dr Larissa Aldridge 
Ethics Secretary 
Research and Development  
Australian Red Cross Blood Service 
 
The Blood Service Ethics Committee is constituted and operates in accordance with the National 
Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in Human 
Research (2007). 
 
